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Human immunodeficiency virus: pathogenesis and epidemiology
Human immunodeficiency virus (HIV) affects the immune system and causes the acquired 
immunodeficiency syndrome (AIDS). AIDS was first clinically observed in the beginning 
of the 80s, the initial cases were a cluster of injection drug users and gay men with no 
known cause of impaired immunity. In 1983, two separate research groups independently 
declared that a novel retrovirus had been infecting AIDS patients, which was later named 
HIV [2, 3]. HIV specifically targets and destroys CD4+ T-lymphocytes (CD4 cells), resulting 
in a decrease of CD4 cells and a compromised adaptive immunity. HIV not only binds to 
the CD4 receptor but also to the chemokine receptors CXCR4 and CCR5; the interaction 
of HIV with these co-receptors is mandatory for cellular invasion [4-6]. Entry of the cell 
begins through interaction of HIV with both CD4 and a chemokine receptor, generally 
either CCR5 or CXCR4, on the cell surface (figure 1). This binding brings membranes 
close together, allowing fusion and subsequent entry into the cell of the HIV RNA and 
various enzymes, including reverse 
transcriptase, integrase, ribonuclease, and 
protease. Shortly after entry in the cell, 
reverse transcriptase liberates the single-
stranded RNA genome and copies it into a 
complementary DNA (cDNA). Together, the 
cDNA and its complement form a double-
stranded viral DNA that is then transported 
into the cell nucleus. The integration of the 
viral DNA into the host cell’s genome is 
carried out by the viral integrase. During 
viral replication, the integrated viral DNA 
is transcribed into mRNA. The mRNA is 
exported out of the nucleus and spliced 
into functional enzymes and a HIV RNA 
copies. These HIV products are then 
transported to the membrane of the host 
cell, where new HIV virion form and leave 
the cell (figure 1). 
Figure 1. HIV replication scheme. 
Source Wikipedia
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Since the beginning of the epidemic, almost 75 million people have been infected by 
HIV and 36 million people have died of HIV related illnesses. Globally, approximately 
35 million people are living with HIV, with 2.3 million people newly infected in and 1.6 
million HIV-related deaths in 2012 [7]. Almost all new HIV infections occur in low- and 
middle-income countries. Sub-Sahara Africa is most affected by HIV, around two-third of 
all new cases and deaths occur in this region (figure 2; [1]). On average five percent of all 
adults in Sub-Sahara Africa are infected with HIV, in some countries the HIV prevalence is 
up to 30%. In this area heterosexual risk behaviour is the main mode of transmission. In 
North-America, Latin America, Western Europe and Oceania the HIV epidemic is limited 
to key populations, with less than one percent of the total population infected. In all these 
areas the HIV epidemic is concentrated in risk groups, such as men having sex with men, 
injecting drug users and female sex workers. In Russia, Eastern Europe and Central Asia 
1.4 million people are living with HIV and the regional epidemic is mostly concentrated 
among people who inject drugs, with reported prevalence rates of 60% among this risk 
group.  South, East and South East Asia has an estimated five million cases, with a HIV 
prevalence rate of less than 0.5 percent. There is no single ‘Asian epidemic’; the HIV 
epidemic differs across the region. However, it remains largely concentrated in three key 
populations: people who inject drugs, men who have sex with men, and sex workers. 
Indonesia has a relatively recent but rapidly growing HIV epidemic that, apart from the 
Papua provinces, is concentrated in some key populations and injecting drug use (IDU) is 
an important route of HIV transmission.
Figure 2. Global prevalence of HIV among adults in 2012. 
Source WHO [1]
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Injecting drug use and HIV 
People who inject drugs are at increased risk for blood borne infections, such as hepatitis 
C (HCV) and HIV, trough sharing needles and syringes. Worldwide IDU is responsible for 
five to ten percent of all HIV infections [8-10]; in Eastern Europe and Central Asia even 
up to 80% of all HIV infections are related to IDU. From the start of the HIV epidemic IDU 
has been recognised as a risk factor for HIV infection, but it may also change the natural 
course of HIV infection. Epidemiological data looking at the association between IDU and 
the natural course of HIV have shown contradicting results [11-17]. Some studies showed 
a faster disease progression in injecting drug users, whereas other studies found no 
differences. Often clinical endpoints were used, such as mortality and AIDS-free survival, 
which could be influenced by other factors [11-15]. The use of clinical endpoints may 
therefore skew the relation between IDU and the progression of HIV. One such factor is 
mortality not related to HIV, which is much higher among HIV-infected drug users than 
among other HIV-infected individuals [18-20]. Also differences in the occurrence of AIDS 
defining illnesses, for example Kaposi sarcoma, can influence the association between 
risk group and AIDS-free survival [12]. In addition, most studies have been conducted in 
high-income countries and mostly among Caucasians; however results might be different 
in low-income settings.
Injecting drug use and other infectious diseases
It has long been recognised that IDU is associated with other infectious diseases [21]. The 
link between opioids and infections cannot simply be explained by transmission route or 
exposure. Various studies have shown that opioids themselves modulate the immune 
response [21-29]. Confounding variables, such as sharing needles, nutrition status and 
homelessness, can influence the frequency of infections. However data suggest that 
immune modulating effects of opioids are also an important contributing factor in the 
increased susceptibility to various infectious agents. In addition to blood borne diseases, 
people who inject drugs often have more pulmonary infections (caused by mycobacteria, 
staphylococci, streptococci) and other diseases, such as endocarditis, cellulitis, and 
sexually transmitted infections. Not only the prevalence, but also the severity of infectious 
diseases can be influenced by opioids. In animal experiments, exposure to opioids leads 
to larger viral and bacterial load, increased morbidity and higher mortality rates [21, 24]. 
Tuberculosis is common among drug users; meanwhile the spread of HIV has significantly 
amplified the spread of tuberculosis, also among drug users. It is generally thought 
that increased exposure accounts for the higher incidence of tuberculosis among 
drug users, but the immune-modulating effects of opioids may also be a contributing 
factor. Interestingly, despite heavy exposure to Mycobacterium tuberculosis and strong 
suppression of specific T-cell immunity, some HIV-infected patients do, and others do not 
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develop active tuberculosis in tuberculosis-endemic countries like Indonesia. As such, 
HIV-infection magnifies differences in innate host susceptibility which help elucidate the 
possible effect of opioids on innate immunity to tuberculosis. 
Opioids and immune response
Experimental studies have shown that binding of opioids to the opioid µ-receptors of 
immune cells affects the function of these cells in various ways [21-29]. In vitro and animal 
experiments have shown that opioids inhibit phagocytosis, chemotaxis and activation of 
immune cells, while the T-cell response is skewed from a T
h
1 towards a more T
h
2-driven 
response ways [21-29]. However, a predominant Th1 response is required to contain 
infections by HIV and by Mycobacterium tuberculosis. 
When looking at a cellular level, opioids may play a role in HIV progression by up-
regulation of the HIV co-receptors on immune cells and thereby contributing to the HIV-
related CD4 cell decline [16, 30-33]. In vitro experiments showed that opioids enhance 
CXCR4 and CCR5 expression on immune cells, via the opioid µ-receptor [33, 34]. This 
enhanced expression of HIV co-receptors results in higher susceptibility [35] and increased 
viral replication of HIV in vitro [36, 37]. Animal studies have shown that opioids inhibit 
cell-mediated immunity and increase circulating HIV-RNA [38-41]. In addition, opioid-
dependent monkeys showed more severe immunsuppression following infection with 
simian immunodeficiency virus (SIV) [41-43] and more neurotropism (i.e. higher levels 
of SIV in the brain) [40, 42]. The effect of opioids on infection with other pathogens, like 
mycobacteria, has not been studied in these experiments. All information available on 
HIV-related effects of opioids is obtained either in animal experiments or in vitro studies. 
The regulation of immune and inflammatory responses is dependent on the functions 
of cytokines, which is especially important in individuals with an already compromised 
immune function, such as HIV-infected individuals. The effects of opioids on cytokine 
production have been investigated in both in vitro and animal experiments, but hardly 
any information is available on in vivo exposure in humans [27, 29, 44-53] . In addition, 
data from previous studies have shown contradicting results. For example the production 
of IFN-γ have shown to be enhanced [44] or suppressed [45] by various opioids in various 
in vitro studies, whereas in animal experiments the IFN-γ production is often diminished 
after exposure to opioids [46, 47]. The production TNF-α is mostly suppressed by opioids 
[49, 51, 52], but some studies show no effect [50] or even an increase in TNF-α [48]. 
In general, the role of opioids in IL-1β and IL-6 synthesis remains unclear [48, 53]. The 
differences in results might be explained by experimental set-up, type of cells or animals 
used and type of opioid.
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Most studies use morphine (or a specific µ-opioid receptor agonist) to test the effects of 
opioids on immune responses. However, in HIV-infected individuals especially heroin and 
methadone are important. The properties of different opioids, like heroin and methadone 
vary as they have different affinity with the various opioids receptors [49]. In addition, 
only few human studies explored the immune modulating properties of opioids while 
indication for opioid use was pain relief, either post-surgery or during cancer treatment 
[54-58]. The main findings of these studies were that morphine suppressed natural killer 
cell activity, reduced mitogen responses and decreased lymphoproliferation. To the 
best of our knowledge, only three studies examine opioid exposure under alternative 
circumstances. In the study of Yeager et al healthy volunteers received morphine 
continuously over 36 hours [59]. Exposure to morphine resulted in suppression of natural 
killer cell cytotoxicity, also IFN-γ stimulated and antibody-dependent cytotoxicity, but virus 
antigen production after lymphocyte infection with HIV was not increased. This study 
suggests that morphine administration can cause measurable suppression of the immune 
system.  Another study examined the effects of methadone and buprenorphine (as opioid 
substitution); no difference was found between these two, but cytokine production was 
significantly depressed compared to controls [60]. Azarang et al examined the in vitro 
cytokine production after stimulation of whole blood from opioid addicts compared 
to healthy controls [61]. This study shows that heroin addicts produce less IFN-γ and 
more IL-10 after stimulation with LPS. In conclusion: limited data from different kind of 
studies indicate that heroin and methadone modulate the immune system. Important 
knowledge gaps therefore remain, including if this effect is also seen in vivo and how 
heroin and methadone interfere with HIV infection.
Aim and outline of this thesis
The aim of the present thesis is to gain more insight into the immune modulating 
properties of opioids in humans and thereby focus on the interaction between drug 
use and HIV infection. Most of the studies were performed in the context of ‘IMPACT’, 
a programme aimed to prevent, control and treat HIV among injecting drug users in 
West-Java (40 million people), Indonesia [62]. IMPACT established or optimized patient 
care in three health facilities in Bandung, the capital of West Java: a teaching hospital, 
a methadone clinic, and a prison clinic. In these health facilities, people at risk for HIV 
infection or who present with signs and symptoms suggesting HIV/AIDS are counselled 
and tested for HIV. All HIV-infected patients are further characterised, among others the 
risk behaviour associated with HIV transmission was categorised as active or previous IDU 
(53%) or sexual transmission (47%). All HIV-infected patients were followed prospectively 
in a cohort study, with regular follow-up and HIV treatment provided according to the 
Indonesian guidelines. All IMPACT studies were approved by the Health Research Ethics 
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Committee at the Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin General 
Hospital in Bandung, Indonesia. 
Chapter 2 reviews worldwide issues related to IDU, HIV prevalence and prevention. 
Epidemiological studies exploring the association between IDU and infection rates, 
including HIV and tuberculosis, are generally performed in Caucasians and high-income 
countries. In these settings, IDU is also associated with other factors that predispose to 
infectious diseases, such as malnutrition, homelessness, crowding and imprisonment. 
In addition, lower utilization of health services and poor treatment compliance among 
drug users may lead to more severe or prolonged disease. However, the situation is very 
different in Indonesia, where people who inject drugs are generally educated, employed 
and married. Therefore, epidemiological aspects of HIV in the IMPACT cohort were 
studied, especially in relation to HIV transmission risk behaviour. In chapter 3 we explored 
the question: do HIV-infected injecting drug users have a faster progression of HIV 
compared to non-drug users, using the natural decline of circulating CD4 cells as marker 
for immunodeficiency? Apart from data on the level of immunodeficiency, information 
regarding the risk to develop opportunistic infections in subsets of HIV-infected subjects 
is equally important. Tuberculosis is the most common opportunistic infection in HIV-
infected individuals, with high mortality rates. Interestingly, IDU has also been associated 
with tuberculosis, but as indicated above, most studies originate from high-income 
countries. In low-income settings, especially those endemic for tuberculosis, the relation 
between IDU and tuberculosis has not been studied and may be very different from 
previous reports. Indonesia is endemic for tuberculosis; it has been ranked as having the 
fourth highest tuberculosis burden. Therefore, we questioned if HIV-infected injecting 
drug users develop active tuberculosis more often than non-drug users, or if they have 
more latent tuberculosis infection (LTBI) (chapter 4). 
In the second part of this thesis (chapter 5 to 8), possible immunological mechanism 
underlying the association between HIV and drug use are further studied. As discussed 
above, the HIV co-receptors CCR5 and CXCR4 are important for HIV infection and many 
studies in HIV-infected subjects have shown that the expression of these co-receptors 
on CD4+ T lymphocytes is important in relation with disease progression. Data on co-
receptor expression in subsets of CD4 cells are however more limited, especially regarding 
memory T-lymphocytes which are the primary target cells of HIV and regulatory T cells, 
that may modulate immune response towards HIV. Most HIV-infected patients exhibit a 
gradual decline in CD4 cells throughout the course of their infection; the rate of disease 
progression from asymptomatic HIV infection to AIDS varies between patients. Some HIV 
patients are able to maintain stable CD4 cell counts for an extended time and remain 
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asymptomatic without ART for years after infection. These patients have been referred 
to as long-term non-progressors (LTNP). The question was asked if the expression of 
CCR5 and CXCR4 on memory (CD45RO+), naïve (CD45RA+) cells and regulatory T-cells 
(CD4+CD25highFoxP3+) in decreased in HIV-infected LTNP compared to normal progressors 
(chapter 5). 
Previous studies reported increased expression of CCR5 and CXCR4 receptors after 
exposure to opioids, however all data were derived from in vitro studies. The question 
was asked if heroin use and methadone maintenance treatment (MMT) in humans also 
increases the expression of CCR5 and CXCR4 in HIV-infected individuals (chapter 6). We 
explored this question in HIV infected individuals using heroin, receiving MMT, using 
heroin over one year ago and those who never used opioids. 
The regulation of immune and inflammatory responses is dependent, among others on 
the functions of chemokines and cytokines. Previous studies examining the effects of 
opioids on chemokine expression and cytokine production have always used and in vitro 
system or animal models. IDU is a major HIV transmission risk behaviour and whether 
or not opioids interfere with co-receptor expression is therefore very important. The 
question was asked if heroin users and individuals receiving MMT have a diminished 
production of chemokines (chapter 6) and cytokines (chapter 7) after ex vivo stimulation 
of whole blood with various pathogens (Mycobacterium tuberculosis, Candida albicans 
and LPS from Escherichia coli).  Additionally, the anti-microbial protein cathelicidin has 
previously shown a strong relation with the occurrence of infections, such as periodontal 
diseases, respiratory tract infections and candidiasis. Interestingly, these infections are 
very common among drug users, but no studies have examined the relation between 
opioid use and cathelicidin. The question was asked if HIV-infected heroin users have 
a reduced expression of cathelicidin compared to individuals who never used opioids 
(chapter 8).
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Samenvatting
Intraveneus drugsgebruik is een groot internationaal gezondheidsprobleem. De transmissie 
van hiv, dat wordt overgedragen wanneer drugsgebruikers hun spuiten of naalden delen, 
speelt hierbij een belangrijke rol. Ook vertonen intraveneuze drugsgebruikers vaak 
seksueel risicogedrag dat de transmissie tussen verschillende groepen faciliteert. In dit 
artikel geven wij een overzicht van intraveneus drugsgebruik in relatie tot hiv wereldwijd. 
Wereldwijd zijn er ongeveer 16 miljoen intraveneuze drugsgebruikers, van wie naar 
schatting 3 miljoen met hiv geïnfecteerd zijn. De hiv-prevalentie in deze risicogroep 
loopt sterk uiteen, zowel tussen als binnen landen. Om hiv-transmissie via drugsgebruik 
te voorkomen, zijn er verschillende interventieprogramma’s, zoals ‘needle and syringe 
exchange programmes’ (NSP’s) en opioïd-substitutietherapie (OST). Deze programma’s 
zijn effectief voor preventie van hiv-transmissie, mits voldoende geïmplementeerd. 80% 
van de landen heeft NSP’s, 65% voorziet ook in OST. Vaak is de dekkingsgraad van deze 
diensten onvoldoende om een impact te hebben op de hiv-transmissie.
Abstract
Intravenous drug use and the spread of HIV; an international perspective
Intravenous drug use is a major international health problem. The transmission of HIV 
through sharing syringes or needles during drug use is an important part of this problem. 
Injection drug users (IDUs) also engage in high-risk sexual behaviour which facilitates the 
transmission between different groups. In this article, we present a global perspective of 
injection drug use in relation to HIV. There are 16 million IDUs worldwide, of whom an 
estimated 3 million are infected with HIV. The prevalence of HIV among IDUs varies greatly 
between countries as well as within them. There are intervention programmes to prevent 
HIV transmission via drug use such as needle and syringe exchange programmes (NSPs) 
and opioid substitution therapy (OST). These programmes are effective for preventing 
HIV transmission, provided that their implementation is adequate. 80% of the countries 
provide NSPs, 65%also provide OST. The coverage of these services is nevertheless 
insufficient to have an impact on the transmission of HIV.
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Introductie
Intraveneus drugsgebruik is een groot internationaal gezondheidsprobleem. De mortaliteit 
en morbiditeit wordt sterk beïnvloed door bloed overdraagbare aandoeningen, zoals HIV 
en Hepatits C, bij het delen spuiten en naalden [1]. Drugsgebruik is ook gerelateerd aan 
risicovol seksueel gedrag waardoor de transmissie van HIV tussen verschillende risico 
groepen bevorderd wordt [2]. In veel landen is er overlap tussen intraveneus drugsgebruik 
en prostitutie, zoals in Groot Brittanië, Syrië en China [3]. 
Intraveneus drugsgebruik is wereldwijd illigaal en het in bezit hebben van of gebruiken 
van drugs is strafbaar. Veel drugsgebruikers komen in de gevangenis terecht, daardoor 
zijn gevangenissen een hoge risico omgeving voor HIV-transmissie en daaraan verbonden 
opportunistische infecties zoals tuberculosis. Voorts is zorgverlening aan druggebruikers 
extra moeilijk vanwege de complexiteit van de medische en psychosociale problemen 
en het soms vertoonde problematische gedrag [4, 5]. Drugsgebruikers wantrouwen vaak 
autoriteiten en daardoor zoeken zij minder snel hulp en maken ze minder gebruik van 
preventie programma’s. Daarnaast zorgt deze situatie ervoor dat het vaak lastig is om 
betrouwbare getallen over prevalentie en incidentie van zowel intraveneus drugsgebruik 
als HIV te verzamelen. 
In dit artikel geven wij een overzicht van intraveneus drugsgebruik in relatie tot HIV, voor 
zover betrouwbare informatie beschikbaar is. De gebruikte data komen voornamelijk uit 
negen verschillende bronnen [6-14], vederop in dit artikel zullen we niet meer naar deze 
bronnen verwijzen.
HIV, drugsgebruik en interventieprogramma’s
Ongeveer 10% van alle nieuwe HIV-infecties wereldwijd wordt veroorzaakt door 
intraveneus drugsgebruik, buiten Sub-Saharisch Afrika zelfs 30%. In veel gebieden is het 
gezamelijk gebruik van naalden zelfs de primaire route van HIV transmissie. In 2007 waren 
er wereldwijd een geschatte 15,9 miljoen intraveneuze drugsgebruikers hiervan woont 
80% in lage of middel inkomenslanden [3]. Van de intraveneuze drugsgebruikers zijn er 
3 miljoen ook met HIV geinfecteerd. De HIV prevalentie loopt echter zeer uiteen, zowel 
tussen landen als binnen één land. De HIV prevalenties in de risicogroep van intraceneuze 
drugsgebruikers variëren van 0,01 tot 72,1% (tabel 1). 
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Tabel 1 Overzicht van het aantal intraveneuze drugsgebruikers en de HIV-prevelentie 
binnen deze groep wereldwijd
Regio IVD; n
HIV-geïnfecteerde 
IVD; n*
HIV-prevalentie 
bij IVD; %
Oost Europa 3.476.500 940.000 27,04
West Europa 1.044.000 114.000 10,92
Oost- en Zuidoost-Azië 3.957.500 661.000 16,70
Zuid-Azië 569.500 74.500 13,08
Centraal-Azië 247.500 29.000 11,72
Caribische gebied 186.000 24.000 12,90
Latijns-Amerika 2.018.000 580.500 28,77
Canada en VS 2.270.500 347.000 15,28
Australië en Nieuw-Zeeland 173.500 2.500 1,44
Midden-Oosten en Noord-Afrika 121.000 3.500 2,89
Sub-Saharisch Afrika# 1.778.500 221.000 12,43
Wereld$ 15.861.500 2.997.500 18,90
IVD=intraveneuze drugsgebruikers. *Alle getoonde schattingen zijn afgerond naar 500. 
#De schatting voor Sub Saharisch Afrika moet met de nodige voorzichtigheid worden 
bekeken, aangezien de prevalentie schattingen zijn gebaseerd op data uit drie van de 
47 landen (Zuid Afrika, Mauritius en Kenia). $De globale schattingen zijn geëxtrapoleerd 
van de regionale schattingen, deze zijn eerst gemaakt daarna afgerond.  Data afkomstig 
uit: Mathers B et al. [10]
Om transmissie van HIV via drugsgebruik te voorkomen zijn er verschillende interventie 
programma’s zoals ‘needle and syringe exchange programmes’ (NSPs) en ‘opioid 
substitution therapy’ (OST). Bij NSPs kunnen drugsgebruikers schone naalden krijgen, 
om de transmissie van HIV en Hepatitis C te voorkomen. OST voorziet opiaat gebruikers 
van middelen die oraal worden ingenomen, zoals methadone en buprenorfine waardoor 
‘afkick’ verschijnselen en daaraan gerelateerd risicogedrag wordt voorkomen. Een hoge 
dekking van NSP en OST wordt geadviseerd om voldoende impact te hebben op de HIV-
epidemie [14]. Dit betekent toegang tot NSP voor minimaal 60% van de intraveneuze 
drugsgebruikers, 200 naalden per persoon per jaar en OST voor 40% of meer van de 
drugsgebruikers. 
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Tabel 2 geeft een overzicht van de dekking van NSP en OST in verschillende delen van de 
wereld. Hieruit blijkt dat preventie programma’s in veel landen wordt aangeboden, maar 
dat de dekking zeer beperkt is. Gemiddeld heeft wereldwijd slechts 8% van intraveneuze 
drugsgebruikers toegang tot NSP en worden 22 naalden per persoon per jaar verstrekt. 
De dekking van OST onder intraveneuze drugsgebruikers is lastiger te meten, doordat 
OST wordt aangeboden aan alle opiaat gebruikers, zowel diegene die injecteren als 
diegene die opiaten op een andere manier innemen. Daarom wordt de OST dekking 
weergegeven als het aantal OST behandelingen (zowel intraveneuze als niet intraveneuze 
drugsgebruikers) per 100 intraveneuze drugsgebruikers. Ook de dekking van OST is laag, 
wereldwijd worden per 100 intraveneuze drugsgebruikers acht OST behandelingen 
gegeven (tabel 2).
Sub-Saharisch Afrika
Sub-Saharisch Afrika is het gebied dat het hardst is getroffen door de HIV epidemie, nog 
steeds vindt 68% van alle nieuwe HIV infecties hier plaats. De overgrote meerderheid 
van de nieuwe HIV infecties wordt veroorzaakt voor onveilig heteroseksueel contact. 
Intraveneus drugsgebruik is een relatief recent fenomeen in Sub-Saharisch Afrika, 
maar recente epidemiologische data laten een zorgelijke toename zien in intraveneus 
drugsgebruik. Geschat wordt dat er 1,78 miljoen intraveneuze drugsgebruikers in deze 
regio wonen, waarvan 221.000 met HIV geïnfecteerd zijn. Slechts een beperkt aantal 
landen hebben preventie programma’s gericht op drugsgebruikers.
Midden Oosten en Noord Afrika
Transmissie van HIV in het Midden Oosten en Noord Afrika vindt vooral plaats via 
homoseksueel contact en intraveneus drugsgebruik. Volgens laatste schattingen wonen 
300.000 intraveneuze drugsgebruikers in deze regio. Informatie over de HIV prevalentie is 
schaars, beschikbare data varieert van 0,14% tot 15%. In een aantal landen in deze regio 
zijn preventie programma’s gestart, maar gegevens over de dekking van deze diensten 
zijn echter zeer beperkt. 
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Tabel 2 Overzicht van interventieprogramma’s ter bestrijding van HIV-transmissie in 
verschillende delen van de wereld
regio
totaal 
aantal 
landen
aantal 
landen 
met 
data 
over 
IVD
‘needle and syringe exchange programmes’* Opioid-substitutietherapie*
aantal 
landen 
met 
NSP 
(%ERIP)
IVD met 
toegang 
tot NSP; % 
(uitersten); 
aantal landen#
naalden per 
IVD per jaar; 
n (uitersten); 
aantal landen#
aantal 
landen 
met OST 
(%ERIP)
aantal OST 
per 100 IVD$; 
n (uitersten); 
aantal landen#
Sub-Saharisch 
Afrika
47 16 2 (2) <1 (<1); 
13 landen
<1 (<1); 
13 landen
4 (27)
<1 (<1); 
13 landen
Midden 
Oosten en 
Noord Afrika
21 21 8 (35) 2 (1-3); 
16 landen
<1 (<1-1); 
18 landen
4 (13)
1 (<1-1); 
20 landen
Oost en 
Zuidoost Azië
17 16 10 (87) 7 (6-9); 
15 landen
30 (7-68); 
16 landen
7 (86)
4 (3-5); 
16 landen
Zuid Azië 9 9
6 (99) 43 (32-57); 
8 landen
37 (27-50); 
9 landen
5 (70%)
19 (15-25); 
8 landen
Centraal Azië 5 5
5 (100) 36 (28-50); 
4 landen
92 (71-125); 
4 landen
2 (51)
<1 (<1); 
5 landen
Oost Europa 18 18 18 (100) 10 (7-15); 
16 landen
9 (7-14); 
17 landen
16 (48)
1 (<1-1); 
18 landen
West Europa 28 27 23 (100) 17 (12-25); 
10 landen
59 (39-89); 
21 landen
25 (100)
61 (48-79); 
23 landen
Latijns Amerika 20 18 5 (67) 2 (1,7-3); 
10 landen
<1 (<1); 
11 landen
2 (29)
<1 (<1); 
12 landen
Het Caribische 
gebied 15 6
1 (16)
1 (16)
5 (4-7); 
2 landen
Canada en VS 2 2 2 (100) 23 (17-33); 2 
landen
2 (100)
13 (9-19); 
alleen VS
Australië en 
Nieuw Zeeland
2 2 2 (100) 202 (148-334); 
2 landen
2 (100)
23 (17-39); 
alleen Australië
Wereld 200 151 82 (80) 8 (5 - 11); 
102 landen
22 (12 - 42); 
124 landen
70 (65)
8 (6-12); 
126 landen
IVD= intraveneus drugsgebruik; NSP=needle and syringe exchange programmes; OST: opioid substitutie 
therapie; % ERIP: percentage van de geschatte regionale IVD populatie. * De getallen in deze kolommen 
zijn schattingen, bedoeld om verschillen in dekking per regio te vergelijken; zij zijn niet bedoeld als 
precieze maat. Aangegeven is het aantal landen waarvan informatie beschikbaar is over de variabele; 
dit geeft een indicatie van de betrouwbaarheid van de data. De schattingen van de dekkingsgraag van 
de interventies zijn ook gebaseerd op landen waarvan bekend is dat deze interventie niet aanwezig 
is.  # Dit betreft het aantal landen waarvan de data zijn gebruikt om de percentages te berekenen. $Dit 
betreft het aantal personen (zowel IVD als niet-IVD) dat OST ontvangt per 100 IVD; hoe lager dit geatl 
des te minder personen OST ontvangen. Alle getoonde data zijn afkomstig uit: Mathers B et al [9].
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Azië
In Azië wonen 4,8 miljoen HIV-geïnfecteerd personen, de landelijke HIV prevalenties 
zijn in bijna alle landen minder dan één procent. Echter, de HIV epidemie is vaak 
geconcentreerd rond een specifieke risicogroep [15]. Een kwart van alle intraveneus 
drugsgebruikers woont in Azië. In veel Aziatische landen wordt de HIV epidemie dan ook 
door intraveneus drugsgebruik gedreven. In deze groep is de HIV prevalentie gemiddeld 
16%, maar in subpopulaties zijn veel hogere prevalenties geregistreerd. Zestien landen 
in deze regio hebben een bepaalde vorm van NSP en twaalf hebben OST. De dekking 
van deze programma’s over de gehele regio blijft ver onder het niveau dat nodig is om 
een impact te hebben op de HIV epidemie. Vaak ontbreekt ook wettelijke en politieke 
ondersteuning, waardoor het voorschrijven van naalden, spuiten, methadon en 
buprenorfine illigaal is. Criminalisering en detentie zijn vaak nog steeds de voornaamste 
aanpak van drugsgebruik in Azië.
Oost Europa en Centraal Azië
In Oost Europa en Centraal Azië wonen ongeveer 3,7 miljoen intraveneuze drugsgebruikers. 
Sommige landen in deze regio’s hebben de hoogste prevalentie van intraveneus 
drugsgebruik in de wereld. In deze regio is de HIV-epidemie, gedreven door drugsgebruik, 
de afgelopen jaren sterk toegenomen; van 410.000 in 2001 naar 1,5 miljoen personen 
in 2010. In dit gebied kunnen op elk moment nieuwe uitbraken ontstaan, daardat de 
prevalentie van drugsgebruik hoog is en de HIV-epidemie er nog relatief kort geleden 
begonnen is. De gemiddelde prevalentie van HIV onder intraveneuze drugsgebruikers 
is 27% in Oost Europa en 12% in Centraal Azië, maar veel landen rapporteren HIV-
prevalenties van meed dan 60%. Zowel NSP als OST is aanwezig in veel landen in dit 
gebied, maar de dekking is onvoldoende. 
Latijns Amerika 
In Latijns Amerika wonen meer dan twee miljoen intraveneus drugsgebruikers, geschat 
wordt dat minstens 25% geïnfecteerd is met HIV. In alle Latijns-Amerikaanse landen 
wordt intraveneus drugsgebruik gerapporteerd, maar vooral Brazilië en Argentinië zijn 
getroffen door HIV, met HIV-prevalenties bij drugsgebruikers van respectivelijk 48% en 
49,7%. Andere landen in deze regio zijn op dit moment weinig aangedaan door HIV, maar 
risicogedrag wordt wel waargenomen. NSPs zijn slechts beschikbaar in vijf landen en de 
dekking is laag. Mexico en Colombia zijn de enige landen waar OST wordt voorschrijven.
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Het Caribisch gebied 
Het Caribisch gebied is, na Sub-Saharisch Afrika, het meest getroffen door HIV.  Transmissie 
vindt voornamelijk plaats via seksueel contact. Intraveneus drugsgebruik is in deze regio 
uitzonderlijk, met uitzondering van Puerto Rico. In dat land zijn 29.130 intraveneuze 
drugsgebruikers, met een HIV- prevalentie van 12,9%. Puerto Rico is ook het enige land 
waar NSPs en OST aanwezig zijn. 
Westerse landen 
In 2010 waren er 2,2 miljoen personen in Noord Amerika en West Europa met HIV; 
intraveneuze drugsgebruikers en homoseksuele mannen vormen hier belangrijke 
risicogroepen voor besmetting met HIV. 
West Europa Geschat wordt dat in West Europa ongeveer één miljoen intraveneuze 
drugsgebruikers wonen. De HIV prevalentie is in de meeste landen langer dan 10%, met 
uitzondering van Frankrijk, Italië, Portugal en Spanje. In 1983 werd de allereerste NSP 
ingevoerd in Nederland [16]. Sinsdien is de drugsgerelateerde transmissie van HIV sterk 
afgenomen in landen met goede preventieprogramma’s. Zwitserland heeft verregaande 
maatregelen genomen en is een van de weinige landen in de wereld waar NSPs in 
gevangenissen zijn ingevoerd. In 2010 waren in bijna alle landen in deze regio zowel NSP 
als OPT aanwezig, er is echter een groot verschil in dekkingsgraad tussen de landen.
Noord Amerika Meer dan 10% van alle intraveneuze drugsgebruikers in de wereld (2,2 
miljoen personen) woont in Canada en de VS. The HIV-prevalentie bij drugsgebruikers is 
zowel in Canada als de VS een stuk hoger dan in andere westerse landen, respectivelijk 
13,4% en 15,6%. Beide landen hebben preventieprogramma’s, maar de aangeboden 
diensten zijn echter inconsistent en worden beïnvloed door lokale wetgeving. Hierbij 
wordt vooral de nadruk gelegd op criminalisering, detentie of abstinentie programma’s. 
Australië en Nieuw Zeeland In Australië en Nieuw Zeeland wonen ongeveer 170.000 
personen die intraveneus drugs gebruiken, hiervan is 1,5% met HIV geïnfecteerd. De 
dekkingsgraad van NSP en OSP is in beide landen goed; Australië heeft zelfs de hoogste 
ratio van ‘schone naalden’verspreiding wereldwijd.
Nederland
In Nederland is de HIV-epidemie in het begin geconcentreerd geweest rond homoseksuele 
mannen en intraveneuze drugsgebruikers. De HIV-prevalentie bij drugsgebruikers in 
het begin van de HIV-epidemie verschilt sterk  per regio. In Arnhem, Groningen en Den 
Haag was de prevalentie maximaal 2%, terwijl er hogere prevalenties werden gevonden 
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in Utrecht (5%), Noord Brabant (5%), Rotterdam (9%) Heerlen/Maastricht (14%) en 
Amsterdam (26%) [17]. Bij herhaalde metingen waren de HIV-prevalenties stabiel over 
tijd, met uitzondering van Heerlen, waar de HIV-prevalentie verdubbelde van 11 naar 
22% [17].
Verschillende onderzoeken laten zien dat de HIV-incidentie onder drugsgebruikers zeer 
sterk is gedaald sinds het begin van de HIV-epidemie in Nederland. In de jaren 80 was de 
HIV-incidentie onder drugsgebruikers nog rond de 10 per 100 persoonsjaren en in 2000 
was deze nul [17-19]. Sindsdien is de incidentie iets gestegen; in 2010 waren vijf van de 
826 nieuwe HIV-diagnoses (0.5%) toe te schrijven aan intraveneus drugsgebruik [19, 20].
Nederland is één van de eerste landen waar maatregelen werden genomen om de schade 
aan gezondheid van intraveneus drugsgebruik te verminderen. Sinds eind jaren 70 is er 
toegang tot OST en in 1984 was Nederland het eerste land dat NSP opzette. Onderzoek 
laat zien dat tussen 1986 en 1992 drugsgerelateerd risicogedrag sterk is afgenomen; het 
lenen van naalden en spuiten is gedaald van 51 naar 20%; uitlenen van 46 naar 10% 
en hergebruik van 63 naar 39%. Het percentage l intraverneuze drugsgebruikers dat 
nooit naalden deelt of uitleent was in dezelfde tijsperiode toegenomen van 36 naar 
77 [18]. Daarnaast was er ook een toename in het gebruik van OST en NST, en lieten 
drugsgebruikers zich steeds vaker testen op HIV [18]. Ook seksueel risicogedrag is 
afgenomen, maar in 2010 had nog steeds 31% onveilig seksueel contact [21]. 
Conclusie
Intravenues drugsgebruik is een belangrijke factor in de HIV-epidemie, met name 
in gebieden als Oost-Europa en Azië. Er bestaan effectieve interventies, zoals ‘needle 
and syringe exchange programmes’(NSP’s) en opioïd-substitutietherapie (OST), om hiv-
transmissie bij intraveneuze drugsgebruikers te reduceren; ervaringen in Nederland en 
Australië laten dit zien.
Wereldwijd worden deze interventies onvoldoende benut en kiest men eerder 
voor criminalisering en detentie.  Ook zijn er vaak maar beperkte middelen voor 
gezondheidszorg, in landen waar  investeringen in drugsgebruikers soms moeilijk te 
verantwoorden zijn. Door prostitutie en sexuele transmissie neemt echter ook het risico 
op HIV-besmetting van de algemene populatie toe. Dit is een extra argument om de 
noodzakelijke interventies te implementeren. In verschillende gebieden, zoals in Oost 
Europa en Afrika, is intraveneus drugsgebruik nog een relatief nieuw fenomeen. Juist 
in deze gebieden kunnen er nieuwe HIV-uitbraken onstaan in deze risicogroep en is het 
essentieel om vroegtijdig in te grijpen. 
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Abstract
Background: It remains unclear whether the natural course of human immunodeficiency 
virus (HIV) differs in subjects infected through injecting drug use (IDU) and no data have 
been published from low- or middle-income countries. We addressed this question in an 
urban cohort in Indonesia, which is experiencing a rapidly growing HIV epidemic strongly 
driven by IDU.
Methods: All antiretroviral therapy (ART) naïve HIV infected patients who had at least 
two subsequent CD4 cell counts available before starting ART were included into this 
study. We examined the association between IDU and CD4 decline using a linear mixed 
model, with adjustment for possible confounders such as HIV viral load and hepatitis C 
antibodies. 
Results: Among 284 HIV-positive ART naïve patients, the majority were male (56%) 
with a history of IDU (79% among men). People with a history of IDU had a statistically 
significant faster decline in CD4 cells (p-value <0.001). Based on our data, patients with 
a history of IDU would have an average 33% decline in CD4 cells after one year without 
ART, compared with a 22% decline among non-users. At two years, the decline would 
average 66 and 40%, respectively. No other factor was significantly associated with CD4 
cell decline.
Conclusions: We show that a history of injecting drug use is associated with a more rapid 
CD4 cell natural decline among HIV-infected individuals in Indonesia. These findings have 
implications for monitoring ART naïve patients with a history of IDU and for starting ART 
in this group. 
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Introduction
Injecting drug use (IDU) is responsible for human immunodeficiency virus (HIV) infections 
in 10% of all cases worldwide, and 30% of cases outside Africa [1]. IDU is not only a risk 
factor for HIV transmission but it may also change the natural course of HIV infection, for 
instance because of co-infections and/or nutritional deficiencies. In addition, heroin and 
other opioids have immune-modulating effects which might alter the progression of HIV 
infection and/or susceptibility to infections [2-7]. 
Epidemiological studies looking at the association between IDU and the natural course 
of HIV infection have shown contradictory results [3, 8-13]. Most studies used clinical 
endpoints, such as mortality and AIDS-free survival, and were conducted in high-income 
countries, mostly among Caucasian subjects [8-12]. However, factors unrelated to HIV 
infection may significantly skew the relation between IDU and AIDS-free survival. One 
such factor is mortality not related to HIV, which is usually higher among individuals 
injecting drugs [14-16]. Actually, various studies have shown that overdose and suicide 
rather than opportunistic infections are the main cause of death in HIV-positive drug 
users [17]. Furthermore, differences in the occurrence of AIDS defining illnesses, for 
example, Kaposi sarcoma, may also affect the association between risk group and AIDS-
free survival [9]. 
HIV reduces the number of CD4+ T-lymphocytes (CD4 cells), thereby compromising 
cellular immunity. As such, the number of circulating CD4 cells is the primary marker 
for immunodeficiency in HIV-positive patients. Therefore, we determined the association 
between IDU and the natural decline of CD4 cells in HIV-positive ART naïve patients. The 
study was performed in a patient cohort in Indonesia, which has a rapidly growing HIV 
epidemic, largely driven by IDU [18]. To our knowledge, this is the first study addressing 
this issue in a low- or middle-income country.
Methods
Setting and study population
This study was embedded in a five-year programme (2006–11) called “IMPACT”, aimed at 
improving prevention, control and treatment of HIV among injecting drug users in West 
Java, Indonesia [18]. IMPACT has helped establish patient care in three clinics in Bandung, 
the capital of West Java (40 million people): a teaching hospital, a methadone clinic, and a 
prison clinic. In these clinics, people with and without a history of IDU, who are at risk for 
HIV infection or who present with signs and symptoms suggesting HIV/AIDS are counselled 
and tested for HIV. All testing is voluntary and informed consent is obtained from all 
study participants. HIV-positive patients are characterized and followed prospectively 
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in a cohort study, which has been approved by the Health Research Ethics Committee 
at the Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin General Hospital 
in Bandung, Indonesia. Data on demographic factors, history of IDU, co-morbidity, self-
reported tuberculosis treatment and history of antiretroviral therapy (ART) are collected 
through interview with standard questionnaires. Laboratory examinations include CD4 
cell measurement at baseline and fixed time points afterwards. Patients are seen by a 
doctor every 3–6 months if not on ART, and more frequently when ART is initiated. At 
the time of this study, ART was indicated in Indonesia for patients presenting with WHO 
clinical stage IV or a CD4 cell count <200 cells/µl in accordance with WHO guidelines from 
2006. Since 2004, ART can be accessed free of charge in Indonesia.
Data analysis and statistics
In this study, we selected all adults (≥16 years) presenting with HIV infection between 
August 2007 and August 2011, who had not yet been exposed to ART. To determine the 
association between IDU and the natural decline of CD4 cells over time, we included 
all patients who had two or more CD4 cell counts measured at least one month apart, 
with all measurements done before the start of ART. We used a linear mixed model 
to describe the decline of CD4 cells over time and to determine the effect association 
with IDU. To meet all criteria, we transformed all CD4 cell counts to the log scale, which 
enabled us to interpret the results of the mixed models as a relative change in CD4 cells 
after anti-logarithmic transformation. The dependent variable in our final model was 
the log(CD4 cells) at a certain time point. The independent variables were a constant 
estimate, time since baseline in months, IDU, and a quadratic interaction term between 
IDU and months. In addition, the model used a random intercept and random slope 
based on time since baseline. The model with the best fit was chosen, based on the 
likelihood-ratio test and Akaike information criterion (AIC) (the model with lowest AIC has 
the best fit). In addition, we examined possible confounders in the final model, such as 
age, gender, Candida infection, hepatitis C virus (HCV) antibodies and HIV viral load. Each 
variable was added to the final model to examine whether it was associated with the CD4 
cell decline or whether it was a confounder for the association with IDU. These models 
were compared using AIC. HCV viral loads were tested with rt-PCR in a selection of HCV 
antibody -positive individuals to distinguish currently active and previous (cleared) HCV 
infection. All statistical analyses were done using STATA statistical software (version 12.0).
Results
From a total of 1500 HIV-positive ART naïve individuals, 284 met the inclusion criteria; 
145 out of 743 (19.5%) individuals with a history of IDU and 123 out of 608 (20.2%) 
without. The majority were male (56%) with a history of IDU (79% among men) (table 1). 
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More than half (53.8%) of all patients were infected with HCV, and this was 89.6% among 
those with a history of IDU. Patients with and without a history of IDU had similar first 
CD4 cell counts (p=0.945) and similar average time between subsequent measurements 
(197 and 218 days, respectively; p=0.173). The total follow-up time between the first 
and last CD4 cell count before initiating ART was 379 days,  which was not statistically 
different between those with and without a history of IDU (p=0.614). 
Table 1. Characteristics of all HIV-positive patients with at least two subsequent CD4 cell counts 
without ART (N=284).
 Variable
Total population
N=284
% (n/N)
Without a history 
of IDU (N=123)
%(n/N)
With a history 
of  IDU  (N=145)
% (n/N)
Male 56.0 (159/284) 26.0 (32/123) 83.5 (121/145)
Senior high school or university 85.5 (194/227) 76.7 (92/120) 96.9 (94/97)
History of IDU 54.1(145/268) n.a. n.a.
Hepatitis C infection 53.8 (135/251) 9.7 (10/103) 89.6 (121/135)
Candida infection 10.7 (22/206) 5.4 (6/111) 18.2 (16/88)
Median(IQR) Median(IQR) Median(IQR)
Age (years) 28 (26-31) 27 (31-35) 28 (26-31)
Haemoglobin (g/dl) 13.7 (12.3-15.1) 12.8 (11.8-13.9) 14.5 (13.5-15.6)
CD4 cell count (cells/µl) 336 (237-459) 336 (249-444) 337 (222-493)
HIV viral load (log(copies/ml)) 3.47 (2.85-4.06) 3.46 (2.46-3.80) 3.64 (3.01-4.38)
Characteristics of the study population according to history of injecting drug use. All variables 
were measured at baseline.  ART= antiretroviral therapy, N=number of patients, IQR=interquartile 
range, IDU=injecting drug use. 
Almost half of the patients (49.3%) had two serial CD4 cell counts, 20.4% had three CD4 
cell counts, and 16.6% had four CD4 cell counts. The remainder (13.7%) had more than 
five CD4 cell counts, with a maximum of 13 CD4 cell counts. The number of serial CD4 
cell counts was similar between people with and without a history of IDU (p=0.803). The 
median CD4 cell count at baseline differed slightly with the number of serial CD4 cell 
counts available (324 cells/µl for two, 306 cells/µl for three, 407 cells/µl for four and 380 
cells/µl for five or more serial CD4 cell counts; p=0.008). 
42
Chapter 3
3
The natural progression of CD4 cells in HIV-positive ART naïve patients could best be 
described with a model including CD4 cell count at baseline, IDU and time between the 
CD4 cell counts (table 2). The final model was significantly better than a model without 
IDU (likelihood-ratio test χ2 47.3=p<0.001). In this final model, the influence of IDU on the 
decline in CD4 cells was taken into account as a quadratic factor, which fit significantly 
better than the model without this quadratic factor (likelihood-ratio test χ2=48.3, 
p<0.001). In addition, we added a random slope to allow differences between subjects 
within the model (likelihood-ratio test χ2=609.9, p<0.001). 
Table 2. Estimated parameters of the final mixed model describing the course of CD4 cell decline 
in ART naïve HIV-positive patients (n=268).
Variable Estimate (95% CI) P-value
Constant 0.0964 ( 0.0306;  0.1623) 0.004
Baseline CD4 cell count* 0.9623 ( 0.9364;  0.9882) <0.001
IDU -0.0083 (-0.0287;  0.0121) 0.427
Months -0.0093 (-0.0133; -0.0054) <0.001
IDU* Months2 -0.0004 (-0.0005; -0.0003) <0.001
Random-effects parameters
Sd(months) 0.0287
Sd(constant) 3.42 e-13
*All CD4 cell counts were transformed to log scale. ART: antiretroviral therapy; CI: confidence 
interval; IDU: injecting drug use; sd: standard deviation. Months are the number of months 
since first CD4 cell count. Months2 is quadratic term of time in months, to account for non-linear 
effects of time on CD4 cell decline. IDU is taken into the model as baseline variable to determine 
effect on the intercept and as interaction with months to examine the effect of IDU on the slope. 
This model with IDU fitted better than the model without IDU: likelihood-ratio test χ2=47.3 ; 
p-value < 0.001 
The estimates in table 2 can be interpreted as relative change in CD4 cells with each 
unit increase in the variable; this means that the decline in CD4 cells can be noted as 
1–10estimate. This translates in an average decline in CD4 cells of 2.1% per month among 
all HIV-positive ART naïve patients (1–10−0.0093). In addition, those with a history of IDU 
have an additional decline in CD4 cells of 0.09% decrease per month2. Based on our 
data, patients with a history of IDU would have an average 33% decline in CD4 cells after 
one year without ART, compared with a 22% decline among non-users. At two years, 
the decline would average 66 and 40%, respectively (figure 1). Based on the model, the 
predicted CD4 cell decline after one year would be from 600 to 387 cells/µl for subjects 
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with a history of IDU, and from 600 to 455 cells/µl for those without a history of IDU. 
After two years without ART, the predicted CD4 cell count in this model would be 196 
cells/µl for those with a history of IDU, and 351 cells/µl for those without a history of IDU 
(figure 1). Our model includes a random intercept and random slope for all individuals 
used to build this model. Figure 2 shows the fitted and observed values of all subjects 
with at least five CD4 cell measurements.  
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Figure 1. The predicted average decline in CD4 cells of HIV-positive ART naïve patients 
for people without (grey) and with (black) a history of injecting drug use (IDU). The 95% 
confidence intervals are given for people without (grey shaded area) and with (black 
dashed lines) a history of IDU. 
The CD4 cells were predicted with the following model: Log(CD4 cells) = 0.0964 + 
0.9623*log(CD4 cells baseline) - 0.0093*months - 0.0083*IDU - 0.0004 IDU*months2 
(table 2)
We also examined if this association could be explained by confounding. However, neither 
plasma HIV-RNA, gender, age, candidiasis and HCV infection could explain the association 
between IDU and CD4 cell decline (table 3). Adding these variables, independently or 
combined, did not improve the overall fit of the model, as shown by the AIC, or alter 
the estimate of IDU (table 3). HCV-status in our study was based on serological testing, 
which correlated relatively well with circulating HCV virus measured with PCR; among 70 
individuals with HCV antibodies, 59 (84.4%) had a positive plasma HCV-RNA. 
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Table 3. The influence of other variables on the predicted CD4 cell decline. 
Variable Estimate P-value# AIC Estimate IDU* Months2
P-value
 IDU* Months2
Complete model* n.a. n.a. -677.8 -0.00043 <0.001
Plasma HIV-RNA 0.0001 0.977 -455.3 -0.00041 <0.001
Gender -0.0014 0.915 -675.8 -0.00043 <0.001
Age 0.0011 0.274 -676.9 -0.00043 <0.001
Candida infection 0.0025 0.883 -640.7 -0.00043 <0.001
Hepatitis C antibodies 0.0055 0.764 -571.0 -0.00044 <0.001
All variables$ n.a. n.a. -385.0 -0.00045 <0.001
Akaike information criterion (AIC) measures the relative goodness of fit of a statistical 
model; model with lowest AIC has the best fit. n.a.: not applicable. # p-value of the change in 
complete model (as described in table 2) by adding the variable. *Model as described in table 
2: Log (CD4 cell count) = 0.0964 + 0.9623*log (CD4 baseline) - 0.0093*months - 0.0083*IDU - 
0.0004*IDU*months2. $ Including all variables, namely plasma HIV-RNA, gender, age, Candida 
infection and hepatitis C antibodies, in the complete model. 
Discussion
In this study, we show that IDU is associated with a more rapid decline of CD4 cells among 
ART naïve HIV-positive patients in Indonesia. It should be noted that individuals with 
a history of IDU in our cohort are not from a lower or impoverished background that 
might affect disease progression; most had senior high school or university education. 
Instead, we suspect that the faster decline in CD4 cells among injecting drug users can be 
explained by biological factors, such as a direct effect of opioids, a difference in tropism 
or virulence of HIV virus transmitted via IDU, or underlying conditions such as hepatitis 
C virus. Irrespective of the exact mechanism, our findings indicate that HIV disease 
progression should be monitored carefully in injecting drug users. 
We used CD4 cell decline as an accurate and meaningful parameter reflecting the natural 
course of HIV infection. Previous studies on the effect of IDU used clinical endpoints, which 
can be very different between low- and high-income countries [8-12]. In industrialized 
countries, violence and suicide are important causes of death among people who inject 
drugs, while in low-income countries tuberculosis is more prevalent [19]. In addition, 
the type of drug can differ: cocaine use among injecting drug users is rare in Indonesia 
[20] and common in high-income settings. Side effects of cocaine include stroke and 
myocardial infarction, which could also contribute to the clinical endpoints. For these 
reasons, CD4 cell decline is a more meaningful marker to investigate. 
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Figure 1. The predicted average decline in CD4 cells of HIV-positive ART naïve patients 
for people without (grey) and with (black) a history of injecting drug use (IDU). The 95% 
confidence intervals are given for people without (grey shaded area) and with (black 
dashed lines) a history of IDU. 
The CD4 cells were predicted with the following model: Log(CD4 cells) = 0.0964 + 
0.9623*log(CD4 cells baseline) - 0.0093*months - 0.0083*IDU - 0.0004 IDU*months2 
(table 2)
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To our knowledge, this study is the first to show that IDU accelerates CD4 cell decline in 
a low-income setting. Our results support a study from McNeil et al. who used models of 
HIV progression with a square root transformation of CD4 cell counts in a high-income 
setting (Scotland) [12]. Similar to our cohort, 70% of patients in that study had a history 
of IDU and 70% were male. Based on their study population, the authors of that study 
created two models which both showed that individuals infected through IDU tended to 
have a faster CD4 cell decline than those infected through heterosexual contact (p=0.13 
and 0.05) [12] Other epidemiological studies on HIV progression in drug users found 
contradictory results [8, 9, 11, 14, 21]. For instance, men having sex with men had a 
higher AIDS incidence compared to other risk groups in a study using data from several 
cohorts. However, this effect could be explained by the high incidence of Kaposi sarcoma 
(often occurring at relatively higher CD4 cell counts) among men having sex with men [9]. 
Others found that the use of drugs, especially heroin, was associated with faster disease 
progression [11]. However, most studies were conducted in high-income settings, which 
have a different distribution of opportunistic infections, such as tuberculosis. In addition, 
many studies used clinical endpoints instead of CD4 cell counts, or other statistical 
methods, such as Markov models and hazard ratios. Consequently, the outcomes of 
these studies are somewhat difficult to compare with our results. 
Older age has been associated with faster disease progression in several studies [9, 22, 
23]. However, in our patient cohort the age range was small (IQR 26–31 years), which 
could explain why we did not find any association between age and the natural CD4 cell 
decline (p=0.312). HIV viral replication is another variable that may influence the natural 
decline of CD4 cells [8, 24, 25]. Plasma HIV RNA measurements, only introduced recently 
in Indonesia [26], were not associated with CD4 cell decline, and did not modify the 
association between IDU and CD4 cell decline. 
HIV tropism has been associated with HIV progression, with faster CD4 cell decline and 
worse clinical outcome associated with the X4 virus [21, 27, 28]. X4 viruses have been 
found more often among recently infected injecting drug users, which could be explained 
by preferential infection of R5 virus through sexual intercourse [29, 30]. However, another 
study found that X4 viruses were not more common among chronically infected drug 
users [29]. As we did not determine HIV tropism in our study, we cannot exclude a higher 
prevalence of X4 as a factor associated with faster CD4 cell decline. 
Another possible explanation for the more rapid CD4 cell decline among IDUs could be the 
high rate of co-infection with HCV, as previous studies have shown deteriorated clinical 
outcome among HIV-positive individuals with HCV antibodies [31-36]. Indeed, the Swiss 
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Cohort study found that both HCV seropositivity and IDU were independently associated 
with clinical outcome of HIV [34]. However, the relation between HCV infection and CD4 
cell decline prior to ART remains unclear, [31-33, 36, 37] indeed the effects of HCV seems 
to be more pronounced among patients receiving ART [37, 38]. In addition, no correlation 
has been reported between HCV and CD4 cell apoptosis, as a possible explanation for 
a more rapid CD4 cell decline [39]. In our study, the high prevalence (89.6%) of HCV 
infection among injecting drug users made it difficult to study the independent effect of 
HCV. 
Finally, immunomodulating effects of heroin and other opioids could affect the CD4 cell 
decline. In vitro studies have indeed shown that opioids increase the expression of the 
HIV co-receptors CXCR4 and CCR5 and consequently increase viral replication of HIV 
[2-6]. In addition, opioids could influence HIV-mediated apoptosis of both HIV-infected 
and uninfected cells, which is considered an important cause of CD4 cell decline during 
HIV infection. In neuronal cells, morphine was shown to enhance HIV-induced apoptosis 
[40, 41]. Also in immune cells (peripheral blood mononuclear cells), significantly more 
apoptosis was observed when cells were exposed to morphine in combination with HIV 
protein gp120 [42].
In this study, we only selected subjects with at least two CD4 cell counts before initiating 
ART. Only 20% of our cohort fits these criteria, since many patients come at a late stage of 
disease and start ART soon after diagnosis. However, there were no differences between 
individuals with and without a history of IDU in terms of proportion of subjects included, 
baseline characteristics and rates of loss to follow-up. Therefore, it seems unlikely that 
the difference we found in CD4 cell decline was due to selection bias. Also, patient 
characteristics were comparable with those of the total population, suggesting that our 
study population is representative of patients diagnosed with HIV in this setting. However, 
active drug users who are HIV positive (and who might have a different prognosis) 
probably have lower access to health services in Indonesia, and might therefore be 
underrepresented. Overall, we believe selection bias within the HIV clinic was limited, 
but we cannot exclude bias due to differences in health seeking behaviour. 
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Conclusions
In conclusion, we have shown that IDU accelerates the natural decline of CD4 cells in 
HIV patients in Indonesia. In a recent study within the same cohort, we have found that 
a history of IDU in HIV-positive patients does not have a negative effect on virological or 
immunological response to ART, nor on retention to treatment and mortality [18]. These 
findings indicate that HIV disease progression should be monitored carefully in injecting 
drugs users and that earlier initiating of ART should be considered for this risk group. 
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Abstract
Introduction: Injecting drug use (IDU) is associated with tuberculosis but few data are 
available from low-income settings. We examined IDU in relation to active and latent 
tuberculosis (LTBI) among HIV-infected individuals in Indonesia, which has a high burden 
of tuberculosis and a rapidly growing HIV epidemic strongly driven by IDU.
Methods: Active tuberculosis was measured prospectively among 2232 consecutive 
antiretroviral therapy (ART)-naïve adult patients entering care in a clinic in West-Java. 
Prevalence of LTBI was determined cross-sectionally in a subset of 518 ART-experienced 
patients using an interferon-gamma release assay.
Results: Patients with a history of IDU (53.1%) more often reported a history of 
tuberculosis treatment (34.8% versus 21.9%, p<0.001), more often received tuberculosis 
treatment during follow-up (adjusted HR=1.71; 95%CI: 1.25-2.35), and more often had 
bacteriologically confirmed tuberculosis (OR=1.67; 95%CI: 0.94-2.96). LTBI was equally 
prevalent among people with and without a history of IDU (29.1% vs. 30.4%, NS).  None 
of these results were explained by differences in CD4 cell count or ART.
Conclusion: HIV-infected individuals with a history of IDU in Indonesia have more active 
tuberculosis, possibly due to higher rates of progression from latent tuberculosis. 
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Introduction
Tuberculosis is a major global health problem, ranking as the second leading cause of 
death from an infectious disease [1]. Individuals who are more often exposed to M. 
tuberculosis, like alcoholics, homeless people and prisoners, develop more tuberculosis 
[2-4]. However, not everyone who is exposed to M. tuberculosis becomes infected, and 
not all who are infected will develop active tuberculosis [5]. HIV infection and other factors 
which suppress host immunity increase the risk of progression to active tuberculosis after 
LTBI [5]. There are also data to suggest that decreased cellular immunity increases the 
risk of becoming infected after exposure to M. tuberculosis [5].
Injecting drug use (IDU) is associated with active tuberculosis, with most studies coming 
from high-income countries [3, 4, 6-9]. This is usually explained by factors related to higher 
tuberculosis exposure in shooting galleries, dormitories, and prisons [2-4]. HIV-infection 
also contributes to the high tuberculosis burden among injecting drug users. In addition, 
lower utilization of health services, poor treatment compliance and low completion 
rates among drug users may lead to more severe or prolonged tuberculosis, and more 
transmission in this group [2, 10, 11]. However, IDU by itself may be an independent 
risk factor for active tuberculosis [6-8, 12]. Studies examining the association of IDU 
with LTBI have yielded mixed results [13-15]. Besides higher exposure to tuberculosis 
leading to more LTBI, factors related to drug use may also increase the incidence and 
severity of active tuberculosis. For instance, opioids as well as HCV co-infection may have 
immunosuppressive effects [16-20]. This may also explain why drug users more often 
present with extrapulmonary tuberculosis, and more slowly respond to treatment [2, 10, 
21].
So far, epidemiological studies on IDU, HIV and tuberculosis mostly come from high-
resource settings with relative low tuberculosis rates. In addition, few studies have looked 
at the relation of IDU with both latent and active tuberculosis. Therefore, we examined 
the association of IDU with the prevalence of LTBI and incidence of active tuberculosis 
among HIV-infected individuals in Indonesia, which has a high tuberculosis burden and a 
rapidly growing HIV epidemic strongly driven by IDU [22].
Methods
Study population and setting. 
This study was embedded in a programme called ‘IMPACT’, aimed to improve prevention, 
control and treatment of HIV in the context of IDU in West-Java, Indonesia. IMPACT has 
helped establish patient care in clinic of the referral hospital in Bandung, the capital of 
West Java (40 million people). In this clinic people with a history of IDU or high sexual 
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risk behaviour are undergoing voluntary counselling and testing (VCT) [23]. In addition, 
patients may be referred for HIV testing if they present with signs and symptoms 
suggesting HIV/AIDS, such as oral candidiasis, chronic diarrhoea, tuberculosis and 
hepatitis C infection. All testing is voluntary and informed consent is obtained from all 
study participants. HIV-infected patients are characterised and followed prospectively 
in a cohort study, which has been approved by the Health Research Ethics Committee 
at the Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin General Hospital 
in Bandung, Indonesia. Data on demographic factors, history of IDU, co-morbidity, self-
reported tuberculosis treatment and history of antiretroviral therapy (ART) are collected 
through interview with standard questionnaires. Laboratory examinations include CD4 
cell measurement at baseline and regularly afterwards. Patients were seen by a doctor 
every month or if they had clinical symptoms, during which patients were examined 
for oral thrush and tuberculosis-suggestive symptoms. ART is indicated in Indonesia for 
patients presenting with WHO clinical stage IV or a CD4 count less than 350 cells/µl in 
accordance with WHO guidelines from 2006. Since 2004, ART can be accessed free of 
charge in Indonesia. 
Cohort study: active tuberculosis
To determine the association between IDU and the incidence of HIV-associated 
tuberculosis we used data collected at the HIV clinic. For this study, we selected all adults 
(≥16 years) presenting with HIV infection between August 2007 and January 2013, and 
who were ART-naïve at time of first presentation (figure 1). Follow-up data was included 
up to August 2013. Patients were censored either at their last visit or on first of August 
2013. Time of follow-up was considered zero for all patients enrolled without a follow-
up visit. We used tuberculosis treatment as an indicator for active tuberculosis, since 
the diagnosis of active tuberculosis and decision to start tuberculosis treatment was 
often based on clinical symptoms and chest X-ray. During clinic visits patients were 
asked whether they were taking tuberculosis treatment, and prescription of tuberculosis 
treatment by the doctors in the HIV clinic was recorded. We also analysed data from all 
HIV-infected patients with sputum examination results. Sputum was collected in the HIV 
clinic and examined using Ziehl-Nielsen or fluorescence microscopy and M. tuberculosis 
culture using solid media or MODS [24]. Bacteriological confirmed tuberculosis was 
defined as positive microscopy (either Ziehl-Nielsen or fluorescence microscopy) or M. 
tuberculosis culture (either solid media or MODS). All patients who already received 
tuberculosis treatment at baseline were excluded from this analysis (figure 1). 
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Cross sectional study: latent tuberculosis infection (LTBI)
Latent tuberculosis infection was examined in a cross sectional study among HIV-infected 
patients visiting the HIV clinic between April 2012 and April 2013. Testing for LTBI was 
implemented in daily practice, in which the first priority is to exclude active tuberculosis 
at time of enrolment in HIV care or shortly after start of ART (‘unmasking tuberculosis’). 
Afterwards patients were screened and tested for LTBI. Patients receiving ART for less 
than three months were excluded, as the CD4 cell count for those patients are often very 
low in this population [22]. After informed consent all patients were interviewed and 
examined. BCG vaccination was based on visual confirmation of a scar and self-report, 
oral thrush was diagnosed by the physician. Exposure to tuberculosis inside and outside 
the household was based on self-reported contact with individuals receiving tuberculosis 
treatment.
Figure 1. HIV-infected subjects, who were ART- and TB-treatment naïve were followed 
prospectively and compared according to tuberculosis treatment status during follow-
up.HIV: Human immunodeficiency; ART: antiretroviral therapy; TB: tuberculosis.
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To determine LTBI we used an interferon-gamma release assay, namely Quantiferon Gold 
In-tube assay, which was performed according to manufacturer’s instruction. Briefly, blood 
was collected in the provided tubes; nil control, tuberculosis antigen and mitogen control. 
Tubes were immediately incubated for 16 to 24 hours at 37°C. After centrifugation, we 
collected the supernatant and stored the samples at 80°C until ELISA could be performed 
to determine IFN-γ production. Individuals were categorised as positive for LTBI when 
the tuberculosis antigen minus the nil control was higher than 0.35 IU/ml and over 25% 
of the nil control. All samples with high nil controls (>8.0 IU/ml) or low mitogen controls 
(<0.50 IU/ml) were seen as indeterminate.  All patients with LTBI were seen by a doctor 
and examined for active tuberculosis. When active tuberculosis was ruled out patients 
received Isoniazid Preventive Therapy (IPT) for six months according to WHO guidelines. 
Data analysis and statistics
Quantitative variables were expressed as median and interquartile ranges (IQR) and 
categorical variables as frequencies. Comparison between groups was performed 
using the Mann-Whiney test and Chi-square. The effect of IDU on the incidence of HIV-
associated tuberculosis was examined using univariate and multivariate Cox proportional 
hazard regression analyses. Proportionality assumption was verified for all variables 
using Kaplan-Meier analyses. Haemoglobin was used as proxy for nutritional status, 
since BMI was missing for a large proportion of the study population (29.6%; 660/2232). 
ART initiation was taken into account as a time-dependent covariate in Cox proportional 
hazard model, since time on ART is associated with decreased risk of progression to 
active tuberculosis. Laboratory confirmed tuberculosis was examined with univariate and 
multivariate logistic regression analyses, since exact time of diagnosis was not always 
provided.
The LTBI prevalence in relation to IDU was examined using univariate regression analyses. 
The influence of possible confounders, such as previous active tuberculosis infection, 
exposure to tuberculosis and CD4 cell counts were explored using multivariate regression 
analyses. The variables tested were chosen based on literature and used in both univariate 
and multivariate analyses. We assessed the fit of all models using -2 log likelihood.  All 
statistical analyses were done using SPSS statistical software (version 20.0). 
Results
In total 2607 HIV-infected patients were enrolled at the HIV clinic during the study period, 
of these 251 already received ART and four individuals had no information about ART 
use (figure 1). Information on IDU was available for 1900 individuals; the 332 individuals 
with missing data did not differ from those with data on IDU. The majority of HIV-
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infected patients had a history of IDU (53.1%; 1009/1900). Those with a history of IDU 
were mostly male (90.6%; 914/1009), often with high education; 33.0% (325/986) had 
a university degree versus 27.4% (225/821) in the group without a history of IDU. At 
baseline, individuals with a history of IDU were more likely to present with advanced HIV 
infection (table 1), with more infections (such as oral thrush) and lower CD4 cell counts; 
the median CD4 cell count in this group was 71 cells/µl compared to 158 cells/µl among 
those without a history of IDU (table 1). Similarly, WHO stage IV was present in 49.5% of 
those with a history of IDU, and 33.7% of those without. 
Table 1. Characteristics of HIV-infected treatment naïve patients with and without a history of 
injecting drug use (IDU).*
With history of 
IDU (n=1009)
Without history of 
IDU (n=891)
p-value
Oral thrush (%) 40.8 29.8 <0.001
Hepatitis C antibodies (%) 90.2 12.8 <0.001
Mortality during follow-up (%) 8.9 6.7 0.078
Start ART during follow-up (%) 69.8 56.7 <0.001
Median CD4 cell count, cells/µl (IQR) 71 (18-249) 157 (31-340) <0.001
Median haemoglobin level, g/dl (IQR) 13.2 (11.3-14.8) 12.1 (10.4-13.4) <0.001
Median BMI, kg/m2 (IQR) 19.2 (17.3-21.6) 19.9 (17.6-22.7) 0.002
Median follow-up, days (IQR) 686 (83-1575) 237 (24-951) <0.001
Tuberculosis symptoms and treatment status (%)
History of tuberculosis treatment (%) 34.8 21.9 <0.001
Weight loss (>10%) 38.4 32.6 0.011
Chronic cough (>3weeks) 21.3 22.2 0.677
Night sweats 1.6 2.7 0.093
Fever (>1 week) 28.5 24.6 0.058
At least one of above symptoms 48.3 41.9 0.005
Tuberculosis treatment during follow-up# 17.5 10.1 <0.001
*Unless stated otherwise, data is given as percentage (numerator/denominators). # Individuals 
receiving tuberculosis treatment either at the HIV clinic or at the hospital, based on medical 
status and pharmacy records. IDU: injecting drug use; ART: antiretroviral therapy; IQR: 
interquartile range; BMI: body mass index.
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Data on reported previous tuberculosis treatment were available for 1824 out of 2232 
patients who were ART-naïve and not taking tuberculosis medication at time of enrolment 
in the study. Almost one third of this group (29.2%) reported to have previously taken 
tuberculosis treatment. HIV-infected patients with a history of IDU significantly (p<0.001) 
more often had a history of tuberculosis treatment (34.8%) than those without a history 
of IDU (21.9%, table 1). At baseline, patients with a history of IDU did not have more 
symptoms suggesting tuberculosis; weight loss and fever were more common, but chronic 
cough and night sweats were not (table 1). Patients with a history of IDU were more likely 
to report any of these symptoms, but this difference disappeared after correction for CD4 
cell count (adjusted OR=0.92; 95%CI: 0.74-1.15). The same was found when symptoms 
were analysed separately (data not shown). 
A history of IDU was also associated with tuberculosis treatment during follow-up, which 
occurred in 293 out of 2232 patients (13.1%), for whom this information was available 
(figure 1). Patients with a history of IDU were 1.7 times more likely to receive tuberculosis 
treatment in the first year after enrolment in HIV care, also after adjustment for possible 
confounders (table 2 and figure 2). Tuberculosis treatment was mostly prescribed in 
the first few months after enrolment in care. The majority of tuberculosis cases (55.3%) 
were diagnosed before start of ART, 18.4% within three months of ART, 12.3% after three 
months of ART, while 14.0% of HIV-infected patients treated for tuberculosis did not 
receive ART during the follow-up period. The higher incidence of tuberculosis among HIV-
infected patients with a history of IDU remained significant with longer follow-up, with 
an adjusted hazard ratio of 1.54 (95%CI: 1.15-2.07) during two years and 1.52 (95%CI: 
1.13-2.06) during three years of follow-up after enrolment in HIV care. When excluding 
everyone with previous tuberculosis, patients with a history of IDU still had significantly 
more tuberculosis (14.0% versus 8.0%), with an adjusted hazard ratio of 2.07 (95%CI: 
1.30-3.28) for patients with a history of IDU in the first year after enrolment in HIV care.
To determine if the higher incidence of active tuberculosis could be explained by a higher 
prevalence of latent tuberculosis, we performed a cross sectional study on the prevalence 
of LTBI (table 3). A total of 524 HIV-infected individuals who were ART-experienced 
(median 41 months; IQR: 26-61 months) and who had a median CD4 cell count of 373 
(IQR: 268 – 518) were included. Table 3 shows the characteristic of the study population 
at the time to testing for LTBI. Among them 29.2% had a positive Quantiferon test; this 
was not different among patients with and without a history of IDU (28.5% and 30.3% 
respectively; figure 3). Also after adjustment for age, CD4 cell count, haemoglobin and 
ART, no association was found between latent tuberculosis and a history of IDU (adjusted 
OR=0.91; 95%CI: 0.59-1.40; p-value=0.658). 
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Table 2. Factors associated with active tuberculosis during one year follow-up of ART-naïve 
patients entering HIV care (n=2232).
Factors*          Univariate        Multivariate
HR (95%CI) p-value HR (95%CI) p-value
History of injecting drug use 1.76 (1.33-2.32) <0.001 1.71 (1.25-2.35) 0.001
CD4 cell count, per 10 cells/µl 0.94 (0.93-0.96) <0.001 0.97 (0.95-0.98) <0.001
Age 1.03 (1.01-1.04) 0.007 1.02 (0.99-1.04) 0.199
Haemoglobin, g/dl 0.78 (0.74-0.81) <0.001 0.83 (0.78-0.88) <0.001
Oral thrush 3.43 (2.64-4.46) <0.001 1.66 (1.19-2.29) 0.002
Antiretroviral therapy# 1.22 (0.95-1.57) 0.122 0.91 (0.68-1.23) 0.555
*Factors are determined at enrolment in HIV care.  #Antiretroviral therapy was taken into account 
as time dependent variable.  All variables tested were chosen for their relation with tuberculosis 
based on literature. All variables were tested in both univariate and multivariate analyses. 
Multivariate analysis was based on 1587 (71.1%) individuals, due to missing information on 
injecting drug use (n=332), CD4 cell count (n=367), age (n=44), haemoglobin (n=381), oral 
thrush (n=333) and antiretroviral therapy (n=2). ART: antiretroviral therapy; HR: hazard ratio; 
CI: confidence interval
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Figure 2. Tuberculosis Incidence for treatment naïve HIV-infected individuals with (black) 
and without (grey) a history of injecting drug use (IDU) in the first year after enrolment 
in HIV care (n=2232). Tuberculosis incidence was more common among patients with a 
history of IDU, also when corrected for age, CD4 cell count, haemoglobin, antiretroviral 
therapy and oral thrush (adjusted hazard ratio 1.71 with 95%CI: 1.25-2.35)
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Table 3. Characteristics of HIV-infected patients (n=524) with and without a history of injecting 
drug use (IDU) who were tested for latent tuberculosis infection (LTBI).*
With history of 
IDU (n=312)
Without history 
of IDU (n=212)
p-value
Median age, years (IQR) 33 (30-35) 31 (28-36) 0.001
Male 91.3 (285/312) 31.1 (66/212) <0.001
Married 56.1 (175/312) 55.7 (118/212) 0.923
Oral thrush 3.6 (11/209) 1.9 (4/210) 0.269
Median BMI, kg/m2 (IQR) 20.8 (19.2-22.7) 21.4 (19.0-23.4) 0.225
Median CD4 cells, cells/µl (IQR) 373 (269-522) 377 (263-510) 0.588
Median haemoglobin, g/dl (IQR) 14.4 (13.3-15.3) 12.9 (11.7-14.0) <0.001
Median time on ART, months (IQR) 49 (34-73) 31 (18-48) <0.001
Tuberculosis related characteristics*
IGRA positive# 28.5 (88/309) 30.3 (63/208) 0.657
BCG vaccination$ 75.2 (233/310) 78.1 (164/210) 0.440
Current smoking 87.8 (274/312) 34.6 (73/211) <0.001
History of tuberculosis treatment 46.9 (144/307) 31.4 (66/144) <0.001
Exposed to tuberculosis in household 9.8 (20/305) 30.0 (61/203) <0.001
Exposed to tuberculosis outside household 33.2 (80/241) 25.8 (41/159) 0.114
*Unless stated otherwise, data is given as percentage (numerator/denominators). # IGRA 
positive:  interferon-gamma release assay (Quantiferon Gold In-Tube) was used to determine 
latent tuberculosis infection. Individuals were classified as positive when tuberculosis antigen 
minus the nil control was higher than 0.35 IU/ml and over 25% of the nil control. $ BCG vaccination 
was based on visual confirmation by a physician or self-reported in case visual confirmation was 
indeterminate. IDU: injecting drug use; IQR: interquartile range; BMI: body mass index; ART: 
antiretroviral therapy; IGRA: interferon-gamma release assay.
Discussion
In this large cohort of patients presenting with advanced HIV infection in Indonesia, those 
with a history of IDU were more likely to have a history of tuberculosis treatment, to 
start tuberculosis treatment, and to have bacteriological confirmed tuberculosis. The 
prevalence of LTBI was not different, which may suggest that HIV-infected patients with a 
history of IDU have a higher risk of progression to active tuberculosis after M. tuberculosis 
infection. 
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Our results on active tuberculosis are consistent with those of other studies, which found 
a two to three times increased risk in active tuberculosis among injecting drug users [6-8, 
25]. Yet these studies took place in high-income countries with low tuberculosis burden. 
One of the few studies in developing countries is that of Cain et al, who evaluated a 
diagnostic algorithm for tuberculosis among HIV-infected individuals in Cambodia, 
Thailand and Vietnam [26]. Although not primarily designed to address this question, 
the prevalence of active tuberculosis was more than three times higher in injecting drug 
users in this cohort. 
Lower access to health services, poor treatment compliance and increased exposure to 
M. tuberculosis, because of homelessness, crowding and incarceration [2-4], increase 
the tuberculosis risk among drug users. However, we do not expect higher exposure to 
M. tuberculosis among HIV-infected patients with a history of IDU in Indonesia, where 
interestingly enough HIV and IDU are often associated with higher education and socio-
demographic background [22, 27]. In addition, they are not a community with additional 
risk factors, such as homelessness, unemployment and crowding, as seen in western 
countries. This and the fact that tuberculosis is endemic in Indonesia implicate that 
tuberculosis exposure is comparable in people with and without a history of IDU in this 
setting. In addition, we previously showed that patients with and without a history of 
IDU receiving ART have similar outcomes with regards to treatment adherence, mortality 
rates, loss to follow-up rates and virological failure [22]. A recent study in China has shown 
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Figure 3 The proportion of HIV-infected with (grey) and without (black) a history of in-
jecting drug use who were IGRA-positive. HIV: Human immunodeficiency virus; IGRA: 
interferon gamma release assay.
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that among people receiving methadone maintenance treatment IDU is a risk factor for 
tuberculosis [28], which is in line with our results. 
The prevalence of LTBI was similar in patients with and without a history of IDU in this 
setting. Earlier studies comparing the prevalence of LTBI between injecting drugs users 
and non-users have shown mixed results [15, 29]. We diagnosed LTBI using IGRA, because 
Indonesia has routine BCG and since IGRA, unlike the Mantoux tuberculin skin test, does 
not require a return visit. There was possibly selection bias, since we did not include 
patients diagnosed with or presenting with symptoms suggestion tuberculosis. However, 
we expect this bias to be limited, since most cases of tuberculosis were diagnosed in the 
first period after enrolment in HIV care (figure 2) and the majority of patients tested for 
LTBI were receiving ART for over two years. Therefore only few patients were excluded 
due to diagnosis of active tuberculosis. In addition, the long duration of ART might affect 
the proportion of individuals with a positive IGRA. However, we do not expect that the 
exposure to tuberculosis is affected by ART and therefore we regard this bias to be 
neglectable. 
Our results provide support for the hypothesis that underlying biological factors in 
addition to increased exposure and infection rates can contribute to a higher risk of 
active tuberculosis in injecting drug users. A possible explanation is that opioids affect 
the immune response directly; in vitro and animal studies have found deleterious effects 
of opioids in infections [20]. In relation to mycobacteria specifically, studies show mixed 
results; some finding advantageous effects of opioids [30], others showing deleterious 
effects [31, 32]. Another explanation could be co-infection with chronic hepatitis C, which 
is highly prevalent among injecting drug users, often in combination with HIV. There is no 
clear association between hepatitis C infection and HIV disease progression [18]. However, 
hepatitis C co-infection could impair cellular immunity, which is not fully explained by 
CD4 cell counts alone. Also hepatitis C infection is known to cause iron overload and 
the risk of tuberculosis disease is correlated with iron levels [33]. Therefore, hepatitis C 
infection could result in an increased risk of tuberculosis disease via iron amplification. 
In our study population hepatitis C is strongly related to IDU [27] and therefore we could 
not examine the separate effect of hepatitis C in this study.
We adjusted our results for CD4 cell count as proxy for immune suppression in HIV 
infection. However, previous studies have shown that the total amount of CD4 cells does 
not correlate with the amount of CD4 cells specific for M. Tuberculosis [34, 35]. HIV-
infected patients with a history of IDU in this cohort have been found to have a faster 
decline in CD4 cells [27]. In theory, they could have a preferential depletion of these 
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specific M. tuberculosis CD4 cells and therefore adjustment for CD4 cells might not be 
adequate. 
Most patients in our cohort were diagnosed with tuberculosis within the first few 
months after enrolment in HIV care. The majority of individuals start ART after diagnosis 
of tuberculosis, which suggests that individuals go to the HIV clinic when symptoms 
of tuberculosis arise. In addition, we show that in 18.4% initiation of ART ‘unmasked’ 
tuberculosis [36]. In our study, HIV-infected patients with a history of IDU more often 
report a history of previous tuberculosis treatment, and were more often treated for 
tuberculosis during follow-up, although rates of latent tuberculosis were similar. 
In this study we used tuberculosis treatment as an indicator for active tuberculosis. 
Ideally, bacteriological examination would be used as endpoint, but unfortunately this 
was only available for a small proportion of patients. Tuberculosis treatment could be 
influenced by indication bias; doctors might be more likely to prescribe tuberculosis 
treatment to people with a history of drug use. However, sensitivity analysis using data 
from the bacteriological examination showed a similar trend, indicating that probably 
no bias took place with regard to prescribing tuberculosis treatment. Possibly, overall 
immune suppression of opioids masks tuberculosis and therefore more tuberculosis 
is unmasked in people with a history of IDU. Yet, we also see a higher prevalence of 
previous tuberculosis treatment and therefore, it seems that HIV-infected individuals 
with a history of IDU are at higher risk of progression to active tuberculosis.
Our findings have implications for health policy and practice. First, people with a history 
of IDU should be actively tested for HIV, and HIV treatment should be started according to 
WHO guidelines. Especially since ART has been shown to protect against development of 
tuberculosis, irrespective of CD4 cell count [37]. In addition, testing for LTBI and IPT could 
be prioritized to patients with a history of IDU. Active case finding might be improved by 
involving local NGOs and educating people about the risk when not treated in time.
 
Conclusion
The results from this study suggest that active tuberculosis is more prevalent among 
people with a history of IDU, which cannot be explained by higher rates of LTBI. However, 
further research in regarding the role of opioids and HCV co-infection would help 
establish the precise contribution of biological factors to the increased tuberculosis risk 
among with a history of IDU.
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Abstract 
Background: The HIV co-receptors CXCR4 and CCR5 play an important role in HIV infection 
and replication. Therefore we hypothesize that long-term non-progressors (LTNP) with 
viral control have lower expression of CCR5 and CXCR4 on CD4+ cells, specifically on 
memory T-lymphocytes since they are the primary target cells of HIV. 
Methods: In this cross-sectional study, we included five HIV-infected LTNP with viral 
control (CD4>750cell/µl & HIV<50 copies for ≥2years), thirteen HIV-infected and seven 
HIV-uninfected individuals at Radboud UMC Nijmegen, the Netherlands. We determined 
the CCR5 and CXCR4 expression among CD4+ and CD8+ lymphocyte subsets; memory 
(CD45RO+), naïve (CD45RA+) cells and regulatory T-cells (CD4+CD25highFoxP3+). In addition, 
CCR5∆32 polymorphism is related with disease progression and was therefore determined 
using polymerase chain reaction.
Results: The percentage of CCR5-expressing CD4+ cells of LTNP was comparable with 
healthy controls; whereas HIV-infected individuals showed more CCR5-expressing cells. 
This was observed in memory and naïve CD4+ cells, but not in regulatory T-cells. The mean 
fluorescence intensity of CCR5-expressing CD4+ cells was similar in all groups. All groups 
had comparable percentages of CXCR4-expressing cells. The mean fluorescence intensity 
of CXCR4-expressing cells was significantly higher in HIV-infected normally progressors 
in both memory and naïve CD4+ cells, but not in CD8+ cells. The CCR5∆32 polymorphism 
was not related to group. 
Conclusions: We show that HIV affects -directly or indirectly- the expression of CCR5 in CD4+ 
T-lymphocytes; yet this effect is not seen in LTNP with viral control. Avoiding upregulation 
of CCR5 could be an important method via which LTNP counteracts the effects of HIV and 
suppresses viral replication. Exploring how LTNP suppress the upregulation of CCR5 could 
be an important step for discovering new therapeutics.
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Introduction
Human immunodeficiency virus (HIV) infects and destroys CD4+ T-lymphocytes. Resting 
CD4+ T-lymphocytes are a reservoir of HIV infection; subsets of these lymphocytes are 
differentially affected by HIV and subdividing these cells in memory and naïve cells can 
provide better understanding of their individual roles [1, 2]. Memory T-lymphocytes 
are preferentially targeted by HIV, whereas increased numbers of regulatory T-cells 
are associated with disease progression [3]. The density of the CD4 surface marker is 
associated with both HIV RNA viral load and disease progression [4]. In addition to CD4 
receptors HIV requires a co-receptor, either CCR5 or CXCR4, to invade cells. In general, HIV 
isolated from newly infected individuals uses CCR5 and these “R5 variants” are detectable 
over the entire course of the HIV infection [5]. The X4 variants, that utilize CXCR4, are 
mostly detectible at a late stage of the disease and in only up to 50% of all patients [6]. 
Both co-receptors are expressed on leukocytes, but to different extents on different T-cell 
subsets [7, 8]. CXCR4 is predominantly found on resting, naive T-lymphocytes, whereas 
CCR5 is expressed on mostly memory T-lymphocytes. Therefore activated CD4+CCR5+ 
T-lymphocytes are the primary target and an optimal subset for virus replication [2]. 
The number of circulating CD4 cells accurately reflects the extent of immunodeficiency 
in HIV-infected patients. Most HIV-infected patients exhibit a gradual decline in CD4 cells 
throughout the course of their infection; the rate of disease progression from asymptomatic 
HIV infection to AIDS varies between patients. Some HIV patients are able to maintain 
stable CD4 cell counts for an extended time and remain asymptomatic without ART for 
years after infection. These patients have been referred to as long-term non-progressors 
(LTNP). Unfortunately, the underlying mechanisms for the interindividual variability and 
slow progression of HIV are poorly understood. Understanding mechanisms that are 
associated with slow progression will help identify new targets for treatment and even 
prevention of HIV infection. 
The HIV co-receptors CCR5 and CXCR4 could play a crucial role in the progression of HIV 
and non-progression among LTNP. A well-known polymorphism in the CCR5 gene, namely 
CCR5∆32 (a 32 base pair deletion in the CCR5 gene) interrupts the entrance of HIV into 
cells and individuals homozygous for this deletion are almost completely resistant to 
HIV infection [9-12]. And individuals who are heterozygous for the CCR5∆32 have shown 
slower progression of HIV [9, 13-15]. Also the expression of CCR5 and CXCR4 is, in 
addition to CD4, extremely important in the susceptibility of cells to HIV infection [16] 
and viral replication [17, 18]. Previous studies have shown that the expression of CCR5 
increased with HIV disease progression, a phenomenon that is reversed by antiretroviral 
therapy (ART) [19]; indicating that CCR5 expression is important in disease progression. 
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Not only the receptors, but also its ligands (MIP-1α/CCL3, MIP- 1β/CCL4 and RANTES/
CCL5 for CCR5 and SDF-1/CXCL12 for CXCR4) have the ability to block HIV activity [12]. 
Unfortunately, only little information is available on the expression of CXCR4 and CCR5 
on different subsets of T-lymphocytes, especially in relation to LTNP. Therefore, we 
have explored differences in the expression of CCR5 and CXCR4 in different subsets of 
T-lymphocytes in LTNP with viral control.
Methods and Materials
Study population
HIV seropositive, ART-naïve subjects above 18 years of age were included at the HIV-clinic 
of the Radboud University Nijmegen Medical Centre, the Netherlands. LTNP with viral 
control were defined as those with a CD4 cell count above 750 cells/µl and a HIV viral 
load below 50 copies/ml for at least 2 years [10, 20]. HIV-infected subjects that did not fit 
these criteria were classified as HIV-infected normal progressors, and HIV seronegative 
healthy individuals were used as controls. Blood samples of LTNP were always examined 
in parallel with samples from a healthy control donor and multiple HIV-infected normal 
progressors. Blood samples were used for standard hematologic blood parameters and 
flow cytometry. 
Ethics 
This study was presented to the institutional review board of Radboud UMC in Nijmegen, 
the Netherlands. We received a waiver for blood collection of HIV infected individuals 
and approval for blood collection of healthy controls from the Medical Ethical Committee 
Nijmegen in the Netherlands. All participants, including healthy controls, were informed 
about giving blood samples for this specific study and provided written consent. During 
a routine appointment, nurses in the clinic collected the blood samples and provided 
these to us anonymously. None of the researchers had access to participants personal 
identifying data and all data was analysed anonymously. 
Flow cytometry
Cells were phenotypically analysed by five-colour flow cytometry (Coulter Cytomics 
FC 500, Beckman Coulter, Fullerton, CA) using Coulter Epics Expo 32 software. Both 
peripheral blood mononuclear cells (PBMC) and whole blood (after red cell lysis) were 
used for flow cytometric analysis. PBMC were isolated by density centrifugation on 
Ficoll-Hypaque (Pharmacia Biotech, Uppsala, Sweden). Red cell lysis of whole blood was 
performed according to the manufacturer’s instruction (BD PharmLyse, Becton Dickinson 
Biosciences, San Jose, USA). Cells were washed with phosphate-buffered saline (PBS) with 
1% bovine serum albumin (BSA) before being incubated with fluorochrome- conjugated 
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mAbs. After incubation for 20 min at room temperature, cells were washed twice to 
remove unbound antibodies and analysed. For cell surface staining, the following mAbs 
were used: CD25-PECy7 (BC96), CD127 PECy5  and PECy7 labelled (RDR5) from eBioscience 
(San Diego, USA); CD3-ECD (UCHT1) and CD4-ECD (SFCI12T4D11) from  Beckman Coulter 
(San Diego, USA); CD4-PECy7 (RPA-T4), CD8-PECy7 (HIT8a), CD45-APC (HI30), CD14-APC 
(M5E2), CD19-PECy7 (HIB19), CD45RO-APC (UCHL1), CD45RA-APC (HI100), CXCR4-PE 
(12G5), CCR5-FITC (HEK/1/85a) from Biolegend (San Diego, USA). Appropriate isotype 
control mAbs were used for gate settings. Due to limited amount of filters per sample 
memory and naïve lymphocytes were identified using CD3 and CD4 in combination with 
CD45RO or CD45RA respectively. The live gate was set based on the forward angle light 
scatter (FSCs) and the side angle light scatter (SSCs). For intracellular staining for FoxP3 
we used FoxP3-APC antibodies (PCP101; eBioscience). Before intracellular staining, cells 
were fixed and permeabilised using Fix and Perm reagent according to the manufacturer’s 
recommendations (eBioscience). 
DNA isolation and polymerase chain reaction
DNA was isolated from PBMCs by Puregene DNA isolation kits (Gentra Puregene blood 
kit, Qiagen, Hilden, Germany) according to manufacturer’s instruction. Briefly, cells 
were lysed overnight at 370C before adding protein precipitation solution. DNA was 
purified using isopropanol, washed with 70% ethanol, and then diluted in 10µl of DNA 
hydrolysation solution and incubated overnight at 370C. Hydrolysation solution without 
DNA was used as a negative control. DNA concentrations were measured using Nanodrop 
and samples were stored at 40C until analysis. To determine the 32bp deletion in the CCR5 
gene (CCR5∆32) we used polymerase chain reaction (PCR) with the following primers: 
forward primer 5’-ATCACTTGGGTGGTGGCTGTGTTTGCGTCTC-3’ and reverse primer 
3’-GACGGCGACGAACAGTACCAGTAGACGATGA-5’, corresponding to bases 505-535 and 
667-697 [21]. Genomic DNA from each individual was amplified in a total volume of 25uL 
in a buffer containing 10µM of each primer. The cycling conditions were: denaturation 
at 94°C for 5 min (1cycle), followed 94°C for 60sec and 70°C for 30 sec for 35 cycles. The 
CCR5∆32 polymorphism was detected with electrophoresis with 4% agarose gel stained 
with ethidium bromide. The normal allele size is 193bp and the allele size for the deletion 
is 161bp.
Statistical analyses
We selected subsets of cells by first gating on live cells and subsequently on CD45+ cells. 
Within these gated cells we defined the subsets as follows: monocytes: CD14+; B-cells: 
CD19+; T-lymphocytes: CD3+. In the CD3+ cells we gated on either on CD4+ or CD8+ cells. 
Further, within these CD4+ or CD8+ cells we identified CD45RA+ (naive), CD45RO+ (memory) 
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and CD25highFoxP3+ (regulatory) (figure 1). For all cell subtypes, expression of HIV co-
receptors CCR5 and CXCR4 was measured as proportion (%) of positive cells, as well as 
mean fluorescence intensity (MFI) of positive cells. The Kruskal Wallis and Mann Whitney 
analyses were used to compare differences between groups. The level of significance was 
set at 10%. All statistical analysis was performed using the Statistical Product and Services 
Solutions package version 18.0 and GraphPad Prism version 5.0.
Results
We included five HIV-infected LTNP with viral control, thirteen HIV-infected normal 
progressors and seven healthy controls. None of the HIV-infected subjects took ART at 
time of blood collection or previously. The characteristics of the subjects are shown in 
table 1; as expected the median CD4 cells were higher and the viral load was lower in 
HIV-infected LTNP than in normal progressors. HIV was diagnosed a median of eight years 
(range: 3-14 years) for LTNP and a median of three and a half years (range: 1-7 years) for 
other HIV infected individuals.
Figure 1 Examples of how CD3+CD4+CD45RO+ (A)  and CD4+CD25highFoxP3+ (B) cells were 
selected. A) Cells were first gated on CD3+CD4+ (green), selected cells were then split in 
CD45RO+ and CD45RO- cells. Within this subset the expression of CCR5 and CXCR4 was 
determined. B) Regulatory T-cells were selected by gating on CD4+ and CD25high cells, and 
only FOXP3+ cells were used for analyses.
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Table 1. Characteristics of ART-naïve HIV-infected individuals and controls (n=25)
HIV-infected Healthy controls
LTNP Normal progressors
Number 5 13 7
Median age, years 49 39 41
Median CD4 cells, cells/µl 1240 565 n.a.
Median Log (viral load) 0 4.3 n.a.
ART: antiretroviral therapy; HIV: human immunodeficiency virus; LTNP: long-term non-
progressors IQR: interquartile range
Differences in cell type distribution between groups were most pronounced for CD4+ 
subtypes (table 2). As expected, HIV-infected normal progressors had significantly lower 
CD4+ T-cell counts compared to LTNP and healthy controls (table 2). This difference 
was found for all CD4+ subsets: memory (CD45RO+), naïve (CD45RA+) and regulatory 
(CD25highFoxP3+ cells) T-lymphocytes. 
Table 2: Overview of cell types and expression of CCR5 and CXCR4 for HIV-infected and 
uninfected individuals.
Cell type* Control LTNP HIV p-value
Total white blood cells,  n (*106/L) 6043 7060 5846 0.214
CD14+ of CD45+ cells 9.0 8.2 10.1 0.186
CD3+ of CD45+ cells 24.7 29.9 30.7 0.188
CD8+CD3+ of CD45+ cells 7.2 11.5 19.1 0.003
CCR5+ 50.6 43.1 57.8 0.161
CXCR4+ 92.2 97.4 95.1 0.590
CD4+CD3+ of CD45+ cells 14.94 16.62 8.99 0.018
CCR5+ 22.5 16.9 30.0 0.014
CXCR4+ 70.2 83.7 71.9 0.185
CD45RO+ of CD3+CD4+ cells 49.6 45.6 52.6 0.360
CCR5+ 40.1 30.5 44.4 0.065
CXCR4+ 45.8 70.6 57.7 0.191
CD45RA+ of CD3+CD4+ cells 45.4 52.6 44.5 0.396
CCR5+ 6.4 8.5 18.6 0.018
CXCR4+ 91.6 94.6 90.3 0.595
CD25highFoxP3+ of CD3+CD4+cells 6.5 4.8 5.4 0.091
CCR5+ 49.1 41.9 49.4 0.790
CXCR4+ 97.9 98.2 95.6 0.712
*Data are given as percentage unless stated otherwise. Groups were compared with 
Kruskal-Wallis analyses. HIV: human immunodeficiency virus; LTNP: long-term non-
progressors; Controls: HIV uninfected healthy controls.
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Expression of the HIV co-receptor CCR5 on CD4+ T-cells was similar in LTNP and healthy 
controls; both groups showed lower CCR5 expression compared to HIV-infected normal 
progressors (figure 2A). When CD4-cell subsets were analysed, this difference was 
observed in memory and naïve T-lymphocytes (p-values: 0.007 and 0.046 respectively), 
but not in regulatory T-cells (p=0.443) (figure 2A). CD8+ T-lymphocytes did not show a 
difference in CCR5 expression. 
The MFI of CCR5-expressing cells in CD4+ T-lymphocytes was slightly higher in LTNP and 
HIV-infected individuals (figure 2B; not significant). In all CD8+ T-lymphocyte subsets the 
MFI of CCR5-expressing cells was lower in HIV-infected normal progressors compared to 
healthy controls (figure 2C). In LTNP, the proportion of CD4+ T-cells that expressed CXCR4 
was similar (figure 3A). However, the MFI of CXCR4-expressing cells was significantly 
higher in HIV-infected normal progressors than healthy controls (figure 3B). In all subsets 
of CD8+ T-lymphocytes the MFI of CXCR4-expressing cells was comparable between all 
groups. The differences between groups can be observed by two representative plots for 
all cell types for CCR5 (figure 4) and CXCR4 (figure 5).
The CCR5∆32 polymorphism in the CCR5 receptor may influence the expression of CCR5 
[17]. Therefore we examined whether this polymorphism is more prevalent among the 
LTNP in this study. In total three people were heterozygote for the CCR5∆32 polymorphism 
(12%), one of which was LTNP (1/5) and two were HIV-infected normal progressors (2/12). 
No statistical difference was found between the prevalence of CCR5∆32 between LTNP 
and HIV-infected normal progressors (p=0.813). In addition, the CCR5∆32 polymorphism 
was not (significantly) associated with the percentage nor the MFI of CCR5-expressing 
and CXCR4-expressing cells. 
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Figure 2 The expression of CCR5 on various subsets of T-lymphocytes. The percentage 
(A) and mean fluorescence intensity (MFI) (B) of CCR5 on several subsets of CD4+ 
T-lymphocytes and the MFI of CCR5 (C) on CD8+ T-lymphocytes for healthy controls, 
HIV-infected long-term non-progressors (LTNP) and HIV infected normal progressors. 
Subsets of are defines as: memory T-cells: CD3+CD4+CD45RO+ cells; naive T-cells: 
CD3+CD4+CD45RA+ cells; regulatory T-cells: CD4+CD25highFoxP3+ cells. 
P-values:  *<0.100; ** <0.050; *** <0.001
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Figure 3 The expression of CXCR4 on various subsets of T-lymphocytes. The percentage (A) 
and mean fluorescence intensity (B) of CXCR4 on several subsets of CD4+ T-lymphocytes 
for healthy controls, HIV infected long-term non-progressors (LTNP) and HIV-infected 
normal progressors. Subsets of are defines as: memory T-cells: CD3+CD4+CD45RO+ 
cells; naive T-cells: CD3+CD4+CD45RA+ cells; regulatory T-cells: CD4+CD25highFoxP3+ cells. 
P-values:  *<0.100; ** <0.050; *** <0.001
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Discussion
In this study we show that HIV infection is -directly or indirectly- associated with the 
expression of CCR5, but not CXCR4, in specific CD4+ T-lymphocyte subsets. This effect is 
most notable in HIV-infected normal progressors, but barely observed in LTNP with viral 
control. 
CCR5 and CXCR4 are crucial for HIV invasion and they are expressed on various cell types, 
including hematopoietic cells and several cells in the central nervous system [7, 12, 17, 22-
27]. The expression of CCR5 can be affected by HIV and we show, in line with other studies, 
that HIV-infected individuals have an increased CCR5 expression on CD4+ T-lymphocytes 
[17, 28-31]. Longitudinal studies show that the percentages of CCR5-expressing CD4+ 
cells increases slightly over time [17], while HAART reduces the percentage of CCR5-
expressing cells [28, 29, 31, 32]. This suggests, that indeed HIV increases the expression 
of CCR5 on CD4+ T-lymphocytes and that this effect is reversible. In contrast, we found 
no association between HIV and the surface density of CCR5, expressed by MFI. This also 
accords with earlier observations, which showed that surface density of CCR5 is stable 
over time [18, 33]. 
Recently, studies suggest that subtle genetic differences of HIV are associated with non-
progression. HIV derived from long-term non-progressors has shown a reduced cell entry 
in vitro [1, 34-37]. Also genetic differences in the host may play a role; the CCR5∆32 
polymorphism is associated with lower numbers of CCR5-expressing CD4+ T-cells [17] and 
slower progression of HIV [9, 13-15]. However, the CCR5∆32 polymorphism is unrelated 
to the elevated expression of CCR5 in HIV-infected individuals, both in our study and that 
of others [15, 17, 30]. Despite these contradictory results, meta-analyses of published 
cohorts associate the CCR5∆32 with lower viral loads, decreased risk of progression to 
AIDS and lower mortality rate [13, 38]. In addition slow progression could be associated 
with pathways including specific cellular proteins, such as restriction factors, APOBEC3, 
TRIM5, and Tetherin. These molecules act at several key steps of the HIV lifecycle and can 
avert viral infection or replication in a cell-specific way. As they control HIV infection, it is 
possible that genetic alterations or levels of expression are related to differences in HIV 
progression [39].
We demonstrate that in LTNP with viral control the expression of CCR5 is lower on both 
memory (CD45RO+) and naive (CD45RA+) CD4+ T-lymphocytes, but not on regulatory 
T-cells (CD4+CD25highFoxP3+). Only few studies examined co-receptors expression among 
specific HIV-infected patients, such as elite controls and LTNP, in combination with specific 
cell subsets [24, 40]. Almeida et al presents the CCR5 expression in dendritic cells of HIV-
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infected patients, including long term non-progressors. They found lower expression of 
CCR5 in all HIV-infected patients [40].Other studies showed lower expression of CCR5 
CD4+ T lymphocytes in HIV controllers [24, 33]. Since CCR5 expression regulates whether 
HIV can infect target cells [41] and CCR5 down-regulation may contribute to the low 
levels of infection in LTNP. 
Several studies analysed the association between the expression of CCR5 and disease 
progression, such as time to AIDS, CD4 cell decline or serum viral load levels. In both 
humans and animals, higher amounts of circulating CD4+CCR5+ T-lymphocytes are 
associated with faster disease progression, higher viral loads and lower CD4 cell counts 
[17, 18, 30, 33, 42, 43]. Our findings further support an association between CCR5 
expression and HIV progression. In addition, Yang et al show that in mangabeys infected 
with SIV (simian immunodeficiency virus) the CCR5 expression is significantly lower on 
all subsets of cells in slow progressors compared to fast progressors; which supports our 
findings [43]. The downregulation of CCR5 in LTNP can be influenced by higher levels 
of chemokines, which activates receptor internalisation and thereby reduces CCR5 
expression [12, 44]. Also the amount of regulatory T cells are associated with disease 
progression; in line with other studies the amount of regulatory T cells was higher in HIV 
normal progressors than in LRNP with viral control [13].
In our study, the amount of CXCR4-expressing cells was comparable between groups, 
but the MFI of CXCR4-expressing CD4+ T-lymphocytes was significantly increased in HIV-
infected individuals. Literature on the expression of CXCR4 is inconclusive; some studies 
revealed no differences [29, 42], whereas others observed reduced CXCR4 expression on 
CD4+ cells [17, 28, 30, 31], CD8+ cells [28, 30, 31], CD14+ cells [30] and natural killer cells 
[32]. CXCR4 is of more importance during later stages of infection [42] and therefore 
CXCR4 is probably less important in LTNP. In addition, all HIV-infected subjects in our 
study were asymptomatic and therefore the expression of CXCR4 might be affected by 
HIV at a later stage. Our study shows that LTNP with viral control tend to have a slightly 
higher number of CXCR4 expressing cells, albeit not significant, and also previous studies 
showed that there is a correlation between disease stage and CXCR4 expression of CD4+ 
T-lymphocytes; with healthier patients expressing more CXCR4 [30].
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Conclusion
In conclusion, preventing upregulation of CCR5 on CD4+ T-lymphocytes could be an 
important method via which LTNP counteract the effects of HIV and suppress viral 
replication. Exploring how LTNP suppress the upregulation of CCR5 could be an important 
step for discovering new therapeutics.  Currently, CCR5 specific blockers, such as Marariroc, 
are already used effectively in HIV treatment regimes, showing the importance of CCR5 
in HIV suppression. 
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Abstract
Background: Human immunodeficiency virus (HIV) needs CCR5 or CXCR4 for cell entry. 
Opioids may alter the expression of these receptors and we therefore studied the relation 
of opioid use with the CCR5 and CXCR4 expression and the chemokine production in HIV-
infected individuals. 
Methods: Treatment naïve HIV-infected individuals in Indonesia were included; 
individuals using 1) heroin 2) methadone opioid substitution 3) heroin over 1 year ago 
and 4) controls (never used opioids). Flow cytometry was used to examine the expression 
of CCR5 and CXCR4. Whole blood was stimulated with M.tuberculosis, C.albicans and LPS 
to study chemokine production (RANTES, MIP-1α, MIP-1β, MCP-2, SDF-1). 
Results: In 84 individuals, the expression of CCR5 on CD4+ cells was significant higher in 
heroin (p=0.007), methadone (p=0.024) and previous users (p=0.003) compared to the 
controls. The percentage of CXCR4-expressing CD4 cells was higher in controls compared 
to other groups (p=0.028). In general the production of chemokines was higher in 
controls; this trend differed per chemokine and pathogen.
Conclusion: Opioids affect the immune system by up-regulation of CCR5 and down-
regulation of CXCR4 and HIV-relevant chemokines. This suggests that opioids could affect 
the HIV susceptibility of cells by decreasing endogenous blocking agents and increasing 
an important HIV co-receptor.
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Introduction
Human immunodeficiency virus (HIV) infects and destroys CD4+ T-lymphocytes. HIV 
requires a co-receptor, either CCR5 or CXCR4, to invade CD4+ T-lymphocytes. In general, 
HIV isolated from newly infected individuals uses CCR5 and these “R5 variants” are 
detectable over the entire course of the HIV infection [1]. The X4 variants, that utilize 
CXCR4, are mostly detectible at a late stage of the disease and in only up to 50% of all 
patients [2]. Both co-receptors are expressed on leukocytes, but to different extents on 
various leukocyte subsets [3, 4].
The HIV co-receptors CCR5 and CXCR4 can play an important role in the progression of 
HIV. A well-known polymorphism in the CCR5 gene, namely CCR5∆32 (a 32 base pair 
deletion in the CCR5 gene) interrupts the entrance of HIV into cells and individuals 
homozygous for this deletion are almost completely resistant to HIV infection [5-8]. Also 
individuals who are heterozygous for the CCR5∆32 have shown slower progression of 
HIV [5, 9-11]. The expression of CCR5 and CXCR4 determines, in addition to CD4, the 
susceptibility of cells to HIV infection [12] and viral replication [13, 14]. Viral replication 
frequently occurs in activated CD4+CCR5+ T-lymphocytes, as these cells are an important 
target for HIV [15]. Previous studies have shown that the expression of CCR5 increases 
with HIV disease progression, a phenomenon that is reversed by antiretroviral therapy 
(ART) [16]; indicating that CCR5 expression is important in HIV progression. Not only the 
co-receptors, but also their ligands (MIP-1α/CCL3, MIP- 1β/CCL4, RANTES/CCL5 and MCP-
2/CCL8 for CCR5 and SDF-1/CXCL12 for CXCR4) have the ability to block HIV activity [6]. In 
addition, in vitro experiments have shown that low levels of chemokines are associated 
with high susceptibility to HIV [17, 18].
Injecting drug use (IDU) is responsible for HIV infections in ten percent of all cases 
worldwide, and 30% of cases outside Africa [19]. IDU is not only a risk factor for HIV 
transmission, but it may also change the natural course of HIV infection, for instance 
because of co-infections and/or nutritional deficiencies. In addition, opioid use has been 
documented to comprise the immune system and thereby the risk of infections [20-26]. 
Confounding variables, such as sharing needles, nutrition status and homelessness, can 
influence the frequency of infections, but data suggest that immune modulating effects 
of opioids are also an important contributing factor [24, 27].  Additionally, the severity of 
disease is affected by opioids, described in animal experiments with various pathogens 
[23]. 
Epidemiological studies looking at the association between IDU and the natural course of 
HIV-infection have shown contradictory results [21, 28-33]. Most studies used however 
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clinical endpoints such as mortality and AIDS-free survival whereby factors unrelated 
to HIV may skew the relation with opoiod use. We have previously shown that HIV-
infected individuals with opioid use as risk behaviour have a faster natural decline in 
CD4 cells, compared to those with sexual transmission [34]. The faster CD4 cell decline 
in drug users may be explained by the fact that opioids can up-regulate the expression 
of HIV co-receptors CCR5 and CXCR4 in vitro and that this up-regulation results in an 
increase of viral replication [20-22]. In addition, in vitro and animal experiments have 
shown that opioids can affect the expression of RANTES [35-38], MIP-1α [37] and MIP-1β 
[39]. Altogether, these studies suggest that IDU might affect the expression of CCR5 and 
CXCR4 and chemokine response to pathogens. This in turn could alter the susceptibility 
to infections and disease progression among individuals who use opioids. In the present 
study, the expression of CCR5 and CXCR4 on CD4 cells in HIV-infected drug users in 
Indonesia was therefore analysed. Indonesia has an emerging HIV epidemic which has 
been largely driven by IDU. In addition, we studied the production of the chemokines 
RANTES, MIP-1α, MIP-1β, MCP-2 and SDF-1 after ex vivo stimulation of whole blood with 
several pathogens. 
Methods
Study setting and population
For this study, we included HIV-infected adults (>16 years) from several settings in 
West-Java, Indonesia; an HIV clinic, a methadone (opioid substitution) clinic and the 
community. The clinics were part of a five-year programme (2006-2011) called ‘IMPACT’, 
aimed to improve prevention, control and treatment of HIV among injecting drug users 
in West-Java, Indonesia [40]. In these clinics, people with and without a history of IDU, 
who are at risk for HIV infection or who present with signs and symptoms suggesting 
HIV/AIDS are counselled and tested for HIV. To contact individuals in the community we 
collaborated closely with Rumah Cemara; a local NGO focussing on increasing the quality 
of life for people with HIV/AIDS and people who use drugs. All testing is voluntary and 
informed consent is obtained from all study participants. 
All subjects selected for this study were antiretroviral therapy (ART) naïve HIV-infected 
subjects and had no signs of opportunistic infections, such as active tuberculosis or oral 
thrush. Individuals had to fit the inclusion criteria of one of the four groups: 1) Active 
drug users: used heroin in the last 30 days; 2) Methadone clients: received methadone 
maintenance treatment (MMT) in the last 30 days; 3) Former users: used heroin or 
methadone over one year ago; 4) Controls: never used heroin or methadone. Individuals 
fitting these criteria and either visiting the HIV clinic or in contact with Rumah Cemara 
were asked to participate in this study. All participants were informed on the study 
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and signed an informed consent. Data on demographic factors, history of drug use, 
co-morbidity, self-reported tuberculosis treatment and history of ART were collected 
through interview with standardized questionnaires. In addition, blood was collected for 
various purposes, including CD4 cell count, general haematology, flow cytometry and cell 
stimulation assays. This study was approved by the Health Research Ethics Committee at 
the Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin General Hospital in 
Bandung, Indonesia. At the time of this study, ART was indicated in Indonesia for patients 
presenting with WHO clinical stage IV or a CD4 count less than 200 cells/µl in accordance 
with WHO guidelines from 2006. Since 2004, ART can be accessed free of charge in 
Indonesia.
Flow cytometry
The expression of CCR5 and CXCR4 on cells were phenotypically examined by three-colour 
flow cytometry (BD FACSCalibur, CellQuest Pro Software) and results were analysed using 
Kaluza software. Briefly, red cell lysis of whole blood was performed according to the 
manufacturer’s instruction (BD PharmLyse, Becton Dickinson Biosciences, San Jose, USA). 
Cells were washed with phosphate-buffered saline (PBS) with 1% bovine serum albumin 
(BSA) before being incubated with fluorochrome- conjugated monoclonal antibodies. 
After incubation for 20 min at room temperature, cells were washed twice to remove 
unbound antibodies and analysed. For cell surface staining, the following mAbs were 
used: CD14 , CD3, CD4, CCR5, CXCR4. CD4-PECy7 (RPA-T4), CXCR4-PE (12G5), CCR5-FITC 
(HEK/1/85a) from Biolegend (San Diego, USA). Appropriate isotype control mAbs were 
used for gate settings. The live gate was set based on the forward angle light scatter (FSCs) 
and the side angle light scatter (SSCs). We selected subsets of cells by first gating on live 
cells and subsequently we defined monocytes as CD14+ and T-lymphocytes as CD3+. In 
the CD3+ cells we gated on either on CD4+ or CD8+ cells. For all cell subtypes, expression 
of HIV co-receptors CCR5 and CXCR4 was measured as proportion (%) of positive cells, as 
well as mean fluorescence intensity (MFI) of positive cells. 
Stimulation assay
Chemokine production was measured in whole blood stimulation. Briefly, venous 
blood was drawn into 5-mL endotoxin-free lithium-heparin tubes (Vacutainer, BD 
Biosciences) and samples were processed within 4hours. Blood was diluted 1:5 with 
culture medium only (RPMI Dutch modified) or in combination with either conidia of 
heath killed Candida albicans (106 cells/ml), Mycobacterium tuberculosis (10 µg/ml), LPS 
isolated from Escherichia coli (10 ng/ml). After 24 or 48 hour incubation, blood cultures 
were centrifuged at 1700rpm for 10 min and supernatants were stored at −20°C until 
assayed. The expression of chemokines SDF-1, MCP-2, MIP-1α, MIP-1β and RANTES were 
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measured using a multiplex beads assay (Merck Millipore, Billerica, MA, USA) according 
to the manufacturer’s instructions. 
Statistical analyses
Subjects with CD4 cell counts below 100 cells/µl were excluded from statistical analyses. 
All chemokine concentrations were corrected for the amount of CD4 cells. We compared 
differences between groups using chi2 for categorical variables, ANOVA for normally 
distributed variables, and Kruskus Wallis and Mann Whitney analyses for non-normally 
distributed variables. Results were found statistically significant (two-sided) at a level 
of 0.05, resulting in 0.016 after Bonferroni adjustment for multiple tests. All statistical 
analysis was performed using the Statistical Product and Services Solutions package 
version 18.0 and graphs were created using GraphPad Prism version 5.0.
Results
In total 84 ART-naïve HIV-infected individuals were included; 17 active heroin users, 18 
individuals receiving MMT, 19 individuals who used heroin over one year ago and 30 
individuals who never used heroin (table 1). Overall individuals who never used any 
opioid were more often younger (p=0.001), but no other differences were found between 
the groups (table 1).
Table 1. Characteristics of ART-naïve HIV-infected study participants (n=84).
Characteristics*
Heroin  user 
(n=17)
MMT 
(n=18)
Former user 
(n=19)
Control
(n=30)
p-value#
Male, % (n/N) 82.4 (14/17) 94.4 (17/18) 89.5 (17/19) 80.0 (24/30) 0.479
Age, years 33 (29 - 37) 33 (30 - 35) 30 (28 - 34) 27 (22 - 32) 0.007
Hb, g/dl 14.6 (13.2-15.7) 14.1 (13.0-15.0) 15.7 (14.9-16.2) 14.8 (13.4-16.0) 0.130
CD4 cells, cells/µl 387 (224-575) 237 (180-461) 385 (270-667) 290 (172-450) 0.518
Monocytes % 6.8 (5.1-8.0) 7.5 (6.5-8.3) 6.5 (5.35-9.0) 7.0 (5.6-10.1) 0.461
Lymphocytes, % 24.6 (17.3-29.6) 23.0 (15.9-26.2) 22.6 (11.5-32.3) 21.9 (13.2-27.1) 0.592
CD4+ lymphocytes, % 24.8 (10.4-30.1) 15.6 (9.9-23.5) 18.9 (10.9-27.3) 16.8 (13.6-23.3) 0.615
CD8+ lymphocytes, % 73.8 (66.8-86.7) 77.7 (69.2-86.5) 75.5 (68.6-80.9) 75.0 (71.9-81.6) 0.787
* Data are given as median (IQR) unless stated otherwise. # Groups were compared with chi2 for 
gender and Kruskal-Wallis for all other variables. Heroin users: individuals who used heroin in the 
last 30 days; MMT: individuals receiving methadone maintenance treatment (MMT) in the last 30 
days; Former users: individuals who used heroin over one year ago; Control: individuals who never 
used opioids.  Monocytes are defined as CD4+CD45+ cells and lymphocytes as CD3+CD45+ cells. 
ART: antiretroviral therapy; HIV: Human immunodeficiency virus; MMT: methadone maintenance 
treatment; Hb; haemoglobin.
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The expression of CCR5 and CXCR4 was measured in 17 active heroin users, 17 MMT 
clients, 15 former heroin users and 28 controls. We focused our analyses on the expression 
these HIV co-receptors on lymphocytes and more specifically on CD4+ lymphocytes. 
Active heroin users had lower percentage of CCR5-expressing lymphocytes than controls 
(not significant), in CD4+ lymphocytes the same trend was observed (figure 1A). The MFI 
of CCR5-expressing lymphocytes seemed higher in MMT client compared to all other 
groups (figure 1B). However, in CD4+ lymphocytes MFI of CCR5-expressing cells was 
significantly higher in active heroin users (p=0.007), MMT clients (p=0.024) and former 
heroin users (p=0.003) compared to controls (figure 1B).
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Figure 1. The expression of CCR5 and CXCR4 on lymphocytes (CD3+ cells) and CD4+ 
lymphocytes (CD4 cells) in various groups of ART-naïve HIV-infected individuals. 
Expression is given as percentage (A and C for CCR5 and CXCR4 respectively) and MFI (B 
and D for CCR5 and CXCR4 respectively).
Heroin users: individuals who used heroin in last 30 days (circle); MMT: individuals 
receiving methadone maintenance treatment (square), Ex users: individuals who used 
heroin over one year ago (triangle) and Controls: those who never used opioids  (reversed 
triangle). *Statistically significant difference (p< 0.016 after Bonferroni adjustment for 
multiple tests). Groups compared with Mann-Whitney U test. MFI: mean fluorescence 
intensity; MMT: methadone maintenance treatment; ART: antiretroviral therapy.
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The percentage of CXCR4-expressing lymphocytes was significantly lower in former 
heroin users than controls (figure 1C). On CD4+ lymphocytes this percentage was lower 
in all drug user groups (active heroin users, methadone clients and former heroin users) 
compared to never users (figure 1C). The MFI of CXCR4-expressing lymphocytes was 
slightly higher in controls compared to active heroin users (p=0.023) and MMT clients 
(p=0.039) (figure 1D). When looking only at CD4+lymphocytes no significant differences 
were observed in the MFI of CXCR4-expressing cells (figure 1D). 
All chemokine concentrations were corrected for the amount of CD4 cells and chemokine 
production are given in picogram per 100.000 CD4 cells. In unstimulated samples we 
found no differences in the amount of chemokines produced, namely SDF-1 (p=0.947), 
MIP-1α (p=0.301), MIP-1β, RANTES (p=0.494) and MCP-2 (p=0.970). The production 
of chemokines was not related to gender (lowest p-value was 0.171) and age (lowest 
p-value was 0.110).
SDF-1 exclusively binds to the CXCR4 receptor and could therefore be important in 
blocking the HIV entry through CXCR4. As expected the overall production of SDF-1 was 
increased after stimulation with the pathogens (figure 2). Controls produced slightly 
more SDF-1 after exposure to C.albicans (figure 2B) and M.tuberculosis (figure 2C), but 
not after E.coli LPS (figure 2A). 
The chemokines MCP-2, MIP-1α, MIP-1β and RANTES bind to the CCR5 receptor as well 
as other chemokine receptors.  After stimulation with LPS the production of MIP-1α 
and MIP-1β was reduced in active heroin users (figure 3A and 4A). This effect was not 
observed in RANTES and MCP-2 (figure 5A and 6A). Exposure to C.albicans resulted in an 
increased production of MIP-1α, MIP-1β and RANTES in MMT clients (figure 3B, 4B and 
5B respectively).  After exposure to M.tubercuosis, the production of MIP-1β was lower 
in both active and former heroin users compared to MMT clients and never heroin users 
(figure 5C). The same trend was observed in MIP-1α, but was only statistically significant 
when comparing former heroin users with controls (figure 3C). The production of MCP-2 
was comparable between all groups with the various stimuli (figure 6).
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Figure 2. The concentration of SDF-1 after ex vivo stimulation with LPS of E.coli (A), 
C.albicans (B) and M.tuberculosis (C) in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of SDF-1 was corrected for baseline level and number of CD4 cells. * Statistically 
significant difference (p< 0.016 after Bonferroni adjustment for multiple tests). Groups 
compared with Mann-Whitney U test. MMT: methadone maintenance treatment; ART: 
antiretroviral therapy.
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Figure 3. The concentration of MIP-1α after ex vivo stimulation with LPS of E.coli 
(A), C.albicans (B) and M.tuberculosis (C) in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of MIP-1α  was corrected for baseline level and number of CD4 cells. 
*Statistically significant difference (p< 0.016 after Bonferroni adjustment for multiple 
tests). Groups compared with Mann-Whitney U test. MMT: methadone maintenance 
treatment; ART: antiretroviral therapy.
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Figure 4. The concentration of MIP-1β after ex vivo stimulation with LPS of E.coli 
(A), C.albicans (B) and M.tuberculosis (C) in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of MIP-1β  was corrected for baseline level and number of CD4 cells.* 
Statistically significant difference (p< 0.016 after Bonferroni adjustment for multiple 
tests). Groups compared with Mann-Whitney U test. MMT: methadone maintenance 
treatment; ART: antiretroviral therapy.
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Figure 5. The concentration of RANTES after ex vivo stimulation with LPS of E.coli 
(A), C.albicans (B) and M.tuberculosis (C) in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of RANTES was corrected for baseline level and number of CD4 cells. * 
Statistically significant difference (p< 0.016 after Bonferroni adjustment for multiple 
tests). Groups compared with Mann-Whitney U test. MMT: methadone maintenance 
treatment; ART: antiretroviral therapy.
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Figure 6. The concentration of MCP-2 after ex vivo stimulation with LPS of E.coli (A), 
C.albicans (B) and M.tuberculosis (C) in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of MCP-2 was corrected for baseline level and number of CD4 cells. * 
Statistically significant difference (p< 0.016 after Bonferroni adjustment for multiple 
tests). Groups compared with Mann-Whitney U test. MMT: methadone maintenance 
treatment; ART: antiretroviral therapy.
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Discussion
In this study we show that active heroin users have an increased expression of CCR5 on 
CD4+ lymphocytes, whereas the percentage of CXCR4+CD4+ lymphocytes is decreased. In 
addition, the production of various chemokines is decreased in active heroin users after 
exposure to various pathogens ex vivo. These results suggest that opioids could affect the 
HIV susceptibility of cells by decreasing endogenous blocking agent and increasing an 
important HIV co-receptor. 
Previous in vitro studies have shown activation of the µ-opioid receptor induces 
significant up-regulation of HIV co-receptors CCR5 and CXCR4 [22, 39]. However, little 
is known about immunomodulating effects of chronic opioid use in vivo, especially in 
humans. In the brains of rats, CCR5 gene expression was unaffected with chronic opioid, 
whereas withdrawal decreased the CCR5 gene expression [35]. A recent study in rhesus 
macaques showed that chronic morphine administration resulted in an increase of CCR5 
and decrease of CXCR4 expression on both CD4+ and CD8+ lymphocytes [41]. Our results 
are in line with these findings, with increased CCR5 expression of CD4+ lymphocytes and 
a decreased percentage of CXCR4-expression CD4+ lymphocytes among all opioid users. 
These findings indicate that the effects of opioids can differ between in vitro and in vivo 
studies, but also in different cells and species. 
To our knowledge, this is the first study to examine the effects of heroin and methadone 
use on the production of chemokines in vivo in humans. In vitro and animal experiments 
have shown that opioids can affect the expression of RANTES [35-38] and MIP-1β [39]. 
Overall these studies show that the expression of RANTES is augmented after exposure 
to opioids [35-39] and we found that current opioid use increased RANTES production 
after stimulation with C.albicans. The gene expression of MIP-1β was found to be down-
regulated by morphine in astrocytes [39]. We showed that after stimulation with E.coli 
LPS and M.tuberculosis the production of MIP-1β was lower in heroin users. Our findings 
are in line with previous studies, even though we looked at in vivo exposure in humans. 
Previous studies have shown a strong relation between chemokine levels and susceptibility 
to HIV, with low chemokine levels associated with high HIV susceptibility [17]. Overall 
we found that opioid users produced less chemokines after stimulation with pathogens. 
This suggests that opioid use could result in higher susceptibility of cells to HIV, which 
supports our previously findings that opioid users have a faster progression of HIV [34]. 
In addition, opioids reduce the chemotaxis of cells in response to chemokines, such as 
MIP-1a, RANTES and MCP-1 [42]. Lower chemotaxis combined with lower chemokine 
production could explain the increased susceptibility to infectious diseases in individuals 
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using opioids [23, 24].
Interestingly we also observed changes in HIV co-receptors and related chemokines in 
individuals with a history of opioid use.  This suggests that opioids may induce long-
term immune modulating effects. Wang et al recently showed that morphine can have 
epigenetic properties, which could explain our results in former heroin users [43]. We 
also observed differences between heroin users and MMT clients; MIP-1α, MIP-1β and 
RANTES seem to be increased, whereas SDF-1 was decreased in MMT clients. Even 
though both opioids work predominantly through the µ-opioid receptor, heroin also 
binds to κ- and δ-opioid receptor while methadone has no affinity with these receptors. 
These differences in affinity for the opioid receptors might explain our findings; however 
more specific research would be needed to determine the effects of the individual opioid 
receptors. 
Our study population is relatively small, including around 20 subjects per group. In 
addition, this research was cross-sectional and not set-up as an experimental study. 
This entails that also within groups there may be a difference in the amount of exposure 
to opioids. We chose for this set-up to have realistic view on the effects of injecting 
drug use in HIV-infected individuals. We selected individuals either via a HIV clinic or 
in the community with help of a local NGO. This method may have resulted in some 
bias, since we only selected individuals already in contact with either facility. Possibly 
these individuals were thus less exposed to opioids than injecting drugs users who are 
not receiving any structured care. Even with these limitations we were able to detect a 
difference in the expression of chemokine receptors and chemokine production, which 
could be especially important in HIV. To our knowledge, this is the first study to study 
the effects of heroin and methadone use on the expression of HIV co-receptors and 
chemokine response in humans.
In our study we determined drug use based on interviews and did not perform any 
toxicological tests, which could perhaps result in a bias. However, we worked closely 
together with employees of a local NGO, who have been in close contact with our subjects 
for years. In addition, drug test will only show recent use of opioids (up to four days) and 
therefore might not be reliable in identifying active users that did not use in the previous 
couple of days. Unfortunately we do not have HIV viral loads of our study population, 
which might related to the expression of chemokines or chemokine receptors. However, 
we have previously shown that the viral load among people with and without a history of 
injecting drug use did not differ [34, 40]. Previous studies have shown that an increase in 
chemokine receptors resulted in more viral replication and thus cause and effect would 
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be difficult to distinguish [22]. In addition, chemokines play an important role in hepatitis 
C infection [44]. Hepatitis C is strongly associated with injecting drug use, in our cohort 
we found that 90% of injecting drug users have a positive hepatitis C serology compared 
to ten percent among non-users [34]. This strong correlation hampers distinguishing the 
effect of hepatitis C from that of drug use.  
Our results suggest that exposure to opioids have long term influences on the immune 
system by up-regulation of CCR5, down-regulation of CXCR4 and down-regulation 
of chemokines relevant for HIV-infection. These findings could partially explain the 
increased occurrence of infections and faster progression of HIV in injecting drug users. 
MMT is used as treatment aimed to reduce illegal use of heroin and thereby stabilize 
the lives of patients and prevent transmission of blood born disease, such as hepatitis 
C and HIV. In general, methadone seems to have less adverse effects on these immune 
markers and therefore MMT might have even more benefits as substitute for heroin. 
Our study was performed in HIV-infected individuals to explore whether opioids could 
affect the HIV susceptibility of cells and modulate immune function. However, opioids are 
also frequently used as painkiller in healthcare settings and modulation of chemokines 
may be important for numerous diseases, such as cardiovascular disease, cancer and 
even psychiatric diseases [45-47]. Therefore, the present results could have even larger 
implications than just among HIV-infected individuals.
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Abstract
Background Opioid use is associated with increased incidence of infectious diseases. 
Although experimental studies have shown that opioids affect various functions of 
immune cells, only limited data are available from human studies. Drug use is an important 
risk factor for HIV transmission, however no data are available whether heroin and/or 
methadone modulate immune response. Therefore, we examined the effect of heroin 
and methadone use among HIV-infected individuals on the production of cytokines after 
ex vivo stimulation with various pathogens.
Methods Naïve HIV-infected individuals from Indonesia were recruited. Several cohorts 
of individuals were recruited: 1) using heroin 2) receiving methadone opioid substitution 
3) using heroin over 1 year ago and 4) controls (never used opioids). Whole blood was 
stimulated with Mycobacterium tuberculosis, Candida albicans and LPS for 24 to 48 
hours. Cytokine production (IL-1 β, IL-6, IL-10, IFN-α, IFN-γ and TNF-α) was determined 
using multiplex beads assay.
Results Among 82 individuals, the cytokine levels in unstimulated samples did not differ 
between groups. Overall, heroin users had significantly lower cytokine response after 
exposure to LPS (p<0.05). After stimulation with either M. tuberculosis or C. albicans the 
cytokine production of all groups were comparable. 
Conclusion The cytokine production after exposure to LPS is significantly down-regulated 
in HIV-infected heroin users. Possibly, opioids directly either affect the TLR4 pathway, 
or induce gut translocation and endotoxin tolerance. Interesting, methadone use did 
not suppress cytokine response, which could have implications guidelines of opioid 
substitution.  
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Introduction
Opioid use is associated with increased incidence of infectious diseases. Variables, such 
as sharing needles, nutrition status and homelessness, can influence the frequency of 
infections, but studies also suggest that immune modulating effects of opioids are a major 
factor in the increased susceptibility to various infectious agents [1-8]. More specifically, 
opioids have shown to modulate several aspects of the immune system. 
In both human and animal studies, opioid use has been associated with increased 
susceptibility to microbial infections, including bacterial infections such as staphylococci, 
streptococci and more specifically Escherichia coli, Salmonella typhimurium and 
Mycobacterium tuberculosis, the fungi Candida albicans, the parasite Toxoplasma gondii, 
and viruses such as the herpes virus and Friend leukemia virus [7]. In addition, there is 
a high risk of blood-born infectious diseases when unsterile needles are used to inject 
drugs, such as endocarditis, cellulitis, sepsis, hepatitis C and human immunodeficiency 
virus (HIV) [6]. Injecting drug use (IDU) is responsible for HIV infections in 10% of all 
cases worldwide, and 30% of cases outside Africa [1]. IDU is not only a risk factor for 
HIV transmission, but it may also change the natural course of HIV infection, for instance 
because of co-infections, nutritional deficiencies and/or the immune modulating 
properties of opioids. Experimental studies have shown that binding of opioids to the 
opioid µ-receptors of immune cells affects the function of these cells in various ways. 
In vitro and animal experiments have shown that opioids modulate phagocytosis, 
chemotaxis, cytokine response and activity of immune cells; which could have detrimental 
results for the cellular immunity [6, 7]. On the other hand, other studies suggest that the 
effects of opioids on the immune system are not necessarily deleterious; cells exposed to 
endogenous opioids in vitro increased natural killer cell activity [9].
The regulation of immune and inflammatory responses is dependent on the functions 
of cytokines, which is especially important in individuals with an compromised immune 
function, such as HIV-infected individuals. The effects of opioids on cytokine production 
have been investigated in both in vitro and animal experiments [10-19], but only little 
information is available on in vivo exposure in humans. In addition, the data from previous 
studies have shown contradicting results. For example the production of IFN-γ can be 
enhanced [10] or suppressed [11] by various opioids in in vitro studies, whereas in animal 
experiments the IFN-γ production is often diminished after exposure to opioids [17, 18]. 
The production TNF-α is mostly suppressed by opioids [13, 15, 16], but some studies 
show no effect [14]  or even an increase in TNF-α [12]. Opioids reduce the IL-8 production 
[13, 19] , whereas IL-1β production is often enhanced [12, 19]. The differences might be 
explained by experimental set-up, type of cells or animals used, and type of opioid. 
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Most studies use morphine to test the effects of opioids on immune system. Only limited 
data are available from human studies and in most of these studies opioids are used for 
pain relief, either post-surgery or during cancer treatment [20-24]. The main findings 
of these studies were that morphine suppressed natural killer cell activity, reduced 
mitogen responses and decreased lymphoproliferation. One study examined the effects 
of morphine in healthy volunteers [25]: continuous exposure to morphine over a period 
of 36 hours resulted in suppression of natural killer cell cytotoxicity as well as IFN-γ 
stimulated and antibody-dependent cytotoxity. All these study suggests that morphine 
administration can cause measurable suppression of the immune system. 
Heroin and methadone are however more commonly associated with HIV infection. As 
the different opioids are known to have different affinity for the opioid receptors [26-
28], one may hypothesize that they exert different immune modulating effects. Only 
two human studies examined the immunological effects of heroin or methadone. One 
study compared the effects of methadone and buprenorphine (as opioid substitution) 
in drug users and found no difference, but cytokine levels were significantly depressed 
compared to controls [29]. Azarang et al compared the ex vivo cytokine production after 
stimulation of whole blood between heroin users and healthy controls and found that 
heroin addicts produce less IFN-γ and more IL-10 after stimulation with LPS. [30]. Even 
though drug use is not uncommon among HIV-infected individuals, no data are available 
regarding the effects of heroin or methadone on the immune response in HIV. In the 
present study, we examined therefore the effect of heroin and methadone use among 
HIV-infected individuals on the production of cytokines after ex vivo stimulation with 
various pathogens relevant in the HIV patients. 
Methods
Study setting and population
For this study, we included HIV-infected adults (>16 years) from several settings in West-
Java, Indonesia; an HIV clinic, a methadone clinic and the community. The collaboration 
with the clinics and the community was part of a five-year programme (2006-2011) 
called ‘IMPACT’, aimed to improve prevention, control and treatment of HIV among 
injecting drug users in West-Java, Indonesia [31]. In these clinics, people with and 
without a history of IDU, who are at risk for HIV infection or who present with signs and 
symptoms suggesting HIV/AIDS are counselled and tested for HIV. All testing is voluntary 
and informed consent is obtained from all study participants. HIV-infected patients 
are characterised and followed prospectively in a cohort study. To contact individuals 
in the community we collaborated closely with Rumah Cemara; a local NGO focussing 
on increasing the quality of life for people with HIV/AIDS and people who use drugs. 
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All subjects selected for this study were antiretroviral therapy (ART) naïve HIV-infected 
and had no signs of opportunistic infections, such as active tuberculosis or oral thrush. 
Individuals had to fit the inclusion criteria of one of the four groups: 1) Active drug users: 
used heroin in the last 30 days; 2) Methadone clients: received methadone maintenance 
treatment (MMT) in the last 30 days; 3) Former users: used heroin or methadone over 
one year ago; 4) Controls: never used heroin or methadone. All participants were 
informed on the study and signed an informed consent. Data on demographic factors, 
history of drug use, co-morbidity, self-reported tuberculosis treatment and history of ART 
were collected through interview with standardized questionnaires. In addition, blood 
was collected for various purposes, including CD4 cell count, general haematology, flow 
cytometry and cell stimulation assays. This study was approved by the Health Research 
Ethics Committee at the Faculty of Medicine of Padjadjaran University/Dr. Hasan Sadikin 
General Hospital in Bandung, Indonesia. At the time of this study, ART was indicated in 
Indonesia for patients presenting with WHO clinical stage IV or a CD4 count less than 200 
cells/µl in accordance with WHO guidelines from 2006. Since 2004, ART can be accessed 
free of charge in Indonesia.
Stimulation assay
Cytokine production was examined after whole blood stimulation with various 
pathogens. Briefly, venous blood was drawn into 5-mL endotoxin-free lithium-heparin 
tubes (Vacutainer, BD Biosciences) and samples were processed within 4 hours. Blood 
was diluted 1:5 with culture medium only (RPMI Dutch modified) or in combination with 
either conidia of heath killed Candida albicans (106 cells/ml), Mycobacterium tuberculosis 
(10 µg/ml), LPS isolated from Escherichia coli (10 ng/ml). After 24 or 48 hour incubation, 
blood cultures were centrifuged at 1700rpm for 10 min and supernatants were stored 
at −20°C until assayed. The expression of cytokines IL-1 β, IL-6, IL-10, IFN-α, IFN-γ and 
TNF-α were measured using a multiplex beads assay (Merck Millipore, Billerica, MA, USA) 
according to the manufacturer’s instructions. We studied the production of IL-1 β and 
IL-6 in 24 hours samples and IL-10, IFN-α, IFN-γ and TNF-α in 48 hour samples. 
Statistical analyses
Subjects with CD4 cell counts below 100 cells/µl were excluded from statistical analyses. 
All cytokine levels after stimulation were corrected for the amount of CD4 cells and the 
unstimulated levels. The production of cytokines was compared between groups using 
Kruskul-Wallis and Mann Whitney analyses. Results were found statistically significant 
at a level of 0.05, resulting in a p-value of 0.016 after Bonferroni adjustment for multiple 
tests. All statistical analysis was performed using the Statistical Product and Services 
Solutions package version 18.0 and GraphPad Prism version 5.0.
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Results 
We included a total of 82 ART-naïve HIV-infected individuals with CD4 cell counts above 
100 cells/µl (table 1). Overall, controls were slightly younger than the drug user groups 
(table 1), but the groups did not differ in CD4 cell counts (p=0.13, table 1). 
Table 1. Characteristics of ART-naïve HIV-infected individuals in this study (n=82).
Heroin users
(n=17)
MMT
(n=17)
Former users
(n=17)
Controls
(n=31)
p-value*
Male (%) 82.4 94.1 88.2 77.4 0.462
Median age (IQR) 32 (29-37) 33 (30-35) 32 (30-34) 28 (22-32) 0.006
Median Hb (IQR) 14.7 (13.2-16.0) 14.0 (12.9-15.1) 15.6 (14.8-16.2) 14.8 (13.2-15.9) 0.039
Median CD4 cells (IQR) 411 (225-651) 240 (169-490) 377 (258-615) 283 (173-399) 0.130
Heroin users: used heroin in the last 30 days. MMT: individuals receiving methadone maintenance treatment 
(MMT) in the last 30 days. Former users: used heroin or methadone over one year ago. Controls: never used 
heroin or methadone. *Groups were compared using Kruskal-Wallis analyses. ART: antiretroviral therapy, 
IQR: interquartile range; Hb: haemoglobin
Whole blood from these individuals was stimulated with various pathogens, namely 
C.albicans, M.tuberculosis and LPS isolated from Escherichia coli. The cytokine production 
of unstimulated controls did not differ between groups, namely for IL-1β (p=0.466), IL-6 
(p=0.845), IFN-α (0.947), IFN-γ (0.431), IL-10 (0.625) and TNF-α (p=0.382).  
The results from the stimulated samples showed that generally the cytokine production 
was significantly lower in heroin users (figure 1) after exposure to LPS. Interesting the 
same was not observed after stimulation with C. albicans (figure 2) and M. tuberculosis 
(figure 3). Analysing the effect LPS exposure, significant less IL-1β, IL-6, TNF-α and IFN-γ 
production was found in heroin users (figure 1). The production of these cytokines in 
MMT and former users was comparable to the controls (figure 1). No differences were 
found in the production of IL-10 after exposure to LPS. Stimulation with C. albicans from 
both heroin users and former users seemed to produce less IL-1β and IL-6 than from 
controls; however these differences were not significant (figure 2). Also the production 
of the other cytokines was comparable between all groups after exposure to C. albicans. 
Compared to controls, the IL-6 production after stimulation with M. tuberculosis was 
lower in heroin users (not significant p=0.73) and former users (p=0.012) (figure 3). Also 
the production of IL-1β and TNF-α seems to have the same trend, but the differences were 
not statistically significant. Overall, not clear differences were found after stimulation 
117
Heroin use affects the production cytokines after whole blood stimulation
7
with M. tuberculosis (figure 3). The production of IFN-α was low in all stimulated samples 
and therefore these data are not shown. 
Heroin users MMT Ex users Controls Heroin users MMT Ex users Controls
Heroin users MMT Ex users ControlsHeroin users MMT Ex users Controls
Heroin users MMT Ex users Controls
Figure 1. The concentration of IL-1B (A), IL-6 (B), TNF-α (C), IFN-γ (D) and IL-10 (E) 
after ex vivo stimulation with LPS of E.coli  in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of cytokines was corrected for baseline level and number of CD4 cells (and 
given in pictogram per 105 cells). * Statistically significant difference (p< 0.016 after 
Bonferroni adjustment for multiple tests). MMT: methadone maintenance treatment; 
ART: antiretroviral therapy.
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Heroin users MMT Ex users Controls Heroin users MMT Ex users Controls
Heroin users MMT Ex users Controls Heroin users MMT Ex users Controls
Heroin users MMT Ex users Controls
Figure 2. The concentration of IL-1B (A), IL-6 (B), TNF-α (C), IFN-γ (D) and IL-10 (E) after 
ex vivo stimulation with Candida albicans  in various groups of ART-naïve HIV-infected 
individuals; individuals who used heroin in last 30 days (circles), individuals receiving 
methadone maintenance treatment (squares), individuals who used heroin over one 
year ago (triangles) and those who never used opioids (reversed triangles). 
The level of cytokines was corrected for baseline level and number of CD4 cells (and 
given in pictogram per 105 cells). * Statistically significant difference (p< 0.016 after 
Bonferroni adjustment for multiple tests). MMT: methadone maintenance treatment; 
ART: antiretroviral therapy.
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Heroin users MMT Ex users Controls Heroin users MMT Ex users Controls
Heroin users MMT Ex users Controls Heroin users MMT Ex users Controls
Heroin users MMT Ex users Controls
Figure 3. The concentration of IL-1B (A), IL-6 (B), TNF-α (C), IFN-γ (D) and IL-10 (E) after 
ex vivo stimulation with Mycobacterium tuberculosis  in various groups of ART-naïve 
HIV-infected individuals; individuals who used heroin in last 30 days (circles), individuals 
receiving methadone maintenance treatment (squares), individuals who used heroin 
over one year ago (triangles) and those who never used opioids (reversed triangles). 
The level of cytokines was corrected for baseline level and number of CD4 cells (and 
given in pictogram per 105 cells). * Statistically significant difference (p< 0.016 after 
Bonferroni adjustment for multiple tests). MMT: methadone maintenance treatment; 
ART: antiretroviral therapy.
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Discussion
In this study we show that the cytokine production is significantly down-regulated in 
HIV-infected heroin users compared to HIV-infected individuals who do not use opioids. 
Interesting, the altered cytokine production was only observed when cells were exposed 
to LPS but not to M. tuberculosis or C. albicans. 
We found that LPS-induced cytokines were affected by heroin use, whereas C. albicans 
and M. tuberculosis -induced cytokines were not. One could argue that the receptors and 
pathways involved in Candida (C-type lectin receptors) and tuberculosis (TLR 2 and NOD2) 
are less affected by opioids. However, previous studies have also found associations 
between opioids and these receptors [32-34]. In the present study we only found effects 
of LPS, which is a specific agonist for TLR4; therefore our results suggest that opioids may 
affect mainly the TLR4-dependent cytokine production. A binding site for opioids on the 
TLR4 protein complex has indeed been demonstrated [35]. Studies have furthermore 
shown that both opioid agonists and antagonists alter the expression of TLR4 [36, 36] 
or affect LPS signalling via the TLR4 signalling pathway [39], which strengthen the data 
of our study. The latter study showed that morphine alone only weakly increased TLR4 
activation, but it significant inhibited TLR4 signalling after LPS stimulation. Interesting 
naltrexone (a µ-opioid antagonist) also significantly inhibited LPS-induced TLR4 activation 
[38]. Apart from its effect on monocyte/ macrophages, animal studies also indicate that 
morphine influences the production of TNF-α in mast cells in a TLR4-dependent manner 
[40]. Interestingly, the interaction between opioids and TLR4 may also work in the opposite 
direction, as activation of TLR4 can increase the production of endogenous opioids, such 
as β-endorphin [40]. Furthermore, some studies find that stimulation of TLR4 affects the 
opioid-induced responses, such as incubated cue-induced heroin-seeking and morphine 
tolerance [41, 42], whereas others find no clear link [43]. Our study is in line with these 
studies, showing decreased signalling of TLR4 after LPS stimulation in individuals exposed 
to opioids.
Apart from the mechanisms described above, bacterial translocation in opioid users might 
also contribute to our findings, as animal studies have shown that morphine increases 
bacterial translocation [44-46]. Opioid induced intestinal permeability may result in 
more exposure to microorganism and endotoxins; continuous exposure could results in 
the well-known process of endotoxin tolerance [47], which may explain our findings of 
reduced ex vivo production of pro-inflammatory cytokines after LPS exposure in heroin 
users. While endotoxin tolerance has been thought of as a protective mechanism against 
septic shock and ischaemia, its incidence is associated with high risks of secondary 
infections [48]. Various molecular mechanisms have been described that underlie the 
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development of endotoxin tolerance, including defects in the TLR4 signalling pathway, 
activation of SOCS molecules, stimulation of anti-inflammatory cytokines such as IL-10, 
or epigenetic regulation [47-49]. In addition to opioids, HIV infection may increase gut 
permeability and exposure to endotoxins [50, 51]. Our data show that response to LPS is 
diminished which could therefore be due to translocation of bacteria, especially since all 
study subjects were HIV positive.
In addition, the opioid-induced immunomodulation may be affected by other factors 
such as chronic hepatitis C infection. Hepatitis C is highly prevalent among injecting drug 
users and we have previous shown that up to 90% of HIV-infected injecting drug users 
in Indonesia are seropositive for hepatitis C [52]. Previous studies have shown worse 
clinical outcomes among HIV-infected individuals with hepatitis C antibodies [53-58]. 
However, the relation between hepatitis C infection and HIV progression prior to ART 
remains unclear [53-56, 59]; the effects of HCV seems to be more pronounced among 
patients receiving ART [59, 60]. A recent study examined the relation between hepatitis 
C and circulating cytokine levels [50]. Overall, cytokine levels were significantly higher 
in individuals co-infected with HIV and hepatitis C, while no data were presented about 
opioid use [50]. Since hepatitis C is strongly correlated with injecting drug use, it is 
therefore difficult to distinguish between the effects of opioids and hepatitis C.
Only one other study analysed the influence of heroin or morphine use on the cytokine 
response [30], showing that HIV-negative heroin users produce less IFN-γ and more 
IL-10 after stimulation with LPS. Interesting, this difference was larger for heroin users 
compared to morphine. In line with these results, we also found a decrease of IFN-γ 
after LPS stimulation; however we did not find an increase of IL-10. Furthermore, we also 
found a significant difference between heroin and methadone users. Clinical and illicit 
opioids, such as morphine, methadone and heroin, exert their effects primarily through 
the µ-opioid receptor, but all with different affinity and some also bind to other opioid 
receptors [26-28, 61]. In addition, multiple isotypes of the µ-opioid receptor exists, with 
differences in ligand binding affinity, rates of internalization and resensitisation. This may 
explain the differences that are observed when heroin, morphine or methadone are used. 
 
Opioid-induced immunosuppression has shown to be mediated either directly via 
immune cells or via the central nervous system. In this study we focussed on the 
peripheral aspects of opioid-induced immunomodulation by using ex vivo stimulation of 
whole blood. However, the immune effects of opioids in vivo may also be affected by the 
central nervous system, as previously found in animal experiments [62, 63]. The effects 
of opioids are especially important among HIV-infected individuals, as chronic opioid use 
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has been shown to modulate HIV progression and facilitate HIV associated neurocognitive 
dysfunctions [52, 64]. Among other aspects, opioids may modulate epigenetic and 
transcriptional regulation of the µ-opioids receptor; this may in turn alter the overall 
physiological effect of opioids which could be important in HIV disease progression [64]. 
In our study we determined drug use based on interviews and did not perform toxicological 
tests, which could perhaps result in a bias. However, we worked closely together with 
employees of a local NGO, who have been in close contact with our subjects for years. In 
addition, drug test will only show recent use of opioids (up to four days) and therefore 
might not be reliable in identifying active users that did not use in the previous couple 
of days. In addition, we do not have HIV viral loads of our study population, which might 
also affect the production of cytokines. However, we have previously shown that the viral 
load among people with and without a history of injecting drug use did not differ [52]. 
In conclusion, we uniquely examined the immonumodulating effects of heroin and 
methadone in HIV-infected individuals. We show that heroin use decreases the cytokine 
response to LPS, but not to M. tuberculosis and C. albicans. Especially in HIV-infected 
individuals these immunomodulating effects of opioids may have deteriorating effects 
and increase the risk of secondary infections. 
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Abstract
The antimicrobial peptide cathelicidin is critical in killing pathogens by innate immune 
cells, including Mycobacterium tuberculosis and Candida albicans. These pathogens 
often cause infections in opioid users, a risk that is greatly increased with concurrent 
human immunodeficiency virus (HIV) infection. Therefore, we examined the association 
between opioid use and cathelicidin in HIV-infected subjects from Bandung, Indonesia. 
Included were the following three groups of HIV-infected individuals: 1) Active drug users: 
used heroin in the last 30 days; 2) Methadone clients: received methadone maintenance 
treatment in the last 30 days; 3) Controls: never used opioids or did not use opioids in the 
year preceding inclusion. In addition to interviews, blood samples were taken to examine 
the RNA expression of cathelicidin. We found that the RNA expression of cathelicidin 
was significantly decreased (p=0.007) in heroin users, compared to controls. Opioids 
are associated with immunosuppression and cathelicidin could be an important factor 
in this association. However, more research is needed to examine the direct effects of 
decreased cathelicidin levels.
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Introduction 
Injecting drug use (IDU) is a global health problem and studies have shown that 
injecting drug users are more susceptible to infections, which are the major cause of 
hospitalization and morbidity [1]. On average one in five injecting drug users is infected 
with the human immunodeficiency virus (HIV), among who tuberculosis is a prevalent 
illness [2]. The increased incidence of HIV and blood-borne diseases is caused by high 
risk behavior, such as using dirty needles and unsafe sex. In addition, the elevated 
risk of other infections, such as tuberculosis,is associated with increased exposure to 
pathogens and is usually attributed to social determinants, such as use of tobacco and 
alcohol, homelessness, and incarceration [3, 4]. Biological aspects related to drug use 
may also play a role, as opioids have immunosuppressive effects [5, 6]. Opioids can affect 
the innate and adaptive immune response, either directly by binding opioid receptors 
on immune cells or indirectly by modulating the hypothalamo-pituitary-adrenal axis [7], 
which deregulates the production of immunosuppressive hormones. 
Chronic opioid use is associated with diminished vitamin D, which is at least partly due to 
overall behavior of addicted individuals [8]. In addition, HIV infection is known to cause 
nutritional deficiencies, such as a diminished vitamin D [9, 10]. Vitamin D deficiency 
has been linked to a wide range of diseases [11] and it is able to modulate the innate 
immune response by up-regulation of antimicrobial peptides (AMPs) [12]. Cathelicidins 
are a large family of AMPs and the only human cathelicidin LL-37/hCAP-18, is regulated 
by the biologically active form of vitamin D: (1,25(OH)2D3) [12, 13]. Cathelicidin targets 
inflammatory pathways and it forms an important link between the innate and adaptive 
immune system. It can modulate the innate immunity, activate different cell types, induce 
chemotaxis and support cytokine secretion [14, 15].
Previous studies have shown a strong relation between the expression of cathelicidin 
and the occurrence of infections. In cathelicidin knock-out mice, infections of cornea, 
gastrointestinal tract, and skin are seen frequently [16-18]. In addition, humans who 
suffer from cathelicidin deficiency are more susceptibility to periodontal diseases [19], 
respiratory tract infections [20, 21] and candidiasis [22]. Interestingly, these infections are 
very common among drug users, especially among those infected with HIV. Therefore, we 
hypothesize that the expression of cathelicidin is down-regulated in opioid users, which 
we examined in HIV-infected individuals in Bandung, Indonesia. 
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Methods
Study setting and subjects
For this study, we included HIV-infected adults (>16 years) from different settings in 
West-Java, Indonesia; an HIV clinic, a methadone clinic and the community. The clinics 
were established as part of a five-year program (2006-2011) called “IMPACT”, aimed to 
improve prevention, control and treatment of HIV among injecting drug users in West-
Java [23]. To contact individuals in the community, we collaborated closely with Rumah 
Cemara, a local NGO focusing on increasing the quality of life for drug users. This study 
was approved by the Health Research Ethics Committee at the Faculty of Medicine of 
Padjadjaran University/Dr. Hasan Sadikin General Hospital in Bandung, Indonesia.
All individuals included were antiretroviral therapy (ART) naïve and had no signs of 
opportunistic infections, such as tuberculosis or oral thrush. We included the following 
three groups of HIV-infected individuals: 1) Active drug users: individuals who used 
heroin in the last 30 days; 2) Methadone clients: individuals who received methadone 
maintenance treatment (MMT) in the last 30 days; 3) Controls: individuals without a 
history of drug use or individuals who did not use opioids in the year preceding inclusion. 
All participants were informed on the study and provided a written consent. Data on 
demographic factors, history of drug use, co-morbidity, self-reported tuberculosis 
treatment and history of ART were collected through interview with standardized 
questionnaires. In addition, blood was collected in EDTA tubes and PAXgene Blood 
RNA tubes (PreAnalytiX, Qiagen) for full blood counts and CD4 cell count respectively 
Quantitative Real-time Polymerize Chain Reaction (qPCR) to detect the RNA expression 
of cathelicidin. 
RNA expression of cathelicidin
PAXgene Blood RNA tubes were placed in a -20°C freezer until RNA extraction. RNA 
was isolated using the PAXgene Blood RNA Kit (PreAnalytiX, Qiagen) according to 
manufacturers’ instructions. RNA (0.2 µg) was reverse transcribed using the iScript cDNA 
Synthesis Kit (Biorad) following manufacturers’ instructions. The cDNA was stored at 
-20°C until qPCR. 
The qPCR was used to determine the RNA expression of cathelicidin. The results were 
normalized using the housekeeping gene GAPDH and quality control was performed by 
measuring multiple melting curve points. We used the following primers systemized by 
Biolegend (Netherlands): cathelicidin forward, TGCCCAGGTCCTCAGCTAC, and reverse, 
GTGACTGCTGTGTCGTCCT. Each reaction contained 5 µl SYBR Green PCR Master Mix 
(Applied Biosystems), 2.92 µl H2O, 0.04 µl of 100µM forward and 100µM reverse primers 
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and 2µl cDNA sample. Amplification of the genes was performed for 10 minutes at 
95°C, followed by 40 cycles at 95°C for 15 seconds, annealed at 60°C for 20 seconds, 
and extended at 90°C for 15 seconds. Data were analyzed using the StepOnePlus Q-PCR 
(Applied Biosystems). Relative changes were analyzed using the 2(-Delta Delta C(T)) 
method, measurements were repeated if the reaction efficiencies were >95%. 
Statistical Analysis
The Kruskal-Wallis and Mann-Whitney-U analyses were used to compare differences 
between groups. For this study we used an alpha of 5%, for Mann-Whitney-U analyses 
this results in a p-value of 0.016 after Bonferonni adjustment. All statistical analysis was 
performed using the Statistical Product and Services Solutions package version 18.0 and 
GraphPad Prism version 5.0.
Results 
In total we included 89 HIV-infected individuals, of which 26 were active heroin users, 25 
individuals received MMT, and 38 had never used opioids or used opioids over one year 
ago (table 1). The majority was male and had an average CD4 cells count of 343cells/
µl (IQR: 192-496). We found no significant differences between the three groups with 
regard to gender, ART and CD4 cells (table 1). However, the group receiving MMT had 
significant lower hemoglobin level (p=0.011) and non-users were significantly younger 
(p=0.001) (table 1).
Table 1. Baseline characteristics of HIV-infected individuals, divided in heroin users, those 
receiving methadone maintenance treatment (MMT) and controls. 
Heroin users MMT Controls p-value
Subjects, n 26 25 38
ART, % (n) 19 (5) 32 (8) 16 (6) 0.297
Male, % (n) 81 (21) 92 (23) 87 (33) 0.504
Median age, years (IQR) 33 (29-36) 34 (31-37) 29 (23-33) 0.001
Median CD4 cells, cells/µl (IQR) 432 (199-550) 410 (174-625) 353 (200-475) 0.705
Median Hb, g/dl (IQR) 14.1 (13.1-15.7) 13.3 (12.2-14.5) 14.6 (13.6-16.2) 0.011
Heroin users: individuals who used heroin in last 30 days; MMT: individuals who received methadone 
maintenance treatment (MMT) in last 30 days; Controls: individuals who never used opioids or did 
not use opioids in the year preceding inclusion. P-values calculated by comparing groups with Kruskal-
Wallis. n=number of people, IQR: interquartile range; ART = antiretroviral therapy; Hb = hemoglobin 
levels
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Figure 1. Gene expression of cathelicidin for treatment naïve HIV-infected individuals 
for those using heroin or receiving methadone maintenance treatment (MMT) in the 
last 30 days, and individuals who never used opioids or did not use opioids in the year 
preceding inclusion (Controls). 
* p-value <0.05. Data are shown as individual and median RNA expression. There was 
a significant difference in expression between groups (Kruskal-Wallis p=0.014). After 
Bonferonni adjustment, a p-value below 0.016.represents a statistically significant 
difference with an alpha of 5%.
We did not find a difference in the production of GAPDH between heroin users, MMT 
client and controls (Kruskal-Wallis: p=0.303). The median relative RNA expression of 
cathelicidin was 0.030 (IQR: 0.018-0.077). We found a significant difference in the 
expression of cathelicidin between groups (KW p=0.014). Figure 1 shows that the 
cathelicidin expression was significantly lower in heroin users compared to not active 
users (p=0.007) and those receiving MMT (p=0.058). The median cathelicidin expression 
was 0.022 in heroin users (IQR: 0.011-0.040), compare to 0.031 in those receiving MMT 
(IQR: 0.18-0.087) and 0.040 in controls (IQR: 0.022-0.130) (figure 1). 
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Discussion
This study indicates that the whole blood cathelicidin expression in HIV-infected 
heroin users is down-regulated compared to non-drug users which may play a role in 
the increased susceptibility to certain opportunistic infections in these patients. To our 
knowledge, no previous studies have examined the association between opioids and 
cathelicidin. 
Cathelicidin is important in the innate and adaptive immunity and for the clearance 
of pathogens, including infections frequently seen in drug users. Infections such as 
tuberculosis and candidiasis are more common among drug users, which cannot be 
completely explained by higher exposure to these pathogens [24, 25]. Over the past few 
decades, studies show that opioids increase the susceptibility to microbial infections 
in experimental animal models by modulating the immune response. Infections with 
herpes simplex virus and C.albicans have proved lethal in opioid treated animals [26, 27]. 
Cathelicidin severely affect the membrane morphology of C.albicans, which results in 
leakage of proteins, release of vital components, and subsequent cell death [28]. Opioids 
might diminish this defense mechanism by decreasing cathelicidin and thus resulting in 
more (severe) candidiasis, as seen in the animal models. An important risk factor for 
these infections is off course HIV itself, however the decreased expression of cathelicidin 
may play a role in the increased risk of opportunistic infections in injecting drug users.
LL-37-mediated inflammasome activation has also been described. Cathelicidin is able to 
activate the P2X7 receptor, resulting in an increase of IL-1β expression and release [29]. 
If opioids indeed decrease the expression of cathelicidin, this would lead to decreased 
clearance of gram-negative bacteria. Supporting this hypothesis, LPS-induced sepsis was 
indeed more common in opioid exposed rats [30].
Cathelicidin enhances the resistance to mycobacterial infections by the activation of 
transcription of autophagy-related genes [31]. Capturing and destroying of the immature 
phagosomes that harbor pathogens is an important host defense mechanism of human 
macrophages against M.tuberculosis [32]. Down-regulation of cathelicidin would result in 
higher susceptibility to M.tuberculosis, since less accumulation of autophagosomes and 
decreased ability to fuse with lysosomes will lead to decreased clearance of intracellular 
pathogens. In line with our hypothesis, M.tuberculosis infection is more common among 
drug users [33].
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Opioid receptors are expressed on immune cells and signal transduction induced by 
opioids modulates the immune function of these cells [7]. However, there has not yet 
been any link with the production of cathelicidin. However, cathelicidin production 
is linked to vitamin D, which is regulated by the biologically active form of vitamin D: 
(1,25(OH)2D3) [12, 13]. Possibly opiates either directly or indirectly affects cathelicidin via 
this pathway. 
In this study, we focused on looking at the whole blood RNA expression of cathelicidin. 
Consequently, we were not able to determine the contribution of each cell type or 
conclude anything on the actual amount of released cathelicidin in the blood or at the 
level of mucous membranes. Therefore, more research is needed to explore the relation 
between opioid use and the cathelicidin. 
Conclusion
In conclusion, cathelicidin could be an important factor in the immunosuppression 
induced by opioids. This study provides unique evidence on decreased expression of 
cathelicidin in opioid users, but more research is essential for better understanding of 
underlying mechanisms and direct effect of this result on risk of infection.
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Summarizing discussion
Drug users are at increased risk for human immunodeficiency virus (HIV); worldwide 
injecting drug use (IDU) is responsible for approximately ten percent of all HIV infections. 
In chapter 2 we present a global perspective of IDU in relation to HIV. There are 16 
million people who inject drugs worldwide, of whom an estimated 3 million are infected 
with HIV. The prevalence of HIV among injecting drug users varies greatly between 
countries as well as within them. There are intervention programmes to prevent HIV 
transmission via drug use such as needle and syringe exchange programmes (NSPs) and 
opioid substitution therapy (OST). These programmes are effective for preventing HIV 
transmission, provided that their implementation is adequate. NSPs are provided in 80% 
of the countries and 65% also provides OST. However, the coverage of these services is 
nevertheless insufficient; only eight percent of injecting drug users has access to NSPs. 
From the start of the HIV epidemic it has been recognised that IDU is not only a risk factor 
for HIV-transmission, but that it may also change the natural course of HIV infection and 
increase the risk of infections, such as tuberculosis. Epidemiological data that explore 
the association between IDU and HIV progression often use clinical endpoints, such 
as mortality and AIDS-free survival. These endpoints could be influenced by other 
factors confounding the relation between IDU and the progression of HIV. Importantly, 
it has long been recognised that opioid use is associated with increased incidence of 
infectious diseases, whereby one may wonder whether the link between opioids and 
infections can merely be explained by sharing needles or increased exposure to microbial 
pathogens. Various studies have shown that opioids themselves modulate the immune 
response. Almost all studies exploring the relation between IDU and infection, such as 
HIV and tuberculosis, have been conducted in high-income countries and mostly among 
Caucasians. In these settings, IDU is also associated with other factors that predispose 
to infectious diseases, such as malnutrition, homelessness, crowding and imprisonment. 
In addition, lower utilization of health services and poor treatment compliance among 
drug users may lead to more severe or prolonged disease. However, the situation is very 
different in Indonesia, where interestingly IDU seems to have started among university 
students in university campuses, a very different group from drug users in western 
countries. Therefore, this thesis examined epidemiological aspects of IDU in relation to 
HIV progression and susceptibility to tuberculosis in a cohort of HIV-infected individuals 
in Indonesia (chapter 3 and 4). 
Injecting drug use is associated with faster HIV disease progression
In chapter 3 the hypothesis was investigated whether individuals with a history of IDU 
have a faster progression of HIV compared to non-drug users, using the natural decline of 
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circulating CD4 cells as marker for the level of immunodeficiency. We therefore included 
all antiretroviral therapy (ART) naïve HIV infected individuals who had at least two 
subsequent CD4 cell counts available before starting ART. We examined the association 
between IDU and CD4 decline using a linear mixed model, with adjustment for possible 
confounders such as HIV viral load and hepatitis C antibodies. Our analysis indicated that 
people with a history of IDU had a statistically significant faster decline in CD4 cells. Based 
on our data, patients with a history of IDU would have an average 33% decline in CD4 
cells after one year without ART, compared with a 22% decline among non-users. No 
other factor significantly affected CD4 cell decline. 
Active tuberculosis is more prevalent among injecting drug users
IDU is also associated with tuberculosis but few data are available from low-income 
settings. In chapter 4, we questioned if HIV-infected people who inject drugs more 
often develop active tuberculosis than non-drug users, without the presence of more 
latent tuberculosis infection (LTBI) in Indonesia, which has a high tuberculosis burden. 
Active tuberculosis was diagnosed prospectively among a cohort of HIV-infected ART-
naïve adults entering care in a HIV clinic in Indonesia. In addition, the prevalence of 
LTBI was determined cross-sectionally in a subset of ART-experienced patients using an 
interferon-gamma release assay (IGRA). People with and without a history of IDU were 
compared using univariate and multivariate Cox and linear regression analyses. We 
found that patients with a history of IDU more often reported a history of tuberculosis 
treatment, more often received tuberculosis treatment during follow-up, and more often 
had bacteriologically confirmed tuberculosis. The prevalence of LTBI was not different, 
which may suggest that HIV-infected patients with a history of IDU have a higher risk of 
progression to active tuberculosis after M. tuberculosis infection. None of these results 
were explained by differences in CD4 cell count or ART. 
The general concept in literature is that the risk of tuberculosis is increased in people who 
inject drugs due to lower access to health services, poor compliance with interventions 
and increased exposure to M. tuberculosis, because of homelessness, crowding and 
incarceration [1-3]. However, we do not expect higher exposure to M. tuberculosis 
among HIV-infected patients with a history of IDU in Indonesia, where interestingly 
enough HIV and IDU are often associated with higher education and wealthier socio-
demographic background [4, 5]. A recent study in China has shown that IDU is a risk factor 
for tuberculosis among people receiving methadone maintenance treatment (MMT) [6], 
which is in line with our results. The increased incidence of tuberculosis and the faster 
progression of HIV among injecting drug users might therefore be explained by biological 
aspects relation to IDU.
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Possible reasons for faster HIV progression and more tuberculosis in injecting drug users
HIV tropism has been associated with HIV progression, with faster CD4 cell decline and 
worse clinical outcome associated with the X4 virus [7-9]. X4 viruses have been found 
more often among recently infected injecting drug users, which could be explained by 
preferential infection of R5 virus through sexual intercourse [10, 11]. Another explanation 
could be co-infection with chronic hepatitis C (HCV), which is highly prevalent among 
injecting drug users, often in combination with HIV. Previous studies have shown 
deteriorated clinical outcome among HIV-infected individuals with HCV antibodies [12-
17]. However, the relation between HCV infection and CD4 cell decline prior to ART 
remains unclear [12-14, 17, 18] and the effects of HCV seems to be more pronounced 
among patients receiving ART [18, 19]. Finally, immunomodulating effects of heroin and 
other opioids could affect HIV progression and susceptibility to tuberculosis; in vitro and 
animal studies have found immunosuppressive effects of  opioids [20]. Furthermore, 
studies have shown that opioids increase the expression of the HIV co-receptors CXCR4 
and CCR5 and consequently increase viral replication of HIV [21-25]. Opioids might 
also influence HIV-mediated apoptosis of both HIV-infected and uninfected cells, which 
is considered an important cause of CD4 cell decline during HIV infection. In neuronal 
cells, morphine was shown to enhance HIV-induced apoptosis [26, 27]. Also in immune 
cells significantly more apoptosis was observed when cells were exposed to morphine in 
combination with HIV protein gp120 [28]. In relation to mycobacteria specifically, studies 
show mixed results; some finding advantageous effects of opioids [29], others showing 
deleterious effects [30, 31]. 
In conclusion, we have shown that IDU is associated with a faster progression of HIV and 
more tuberculosis among HIV-infected individuals in Indonesia. To determine if there is 
a causal relation, individuals would ideally be examined regularly from time of infection 
until initiation of treatment. Unfortunately in clinical practice, this is rarely the case. We 
have posted several hypotheses above about the underlying mechanisms responsible for 
the relation between IDU, HIV disease progression and susceptibility to tuberculosis. It 
is crucial to study underlying mechanism in these finding and test the posed hypothesis. 
This thesis also discussed the effects of in vivo exposure to opioids in humans on HIV co-
receptors and immunological markers (such as cytokines and chemokines).
Altered expression of HIV co-receptors 
In addition to a CD4 receptor, HIV also requires a co-receptor, either CCR5 or CXCR4, 
to invade cells. In general, HIV isolated from newly infected individuals uses CCR5 and 
these “R5 variants” are detectable over the entire course of the HIV infection [32]. The 
X4 variants, that utilize CXCR4, are mostly detectable at a late stage of the disease and in 
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only up to 50% of all patients [33]. Both co-receptors are expressed on leukocytes, but to 
different extents on different T-cell subsets [34, 35]. CCR5 and CXCR4 could play a crucial 
role in the progression of HIV; a well-known polymorphism in the CCR5 gene, namely 
CCR5∆32 (a 32 base pair deletion in the CCR5 gene) interrupts the entrance of HIV into 
cells. Individuals homozygous for this deletion are almost completely resistant to HIV 
infection [36-39] and those heterozygous for CCR5∆32 have shown slower progression 
of HIV [36, 40-42]. Furthermore, the (level of) expression of CCR5 and CXCR4, on CD4+ 
T-lymphocytes, is extremely important in the susceptibility of cells to HIV infection [43] 
and viral replication [44, 45]. 
Most HIV-infected patients exhibit a gradual decline in CD4 cells throughout the course of 
their infection; the rate of disease progression from asymptomatic HIV infection to AIDS 
varies between patients. Some HIV patients are able to maintain stable CD4 cell counts 
for an extended time and remain asymptomatic without ART for years after infection. 
These patients have been referred to as long-term non-progressors (LTNP). In chapter 5 
the question was asked if the expression of CCR5 and CXCR4 on memory (CD45RO+), naïve 
(CD45RA+) cells and regulatory T-cells (CD4+CD25highFoxP3+) was lower in HIV-infected 
LTNP compared to normal progressors. We examined this question in a cross-sectional 
study, including five HIV-infected LTNP with viral control, thirteen HIV-infected and seven 
HIV-uninfected individuals in the Netherlands. The percentage of CCR5-expressing CD4+ 
cells of LTNP was comparable with healthy controls; whereas HIV-infected individuals 
showed more CCR5-expressing cells. This was observed in memory and naïve CD4+ cells, 
but not in regulatory T-cells. All groups had comparable percentages of CXCR4-expressing 
cells, but the mean fluorescence index (MFI) of CXCR4-expressing cells was significantly 
higher in HIV-infected normal progressors in both memory and naïve CD4+ cells. In 
addition, the CCR5∆32 polymorphism was not related to any group. Our results indicate 
that HIV affects -directly or indirectly- the expression of CCR5 in CD4+ T-lymphocytes; yet 
this effect is not seen in LTNP with viral control. In conclusion, preventing up-regulation 
of CCR5 on CD4+ T-lymphocytes could be an important method via which LTNP counteract 
the effects of HIV and suppress viral replication. 
In vitro studies have shown that opioids may alter the expression of the HIV co-receptors 
CCR5 and CXCR4 and could thereby affect the natural course of HIV infection. In chapter 
6 the hypothesis was explored whether heroin use and MMT in humans increase the 
expression of CCR5 and CXCR4 in HIV-infected individuals. For this study we included 
individuals using heroin, MMT, heroin over one year ago and controls (never used 
opioids). The expression of CCR5 and CXCR4 was examined using flow cytometry. The 
expression of CCR5 on CD4+ cells was significant higher in heroin users, methadone 
146
Chapter 9
9
clients and previous drug users compared to the controls. The percentage of CXCR4-
expressing CD4 positive cells was significantly higher in controls compared to the other 
groups. Our data therefore indicate that exposure to opioids may have long-term effects 
on the immune system by up-regulation of CCR5 and down-regulation of CXCR4. In line 
with our findings, a recent study in rhesus macaques showed that chronic morphine 
administration resulted in an increase of CCR5 and decrease of CXCR4 expression on 
both CD4+ and CD8+ lymphocytes [41]. These results suggest that opioids could affect 
the HIV susceptibility of cells by increasing important HIV co-receptor and might partially 
explain the increased occurrence of tuberculosis (chapter 4) and faster progression of HIV 
(chapter 3) in people who inject drugs.
Opioids affect the production of chemokines, cytokines and cathelicidin
Not only the HIV co-receptors, but also their ligands (MIP-1α/CCL3, MIP- 1β/CCL4, 
RANTES/CCL5 and MCP-2/CCL8 for CCR5 and SDF-1/CXCL12 for CXCR4) have the ability 
to block HIV activity [39]. In vitro experiments have shown that low levels of chemokines 
are associated with high susceptibility to HIV [46, 47]. In addition, in vitro and animal 
experiments have shown that opioids can affect the expression of RANTES [48-51], 
MIP-1α [50] and MIP-1β [52]. Altogether, these studies suggest that opioid use might 
affect the chemokine response to pathogens, which in turn could alter the susceptibility 
to infections and disease progression among individuals who use opioids. In chapter 
6 we explored the hypothesis that heroin users and individuals receiving MMT have 
a diminished production of chemokines after ex vivo stimulation of whole blood with 
various pathogens. For this study, individuals had to fit the inclusion criteria of one of 
the four groups: 1) Active drug users: used heroin in the last 30 days; 2) Methadone 
clients: received MMT in the last 30 days; 3) Former users: used heroin or methadone 
over one year ago; 4) Controls: never used heroin or methadone. Whole blood of these 
subjects was stimulated with M. tuberculosis, C. albicans and E. coli LPS for 24 to 48 
hours. The chemokine production, namely RANTES, MIP-1α, MIP-1β, MCP-2, and SDF-
1, in these samples was determined with Luminex. In unstimulated samples we found 
no differences in the amount of chemokines produced. Controls produced slightly more 
SDF-1 after exposure to C. albicans and M. tuberculosis, but not after E. coli LPS. After 
stimulation with LPS the production of MCP-2, MIP-1α and MIP-1β was reduced in heroin 
users. The production of MIP-1α and MIP-1β was lower among both active and former 
heroin users after exposure to M. tubercuosis. These results indicate that opioids affect 
the immune system by down-regulation of HIV-relevant chemokines, but that the effect 
is different using heroin or methadone. The chemokine levels are stronly related to the 
susceptibility to HIV, with low chemokine levels associated with high HIV susceptibility 
[46]. Overall we found that opioid users produced less chemokines after stimulation with 
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pathogens. This suggests that opioid use could result in higher susceptibility of cells to 
HIV, which supports our previously findings that opioid users have a faster progression of 
HIV (chapter 3) [5]. 
Cytokines regulate the immune and inflammatory response, and compromised immune 
function may be a result of altered cytokine production. The effects of opioids on cytokine 
production have been investigated in both in vitro and animal experiments, but hardly 
any information is available on in vivo exposure in humans. In chapter 7 the question 
was asked if individuals using heroin or receiving MMT have a diminished production of 
cytokines after ex vivo stimulation of whole blood with various pathogens. For this study 
we aslo included HIV-infected heroin users, MMT clients, former users and controls. 
Whole blood of these subjects was stimulated with M. tuberculosis, C. albicans and E. coli 
LPS for 24 to 48 hours. The cytokine production, namely IL-1β, IL-6, IL-10, IFN- α, IFN-γ 
and TNF-α, in these samples was determined using Luminex. The cytokine production 
of unstimulated controls did not differ between groups. The production of IFN-α was 
low in all stimulated samples and therefore these data were not analysed. In general, 
the cytokine production was significantly lower in heroin users after exposure to LPS. 
Interesting the same was not observed with C. albicans and M. tuberculosis. When looking 
at LPS exposed cells, IL-1β, IL-6, TNF-α and IFN-γ production was decreased in heroin 
users. The production of these cytokines in MMT and previous users was comparable 
to the controls. The production of cytokines was comparable between all groups after 
exposure to C. albicans and M. tuberculosis. This is the first study to examine the effects 
of heroin and methadone on cytokine response in HIV-infected individuals. Our finding 
of decreased cytokine responsiveness to LPS indicate that opioids may specifically affect 
the TLR4 pathway, possibly through intestinal function, thereby increasing microbial 
translocation and as such induce endotoxin tolerance. 
The antimicrobial peptide cathelicidin is critical in killing pathogens by innate immune 
cells, including M. tuberculosis and C. albicans. These pathogens often cause infections in 
opioid users, a risk that is greatly increased with concurrent HIV infection. In chapter 8 we 
explored whether the expression of cathelicidin was alter in HIV-infected heroin users and 
individuals receiving MMT compared to other HIV-infected individuals. For this study we 
included individuals using heroin, MMT and controls (never used opioids or did not use 
opioids in the year preceding inclusion). In addition to interviews, blood samples were 
taken to examine the RNA expression of cathelicidin using polymerase chain reaction. 
We found that the RNA expression of cathelicidin was significantly decreased in heroin 
users, compared to non-drug users. Opioids are associated with immunosuppression and 
cathelicidin could be an important factor in this association. 
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Conclusion
This thesis shows that opioid use affects HIV disease progression and the susceptibility to 
tuberculosis; we presented various biological factors that were indeed affected by opioid 
use (figure 1). Uniquely, we looked at the in vivo exposure to heroin and methadone, 
whereas previous research has typically been performed using in vitro or animal 
experiments.  These studies showed that IDU indeed down-regulated CCR5 and up-
regulated CXCR4, which may be important for HIV progression. In addition, chemokines, 
cytokines and cathelicidin were altered in heroin users; this could be important in 
susceptibility to infection.
Figure 1. Overview of the effects of opioids related to HIV infection. Black lines represent 
results from this thesis, dotted lines are theoretical relations based on literature.
It should be noted that individuals with a history of IDU in our cohort are not from a 
lower or impoverished background which might affect disease progression or exposure 
to tuberculosis; most had higher education and higher social economic background. 
Instead we suspect that a biological factors related to IDU play a major role, such as a 
direct effect of opioids, a difference in tropism or virulence of HIV virus transmitted via 
sharing needles, or underlying conditions such as HCV infection. In this study we have 
examined the direct effect of opioid use on biological factors, namely the expression of 
CCR5 and CXCR4, the production of cytokines and chemokines, and the RNA expression 
of cathelicidin. Our results show that all these factors are indeed affected by opioid use 
and could play a role in deleterious clinical outcome among HIV-infected injecting drug 
users. However, other biological aspects related to IDU may also be of importance and 
should be studied.  
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We have shown that CCR5 is important for HIV disease progression and that this receptor 
is up-regulated in HIV-positive heroin users. However, CCR5 is also of importance in 
other infectious diseases. In Cryptococcus neoformans, Schistosomiasis mansoni and 
Toxoplasma gondii infection, CCR5 plays a role in host defence [53-55]; whereas during 
Leishmania major, Histoplasma capsulatum and Paracoccidioides brasiliensis CCR5 
favours pathogen persistence [56-58]. In M. tuberculosis infection the expression of 
CCR5 is increased [59, 60], which helps subverting the host immune response by M. 
tuberculosis [61]. This thesis has shown that opioid use affects the expression of CCR5; 
which may thus be important for not only for HIV infection, but also for a range of other 
infection.
Interestingly we found that heroin and methadone have different immunomodulating 
effects. Even though both opioids work predominantly through the µ-opioid receptor, 
heroin also binds to κ- and δ-opioid receptor while methadone has no affinity with these 
receptors [62-65]. These differences in affinity for the opioid receptors might possibly 
explain our findings. Our results indicate that methadone has less immunomodulating 
effects compared to heroin. MMT is given among others to prevent craving and thereby 
reduce “risk” behaviour and as such prevent transmission of blood born disease, such 
as hepatitis C and HIV. Our findings that methadone has less immunomodulating effects 
indicate that MMT might have more benefits than merely substitute for heroin to prevent 
craving and improve quality of life. 
Our studies have shown that also a former history of IDU is also associated with faster 
disease progression, increased susceptibility of tuberculosis and altered expression of 
cytokine, chemokines and cathelicidin. This suggests that opioids may induce long-term 
immune modulating effects on the immune system, possibly trough epigenetic changes. 
Studies have shown that epigenetic changes by opioids can affect the expression, splicing 
and/or internalisation of opioid receptors [66]. In addition, a recent study showed that 
morphine induced epigenetic changes of a protein involved in morphine conditioning 
[67], indicating that opioid-induced epigenetic changes may affect both biological and 
behavioural aspects related to opioid use.
Our studies were focussed on HIV-infected individuals; however, the present results could 
also have implications outside this specific group of patients. Opioids are frequently used 
as analgesics in various patient categories whereby opioid modulation of chemokines 
may have consequences for different diseases, such as cardiovascular disease, cancer and 
even psychiatric diseases [45-47]. 
150
Chapter 9
9
Implications for clinical practice
Our findings may have implications for health policy and practice related to HIV prevention 
or care.
Increased monitoring of HIV disease progression among injecting drug users
Our results indicate that IDU is associated with faster disease progression and higher 
incidence of tuberculosis. We recommend therefore active HIV testing in people with 
a history of IDU (current and former). In addition, HIV treatment should be given 
irrespectively of CD4-cell numbers, as a suppressed viral load reduced the risk of HIV 
transmission [68]. Additionally ART protects against development of tuberculosis, 
irrespective of CD4 cell count [69]. Active case finding might be improved by involving 
local NGOs and educating people about the risks when not treated in time. 
Prioritising testing for latent tuberculosis infection
We have shown active tuberculosis to be much more common among people who inject 
drugs. Testing for LTBI should be considered for current and former injecting drug users, 
irrespectively of HIV status. Within the HIV clinic, testing for LTBI and isoniazid preventive 
therapy should be prioritised to patients with a history of IDU. 
Advising methadone maintenance treatment
We recommend prioritisation of up-scaling of MMT facilities in countries where injecting 
drug users live, not only because MMT reduces the (uncontrolled) use of heroin and 
thereby stabilize the lives of patients and as such quality of life but also because MMT 
prevents transmission of blood born disease, such as hepatitis C and HIV and has less 
adverse effects on the immune system. 
Options for future research
Several research questions remain unanswered because of limitations in our studies, 
subjects out of the scope of this thesis or novel research questions for future studies. A 
selection of these questions is listed below.
The association between injecting drug use and immunity in HIV-negative individuals. 
The studies in this thesis were performed in HIV-positive individuals to explore whether 
opioids could affect the HIV susceptibility of cells and modulate immune function. However, 
opioids are also frequently used as analgesics in healthcare settings and modulation of 
chemokines may be important for numerous diseases, such as cardiovascular disease, 
cancer and even psychiatric diseases [70-72]. Therefore, the present results could have 
even larger implications than just among HIV-infected individuals.
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Differentiation between the immunomodulating effect of hepatitis C and opioids.
In this thesis we looked at immunomodulating aspects of heroin and methadone. However, 
HCV is strongly associated with IDU, thus this might be an underlying mechanism that 
affects biological aspects related to the immune system. To differentiate between opioids 
and hepatitis C research needs to be done among individuals with and without hepatitis 
C in combination with opioid use. 
HIV tropism among injecting drug users and the effects on immunity.
The mode of HIV transmission differs between HIV-positive injecting drug users and other 
risk groups. Possibly this could result in a difference of HIV tropism. HIV tropism has been 
associated with HIV progression, with faster CD4 cell decline and worse clinical outcome 
associated with the X4 virus [7-9]. X4 viruses have been found more often among 
recently infected injecting drug users, which could be explained by preferential infection 
of R5 virus through sexual intercourse [10, 11]. Future research is needed to examine the 
effects of HIV tropism in relation to HIV, susceptibility to infections and immune response. 
Effects of maraviroc (a CCR5 blocker) on infectious disease such as tuberculosis
The CCR5 receptor is not only a co-receptor for HIV, but is also important for other 
diseases such as tuberculosis. A relatively new type of HIV treatment, maraviroc, works 
as a CCR5 antagonist. It has proven to have potent anti-HIV activity, however further 
research should explore the effects of maraviroc on immune responses related to other 
infection diseases, such tuberculosis.  
Test whether the change in expression of HIV co-receptors also has a functional effect
Our results show that opioids affect the expression of HIV co-receptors CCR5 and CXCR4. 
Based on previous research we hypothesize that this will result in increased infectiousness 
and viral replication. However, functional assays are needed to confirm whether this is 
indeed the case. For these studies cells from individuals who do and do not use opioids 
should be isolated and tested for migration, HIV infectiousness and replication. 
Cathelicidin production
In our study we focused on whole blood RNA expression of cathelicidin. Consequently, 
we were not able to determine the contribution of each cell type or conclude anything 
on the actual amount of released cathelicidin in the blood or at the level of mucous 
membranes. Therefore, more research is needed to explore the relation between opioid 
use and the cathelicidin, both in in vitro and in vivo studies.
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Dopamine, immune response and injecting drug use
HIV-tat protein has been shown to interfere with blood-brain-barrier integrity and 
damage cerebral dopamine systems. Since dopamine plays a crucial role in impulse 
control, damage to the dopamine system may increase risk behaviour and might also 
affect the immune function. Especially in people who inject drugs this could affect for HIV 
transmission, immune function and increase susceptibility to infections. 
HIV in Indonesia
 Most of the studies in this thesis were performed in the context of ‘IMPACT’, a programme 
aimed to prevent, control and treat HIV among injecting drug users in West-Java (40 
million people), Indonesia [73]. Since the start of IMPACT many researchers and clinicians 
have provided evidence-based research for good clinical practises and interventions. This 
thesis focussed on differences in disease progression and immune responses among 
HIV-infected injecting drug users. Results on faster progression of HIV and the higher 
prevalence of tuberculosis among injecting drug users help with setting guidelines in the 
HIV clinics. We showed heroin use affects immune responses and methadone seems to 
have less deleterious effects, which could affect the recommendation and acceptation of 
MMT in Indonesia. Its results are closely linked with the work of other researchers who 
conducted an international PhD in the context of the IMPACT program. Rudi Wisaksana, 
an infectious disease specialist, has previously showed that injecting drug users have 
similar responses to HIV treatment, insuring that treatment is also prescribed to this risk 
group [74]. Shelly Iskander, psychiatrist, looked at risk behaviour among drug users and 
the impact of MMT, which resulted in improved integration of HIV and MMT services 
[75]. Azzania Fibriani, virologist, has developed an in-house assay for HIV viral load 
measures, ensuring that more individuals have access to viral load measurements [76]. 
In addition, Rudi Wisaksana and Azzania Fibriani have worked on drug resistance in HIV 
infected individuals from Indonesia [74, 76]. Rosie Hinduan, psychologist, set up a HIV 
prevention program through sex and drug education in junior high schools, which is now 
being adapted by many more schools [77]. Adiatma Siregar, economist, evaluated costs 
and cost-effectiveness of HIV-testing, opioid substitution and ART in various settings in 
Indonesia [78]. Erni Nelwan is examining HIV care in Indonesian prisons, where most 
individuals are HIV-infected have a history of IDU. Noor Tromp, working in health 
technology assessment, has conducted studies focussing on how priorities are set for HIV 
prevention and care in Indonesia, using ‘multi criteria decision analysis’ [79, 80]. Annisa 
Rahmalia is focussing on HIV and sexual reproductive health in women, who make up a 
growing proportion of HIV-infected individuals in Indonesia. Together with all these other 
projects I hope the work in this thesis can contribute to better prevention and care of HIV, 
and to evidence-based guidelines for HIV in Indonesia.  
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Summary
Drug users are at increased risk for human immunodeficiency virus (HIV) infection; 
injecting drug use (IDU) is responsible for approximately ten percent of all HIV infections 
worldwide. In chapter 2 we present a global perspective of IDU in relation to HIV. There 
are 16 million people who inject drugs worldwide, of whom an estimated 3 million 
are infected with HIV. The prevalence of HIV among injecting drug users varies greatly 
between countries as well as within them; on average HIV prevalence in this risk group 
varies from 0.01 to 72.1%. 
From the start of the HIV epidemic IDU has been recognised as a risk factor for HIV-
infection, but it may also change the natural course of HIV infection and increase the risk 
of opportunistic infections, such as tuberculosis and candida. In chapter 3 we examined 
the progression of HIV using the natural decline of the number of circulating CD4 cells as 
marker for immunodeficiency. Among 284 HIV-infected treatment naïve patients, people 
with a history of IDU had a statistically significant faster decline in CD4 cells. Based on 
our data, patients with a history of IDU would have an average 33% decline in CD4 cells 
after one year without ART, compared with a 22% decline among non-users. No other 
factor significantly affected CD4 cell decline. We show that a history of IDU is associated 
a faster progression of HIV. These findings have implications for monitoring treatment 
naïve patients with a history of IDU and for starting treatment in this group.
IDU is also associated with tuberculosis, but most data originate from high-income 
countries, were this relation is usually explained by factors related to higher tuberculosis 
exposure. However, we do not expect higher exposure to M. tuberculosis among injecting 
drug users in Indonesia, where people who inject drugs are mostly found among those 
with higher education and better socio-demographic background. In chapter 4 we 
examine IDU in relation to active and latent tuberculosis infection (LTBI) among HIV-
infected individuals in Indonesia. We found that patients with a history of IDU more 
often reported a history of tuberculosis treatment (34.8% versus 21.9%, p<0.001), more 
often received tuberculosis treatment during follow-up (HR=1.71; 95%CI: 1.25-2.35), and 
more often had bacteriologically confirmed tuberculosis (OR=1.67; 95%CI: 0.94-2.96). 
The prevalence of LTBI was not different, which may suggest that HIV-infected patients 
with a history of IDU have a higher risk of progression to active tuberculosis after M. 
tuberculosis infection. 
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In addition to CD4 receptors, HIV requires a co-receptor, either CCR5 or CXCR4, to invade 
cells. The expression of CCR5 and CXCR4 is important in the susceptibility of cells to HIV 
infection and viral replication. Unfortunately, only little information is available regarding 
the expression of CXCR4 and CCR5 on different subsets of T-lymphocytes, especially in 
long-term non-progressors (LTNP). LNTP refers to HIV patients that are able to maintain 
stable CD4 cell counts for an extended period of time and remain asymptomatic without 
ART for years after infection. In chapter 5 we show that the percentage of CCR5-expressing 
CD4+ cells of LTNP was comparable with healthy controls; whereas HIV-infected individuals 
showed more CCR5-expressing cells. This was observed in memory and naïve CD4+ cells, 
but not in regulatory T-cells. All groups had comparable percentages of CXCR4-expressing 
cells, but the mean fluorescence intensity (MFI: a marker for the amount of receptors per 
cell) of CXCR4-expressing cells was significantly higher in HIV-infected normal progressors 
in both memory and naïve CD4+ cells. We show that HIV -directly or indirectly- affects the 
expression of CCR5 in CD4+ T-lymphocytes; yet this effect is not seen in LTNP with viral 
control. 
Opioids may alter the expression of the HIV co-receptors CCR5 and CXCR4 and thereby 
affect the natural course of HIV infection. Not only the HIV co-receptors, but also their 
ligands (MIP-1α/CCL3, MIP- 1β/CCL4, RANTES/CCL5 and MCP-2/CCL8 for CCR5 and 
SDF-1/CXCL12 for CXCR4) have the ability to block HIV activity. However, no study has 
examined whether exposure to opioids in vivo has an effect on the expression of CCR5, 
CXCR4 or relevant chemokines in HIV-infected individuals (chapter 6). The expression of 
CCR5 on CD4+ cells was significant higher in heroin users, methadone clients and previous 
users compared to the controls. The percentage of CXCR4-expressing CD4 cells was 
significantly higher in controls compared to other groups. Overall, heroin users produced 
less chemokines after ex vivo exposure to pathogens (M. tuberculosis, C. albicans and 
LPS), but results varied per chemokine and stimulus. Exposure to opioids may therefore 
have long term effects on the immune system by up-regulation of CCR5, down-regulation 
of CXCR4 and HIV-relevant chemokines. This suggests that opioids could affect the HIV 
susceptibility of cells by decreasing endogenous blocking agents and increasing an 
important HIV co-receptor.
The regulation of immune and inflammatory responses is dependent on the functions 
of cytokines, which is especially important in individuals with an already compromised 
immune function, such as HIV-infected individuals. This is the first study to examine 
the effects of heroin and methadone on cytokine response in HIV-infected individuals. 
Chapter 7 shows that, in general, cytokine production was significantly lower in heroin 
users compared to non-opioid users after exposure to LPS. Interesting the same was 
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not observed with C. albicans and M. tuberculosis. When looking at LPS exposed cells, 
IL-1β, IL-6, TNF-α and IFN-γ production was lower in heroin users; the production of 
these cytokines in methadone maintenance treatment (MMT) and previous users was 
comparable to the controls. No differences were found in the production of IL-10 after 
exposure to LPS. With C. albicans and M. tuberculosis heroin users, individuals receiving 
MMT, ex-heroin users and non-opioid users produced comparable amounts of cytokines. 
The antimicrobial peptide cathelicidin is critical in killing pathogens by innate immune 
cells, including M.tuberculosis and C.albicans. These pathogens often cause infections in 
opioid users, a risk that is greatly increased with concurrent HIV infection. In chapter 8 we 
explored the association between opioid use and cathelicidin in HIV-infected individuals 
in Indonesia. We found that the RNA expression of cathelicidin was significantly 
decreased in heroin users, compared to non-drug users. Opioids are associated with 
immunosuppression and cathelicidin could be an important factor in this association.
In conclusion, this thesis shows that opioid use affects HIV disease progression and 
the susceptibility to tuberculosis; we presented various biological factors that were 
indeed affected by opioid use. Uniquely, we looked at the in vivo exposure to heroin 
and methadone, whereas previous research has typically been performed using in vitro 
or animal experiments. These studies showed that IDU indeed down-regulated CCR5 
and up-regulated CXCR4, which may be important for HIV progression. In addition, 
chemokines, cytokines and cathelicidin were altered in heroin users; this could be 
important in susceptibility to infection.
Individuals with a history of IDU in our cohort are not from a lower socioeconomic status 
or impoverished background. This is an important fact, since such circumstances can 
affect disease progression or exposure to infectious diseases. Instead we suspect that 
biological factors related to IDU play a important role, such as a direct effect of opioids, 
a difference in tropism or virulence of HIV virus transmitted via sharing needles, or 
underlying conditions such as hepatitis C virus. Our results show that all biological factors 
are indeed affected by opioid use and could play a role in deleterious clinical outcome 
among HIV-infected injecting drug users. However, other biological aspects related to IDU 
may also be of importance and should be studied.  Interestingly, we found that heroin 
and methadone have different immunomodulating effects in HIV-infected individuals. 
Methadone is used as a treatment aimed to reduce illegal use of heroin and stabilize 
the lives of patients and prevent transmission of blood-borne disease, such as HCV and 
HIV. In general, we found that methadone has less adverse effects on immune markers 
studied and therefore MMT might have even more benefits as a substitute for heroin. 
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Our study was performed in HIV-infected individuals to explore whether opioids could 
affect the HIV susceptibility of cells and modulate immune function. However, opioids are 
also frequently used as a painkiller in healthcare settings. Modulation of chemokines may 
be important for numerous conditions, such as cardiovascular disease, cancer and even 
psychiatric disorders. Therefore, the present results could have even larger implications 
than just among HIV-infected individuals.
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Samenvatting
Drugsgebruikers hebben een verhoogd risico op infectie met humane immunodeficiëntie 
virus (HIV); ongeveer tien procent van alle geïnfecteerde personen is met HIV besmet 
geraakt door het injecteren van drugs. In hoofdstuk 2 laten we een overzicht zien van 
intraveneus drugsgebruik (IVD) en HIV situatie wereldwijd. Wereldwijd zijn er 16 miljoen 
personen die drugs injecteren, waarvan ongeveer 3 miljoen geïnfecteerd zijn met HIV. De 
prevalentie van HIV in drugsgebruikers varieërt enorm zowel tussen landen als binnen 
landen; gemiddeld zijn tussen de 0,01 en 72,1% van deze risicogroep geïnfecteerd.
Sinds het begin van de HIV epidemie is bekend dat IVD een risicofactor is voor het krijgen 
van HIV. Drugs, met name opiaten, zouden echter ook het natuurlijke beloop van de HIV 
infectie alswel het risico op opportunistische infecties, zoals tuberculose en candida, 
kunnen beïnvloeden. In hoofdstuk 3 bestuderen wij het beloop van HIV door te kijken 
naar de daling van CD4 cellen, als marker voor de ernst van immuunsuppressie. Bij 
284 onbehandelde HIV-geïnfecteerde personen, vonden wij dat personen met IVD een 
significant snellere daling in CD4 cellen hadden. Op basis van onze data betekent dit dat 
diegene met een voorgeschiedenis van IVD na één jaar een gemiddelde daling van 33% 
in CD4 cellen hadden ten opzichte van 22% bij personen zonder voorgeschiedenis van 
IVD. We hebben aangetoond dat een voorgeschiedenis van IVD gerelateerd is met een 
snellere progressie van HIV. Deze bevindingen hebben mogelijk invloed op het monitoren 
en starten van behandeling in deze risicogroep.
Drugsgebruik is ook gerelateerd aan tuberculose, maar de meeste informatie komt 
uit landen waar deze relatie verklaard kan worden door verhoogde blootstelling. Wij 
verwachten echter geen verhoogde blootstelling aan tuberculose in Indonesië, waar 
IVD vooral voorkomt bij hoger opgeleiden en personen met een hogere sociale status. 
In hoofdstuk 4 onderzoeken wij de relatie van IVD met actieve en latente tuberculose 
infecties (LTBI) in HIV geïnfecteerde personen in Indonesië. Uit ons onderzoek blijkt dat 
patiënten met een voorgeschiedenis van IVD vaker tuberculose behandeling hadden 
gehad (34.8% versus 21.9%, p<0.001), vaker tuberculose behandeling kregen tijdens de 
follow-up (HR=1.71; 95%CI: 1.25-2.35), en dat bacteriële tuberculose vaker was bevestigd 
(OR=1.67; 95%CI: 0.94-2.96). De prevalentie van LTBI verschilde niet tussen personen met 
en zonder een voorgeschiedenis van IVD. Dit suggereert dat HIV geinfecteerde personen 
met een geschiedenis van IVD mogelijk een verhoogd risico hebben op actieve ziekte na 
besmetting met M. tuberculosis.
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Naast de CD4 receptor heeft HIV ook een co-receptor nodig, CCR5 of CXCR4, om cellen te 
infecteren. De expressie van CCR5 en CXCR4 is belangrijk voor de vatbaarheid van cellen 
voor HIV en virale replicatie. Er is echter weinig informatie beschikbaar over de expressie 
van CCR5 en CXCR4 op verschillende subsets van cellen, met name onder ‘long-term non-
progressors’ (LTNP). LTNP verwijst naar HIV patienten die stabiele CD4 cellen hebben voor 
een lange periode en jaren asymptomatisch blijven zonder behandeling. In hoofdstuk 5 
laten we zien dat het percentage CD4+ cellen dat CCR5 tot expressie brengt vergelijkbaar 
was tussen LTNP en gezonde controles; HIV-infecteerde personen hadden een verhoogde 
expressie van CCR5. We vonden dit in memory en naïve cellen, maar niet in regulatoire 
T cellen. Het percentage CD4+ cellen dat CXCR4 tot expressie bracht was vergelijkbaar 
tussen groepen, maar de ‘mean fluorescence intensity’ (MFI; een marker voor het aantal 
receptoren per cel) was significant hoger in HIV geinfecteerde personen in zowel memory 
als naïeve CD4+ cellen. We hebben laten zien dat HIV - direct of indirect -  een effect heeft 
op de expressie van CCR5 en CXCR4, maar dat we dit niet vinden bij LTNP.
Opiaten beïnvloeden mogelijk ook de expressie van CCR5 en CXCR4 en daardoor mogelijk 
ook het beloop van HIV. Niet alleen de HIV co-receptoren, maar ook de liganden van 
deze receptoren (MIP-1α/CCL3, MIP- 1β/CCL4, RANTES/CCL5 en MCP-2/CCL8 voor CCR5 
en SDF-1/CXCL12 voor CXCR4) kunnen HIV activiteit blokkeren. Geen studie heeft echter 
ooit bekeken of de blootstelling aan opiaten in vivo een effect hebben op de expressie van 
CCR5, CXCR4 of de relevante chemokines in HIV geïnfecteerde personen (hoofdstuk 6). De 
expressie van CCR5 op CD4+ cellen was significant hoger in heroïne gebruikers, personen 
op ‘methadone maintanance treatment’ (MMT) en  personen met een geschiedenis van 
heroine gebruik in vergelijking met controles. Het percentage CD4 cellen dat CXCR4 tot 
expressie brengt was significant hoger in controles. Over het algemeen, produceerden 
heroine gebruikers minder chemokines nadat cellen ex vivo waren blootgesteld aan 
pathogenen (M. tuberculosis, C. albicans and LPS), maar de resultaten verschilden per 
chemokine and stimulus. Blootstelling aan opiaten kunnen mogelijk ook op lange termijn 
het immuun systeem beinvloeden. Dit suggereert dat opiaten de vatbaarheid van cellen 
voor HIV kunnen beinvloeden door het verlagen van endogene blokkerende faktoren en 
verhogen van belangrijke receptoren. 
De regulatie van immuun en inflammatoire responsen zijn onder andere afhankelijk 
van cytokines, die mogelijk een nog belangrijke rol spelen bij personen die al een 
gecomprimenteerde immuun functie hebben, zoals HIV-geïnfecteerde personen. Dit is 
de eerste studie die de effecten van heroine en methadone op het cytokine response van 
HIV geïnfecteerde personen bekijkt. In hoofdstuk 7 laten we zien dat over het algemeen 
de cytokine response in heroïne gebruikers lager is dan in personen die geen opiaten 
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gebruiken, na ex vivo blootstelling aan LPS. Echter, we vonden dit niet na blootstelling 
aan C. albicans en M. tuberculosis. Cellen blootgesteld aan LPS produceerden minder 
IL-1β, IL-6, TNF-α en IFN-γ in heroïne gebruikers; de productie van deze cytokines 
was vergelijkbaar met de controles in personen die MMT ontvingen of meer dan een 
jaar geleden heroïne gebruikten. Na blootstelling aan C. albicans en M. tuberculosis 
produceerden alle groepen vergelijkbare hoeveelheden cytokines. 
De antimicrobiële peptide cathelicidine is cruciaal voor de bestrijding van pathogenen 
door immuun cellen, zo ook M.tuberculosis en C.albicans. Deze pathogenen veroorzaken 
vaak infecties bij drugsgebruikers, een risiko dat verhoogd is bij HIV infectie. In hoofdstuk 
8 bekijken wij de relatie tussen opiate gebruik en cathelicidine in HIV geïnfecteerde 
personen in Indonesië. We laten zien dat de RNA expressive van cathelicidine significant 
lager is in heroïne gebruikers in vergelijking met de controles. Opiaten zijn gerelateerd 
met immuunsuppressie en cathelicidine zou hierbij een belangrijke factor kunnen zijn. 
In conclusie, dit proefschrift laat zien dat opiate gebruik het beloop van HIV en de 
vatbaarheid voor tuberculose beïnvloedt; we hebben verscheidene biologische factoren 
laten zien die door opiate gebruik worden beinvloedt. Uniek is dat wij hebben gekeken 
naar in vivo blootstelling aan heroine en methadone, waar voorheen vooral onderzoek 
is gedaan naar in vitro blootstelling aan opiaten of in dierexperimenten. Onze studies 
laten zien dat IVD inderdaad CCR5 down-reguleert en CXCR4 up-reguleert, wat mogelijk 
belangrijk is voor HIV progression. Daarnaast was de productie van chemokines, cytokines 
en cathelicidine anders in personen die opiaten gebruiken, hetgeen invloedt kan hebben 
op de vatbaarheid van infectieziekten. 
De personen in ons cohort met een voorgeschiedenis van IVD zijn niet van een lager 
sociaal-economische status. Dit is belangrijk, omdat zulke omstandingheden ziekte 
progressie of blootstelling aan infectieziekten kan beïnvloeden. Wij verwachten daarom 
dat biologische factoren ook een belangrijke rol spelen, zoals directe effecten van opiaten, 
verschil in HIV tropisme of virulentie en/of andere condities zoals hepatitis C infectie. 
Onze resultaten laten zien dat biologische factoren inderdaad ook beïnvloed worden 
door het gebruik vam opiaten en mogelijk een rol kunnen spelen in de verslechterde 
klinische uitkomst bij HIV geinfecteerde drugsgebruiker. Andere biologische factoren 
gerelateerd aan drugsgebruik kunnen echter ook van belang zijn en zouden bestudeerd 
moeten worden. 
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Samenvatting
We hebben laten zien dat heroïne en methadone verschillende immunomodulerende 
effecten op HIV geïnfecteerde personen hebben. In de behandeling van verslaafden 
wordt methadone toegepast om heroïne gebruikt te verminderen en daardoor de levens 
van patienten te stabiliseren en transmissie van bloed overdraagbare ziekten, zoals HCV 
en HIV, te reduceren. In het algemeen had methadone minder schadelijke effecten op 
immuunmarkers en daarom zou MMT dus nog gunstiger kunnen zijn als vervanging van 
heroïne. Een rede temeer om MMT toe te passen als vervanging van heroïne.
Onze studie was uitgevoerd in HIV geïnfecteerde personen om te onderzoeken of 
opiaten de vatbaarheid van cellen voor HIV en immune functie kon beïnvloeden. 
Opiaten worden echter ook vaak gebruik als pijnstiller in gezondheidssettings. Het 
veranderen van chemokines en cytokines kunnen van belang zijn voor veel andere 
ziektes, zoals cardiovasculaire ziektes, kanker en zelfs psychiatrische stoornissen. De 
huidige bevindingen kunnen dus nog meer consequenties hebben dan alleen bij HIV 
geïnfecteerde individuen. 
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Pengguna narkoba suntik (penasun) berisiko tinggi terinfeksi virus human 
immunodeficiency (HIV); penggunaan narkoba suntik menyebabkan sekitar sepuluh 
persen infeksi HIV di seluruh dunia. Dalam bab 2 disajikan perspektif global penggunaan 
narkoba suntik sehubungan dengan HIV. Ada 16 juta penasun di dunia, di mana sekitar 
3 juta di antaranya terinfeksi HIV. Prevalensi HIV di antara penasun beragam di berbagai 
negara serta di dalam satu negara; rata-rata prevalensi HIV di kelompok risiko ini berkisar 
antara 0.01 sampai 72.1%. 
Sejak awal epidemic HIV penggunaan obat suntik telah diketahui merupakan salah satu 
faktor risiko infeksi HIV, namun bisa juga mengubah perjalanan alami infeksi HIV dan 
meningkatkan risiko infeksi oportunistik, seperti tuberculosis dan candida. Dalam bab 
3 diselidiki perjalanan penyakit HIV menggunakan penurunan alami dari jumlah sel CD4 
yang bersirkulasi sebagai penanda imunodefisiensi. Di antara 284 pasien terinfeksi HIV 
yang belum diobati, orang yang memiliki riwayat penggunaan narkoba suntik memiliki 
penurunan sel CD4 yang lebih cepat dan bermakna secara statistik. Berdasarkan data 
kami, pasien dengan riwayat penggunaan obat suntik memiliki rata-rata penurunan CD4 
sebesar 33% dalam setahun tanpa pengobatan, dibandingkan dengan penurunan 22% 
pada non-penasun. Tak ada faktor lain yang secara signifikan mempengaruhi penurunan 
sel CD4. Kami menunjukkan bahwa riwayat penggunaan narkoba suntik berkaitan dengan 
perjalanan penyakit HIV yang lebih cepat. Hasil temuan ini berdampak pada pemantauan 
pasien dengan riwayat penggunaan obat suntik yang belum diobati dan untuk memulai 
pengobatan pada kelompok ini. 
Penggunaan obat suntik juga berkaitan dengan tuberculosis tetapi sebagian besar data 
berasal dari negara berpendapatan tinggi, di mana hubungan ini biasanya memiliki 
penjelasan yang terkait dengan tingginya pajanan tuberculosis. Akan tetapi, kami tidak 
memperkirakan pajanan M. tuberculosis yang lebih tinggi pada penasun di Indonesia, 
di mana penggunaan obat suntik umumnya ditemukan di antara orang dengan tingkat 
pendidikan dan sosio-demografik yang lebih tinggi. Dalam bab 4 diteliti penggunaan 
obat suntik terkait dengan infeksi tuberculosis aktif dan laten (LTBI) pada orang terinfeksi 
HIV di Indonesia. Kami menemukan bahwa pasien dengan riwayat penggunaan obat 
suntik lebih sering melaporkan riwayat pengobatan tuberkulosis (34,8% vs. 21,9%, 
p<0,001), lebih sering menerima pengobatan tuberkulosis selama follow-up (HR=1,71; 
95%CI: 1,25-2,35), dan lebih sering mengidap tuberkulosis yang bisa dikonfirmasi 
secara bakteriologis (OR=1,67; 95%CI: 0,94-2,96). Prevalensi LTBI tidak berbeda, yang 
menunjukkan kemungkinan pasien terinfeksi HIV dengan riwayat penggunaan obat 
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suntik setelah terinfeksi M. tuberculosis  memiliki risiko lebih tinggi untuk berkembang 
menjadi tuberkulosis aktif. 
Selain reseptor CD4, HIV memerlukan ko-reseptor, yaitu CCR5 atau CXCR4, agar dapat 
menginvasi sel. Ekspresi CCR5 dan CXCR4 penting dalam kerentanan sel terhadap infeksi 
HIV dan replikasi virus. Sayangnya, hanya sedikit informasi tersedia mengenai ekspresi 
CXCR4 dan CCR5 pada subset limfosit-T yang berbeda, khususnya pada long-term non-
progressors (LTNP). LNTP adalah pasien HIV yang memiliki hitung sel CD4 yang stabil 
selama waktu yang lama dan tetap asimptomatik tanpa ART bertahun-tahun setelah 
terinfeksi. Di bab 5 ditunjukkan bahwa persentase sel CD4+ yang mengekspresi CCR5 
pada LTNP sebanding dengan kelompok kontrol yang sehat; sementara pengidap infeksi 
HIV memiliki lebih banyak sel yang mengekspresi CCR5. Pengamatan ini didapatkan pada 
sel CD4+ memori dan naïf, tetapi tidak pada sel-T regulasi. Semua kelompok memiliki 
persentase sel yang mengekspresi CCR5 yang sebanding, tetapi mean fluorescence 
intensity (MFI: penanda jumlah reseptor per sel) dari sel yang mengekspresi CXCR4 lebih 
tinggi secara bermakna pada pasien terinfeksi HIV dengan perjalanan penyakit normal 
baik pada sel CD4+ memori dan naïf. Terbukti bahwa HIV baik secara langsung mau pun 
tidak langsung mempengaruhi ekspresi CCR5 pada limfosit-T CD4+; namun efek ini tidak 
ditemukan pada LTNP tanpa kontrol virus. 
Opioid mungkin mengubah ekspresi koreseptor HIV CCR5 dan CXCR4 sehingga 
mempengaruhi perjalanan alami dari infeksi HIV. Bukan hanya ko-reseptor HIV, tetapi 
juga ligands (MIP-1α/CCL3, MIP- 1β/CCL4, RANTES/CCL5 dan MCP-2/CCL8 bagi CCR5 
dan SDF-1/CXCL12 bagi CXCR4) memiliki kemampuan memblok aktivitas HIV. Namun 
demikian, belum ada penelitian yang menyelidiki apakah pajanan opioid in vivo berefek 
pada ekspresi CCR5, CXCR4 atau kemokin yang relevan pada orang terinfeksi HIV (bab 
6). Ekspresi CCR5 pada sel CD4+ secara bermakna lebih tinggi pada pengguna heroin, 
klien metadon dan mantan penasun dibandingkan dengan kelompok kontrol.  Persentase 
sel CD4 yang mengekspresi CXCR4 secara bermakna lebih tinggi pada kelompok kontrol 
dibandingkan kelompok lain. Secara keseluruhan, pengguna heroin memproduksi lebih 
sedikit kemokin setelah pajanan ex vivo terhadap patogen (M. tuberculosis, C. albicans 
dan LPS), namun hasilnya beragam untuk setiap kemokin dan stimulus. Pajanan opioid 
oleh karenanya mungkin memiliki efek jangka panjang terhadap sistem kekebalan 
dengan up-regulation CCR5, down-regulation CXCR4 serta kemokin yang relevan bagi 
HIV. Ini menunjukkan bahwa opioid bisa mempengaruhi kerentanan sel terhadap HIV 
dengan mengurangi agen yang memblok secara endogen dan meningkatkan ko-reseptor 
yang penting bagi HIV. 
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Regulasi imun dan respon inflamasi tergantung pada fungsi sitokin, yang khususnya 
penting bagi orang yang memiliki fungsi imun yang sudah lebih rendah, seperti orang 
yang terinfeksi HIV. Ini adalah penelitian pertama yang menyelidiki efek heroin dan 
metadon pada respon sitokin di antara orang terinfeksi HIV. Bab 7 menunjukkan bahwa, 
secara umum, produksi sitokin secara bermakna lebih rendah pada pengguna heroin di 
antara pengguna non-opioid setelah pajanan terhadap LPS. Yang menarik hal serupa 
tidak tampak bagi C. albicans dan M. tuberculosis. Jika mengamati sel yang terpajan 
LPS, produksi IL-1β, IL-6, TNF-α dan IFN-γ production lebih rendah di antara pengguna 
heroin, produksi sitokin ini dalam substitusi opioid metadon (MMT) dan mantan penasun 
sebanding dengan kelompok kontrol. Tak ditemukan perbedaan produksi IL-10 setelah 
pajanan LPS. Dengan C. albicans dan M. tuberculosis pengguna heroin, orang yang 
mendapat MMT, mantan pengguna heroin dan pengguna non-opioid memproduksi 
sitokin dalam jumlah yang sebanding. 
Peptide antimikroba katelisidin penting untuk membunuh pathogen oleh sel imun 
bawaan, termasuk M.tuberculosis dan C.albicans. Patogen ini seringkali menimbulkan 
infeksi pada pengguna opioid, sebuah risiko yang sangat berkurang dengan infeksi HIV 
yang serentak. Di bab 8 dieksplorasi hubungan antara penggunaan opioid dan katelisidin 
pada orang terinfeksi HIV di Indonesia. Ditemukan bahwa ekspresi RNA katelisidin 
menurun secara bermakna pada pengguna heroin, dibandingkan dengan non-penasun. 
Opioid berkaitan dengan imunosupresi dan katelisidin bisa jadi merupakan salah satu 
faktor penting dalam hubungan ini. 
Kesimpulannya, tesis ini menunjukkan bahwa penggunaan opioid mempengaruhi 
perjalanan penyakit HIV dan kerentanan terhadap tuberkulosis; disajikan berbagai faktor 
biologis yang memang dipengaruhi oleh penggunaan opioid. Yang  istimewa dalam 
tesis ini adalah pengamatan pajanan heroin dan metadon in vivo, sementara penelitian 
terdahulu dilakukan menggunakan eksperimen in vitro atau pada hewan. Penelitian 
ini menunjukkan bahwa penggunaan narkoba suntik memang menyebabkan down-
regulation CCR5 dan up-regulation CXCR4, yang mungkin penting bagi perjalanan HIV. 
Selain itu, kemokin, sitokin dan katelisidin juga berubah pada pengguna heroin; ini bisa 
jadi penting bagi kerentanan terhadap infeksi. 
Orang dengan riwayat penggunaan narkoba suntik dalam kohort kami bukan berasal dari 
status sosioekonomi rendah atau latar belakang miskin. Ini adalah fakta penting, karena 
situasi tersebut bisa mengubah perjalanan penyakit atau pajanan terhadap penyakit 
infeksi. Oleh karenanya diduga faktor biologis terkait dengan penggunaan narkoba suntik 
memegang peran penting, seperti efek langsung dari opioid, perbedaan tropisme atau 
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virulensi virus HIV yang ditularkan melalui berbagi jarum, atau kondisi awal seperti virus 
hepatitis C. Hasil penelitian ini menunjukkan bahwa semua faktor biologis memang 
dipengaruhi oleh penggunaan opioid dan bisa memegang peran dalam menimbulkan 
efek klinis yang berat pada penasun yang terinfeksi HIV. Akan tetapi, aspek biologis lain 
yang terkait dengan penggunaan narkoba suntik juga mungkin penting dan perlu diteliti. 
Yang menarik, didapati bahwa heroin dan metadon memiliki efek imunomodulasi yang 
berbeda pada orang terinfeksi HIV. Metadon digunakan sebagai pengobatan dengan 
maksud mengurangi penggunaan heroin yang illegal dan oleh karenanya menstabilkan 
hidup pasien dan mencegah penularan penyakit yang ditularkan melalui darah, seperti 
hepatitis C dan HIV. Secara umum, didapatkan bahwa metadon memiliki lebih sedikit efek 
samping pada penanda imun yang diteliti sehingga terapi rumatan metadon (methadone 
maintenance treatment; MMT) sebagai pengganti heroin mungkin memiliki lebih banyak 
manfaat. 
Penelitian kami dilakukan pada orang terinfeksi HIV untuk mempelajari apakah opioid bisa 
mempengaruhi kerentanan sel terhadap HIV dan modulasi fungsi imun. Namun, opioid 
juga sering digunakan sebagai penghilang rasa nyeri di pelayanan kesehatan. Modulasi 
kemokin mungkin penting bagi berbagai kondisi, seperti penyakit kardiovaskuler, kanker 
dan bahkan gangguan psikiatrik. Maka, hasil penelitian ini bahkan bisa memiliki implikasi 
yang lebih besar dan bukan hanya bagi orang terinfeksi HIV. 
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List of abbreviations
AIDS   Acquired immunodeficiency syndrome
AMPs   Antimicrobial peptides
ART   Antiretroviral therapy
CD4 cells  CD4+ T lymphocytes
cDNA   Complementary deoxyribonucleic acid 
Hb   Haemoglobin
HCV   Hepatitis C virus
HIV   Human immunodeficiency virus
IDU   Injecting drug use
IFN   Interferon gamma
IGRA   Interferon gamma release assay
IL   Interleukin
IQR   Interquartile range
LPS   Lipopolysaccharide 
LTBI   Latent tuberculosis infection
LTNP   Long-term non-progressors
MFI   Mean fluorescence intensity
MMT   Methadone maintenance treatment
NGO   Non-governmental organisation
NSPs   Needle and syringe exchange programmes
OST   Opioid substitution therapy
RNA   Ribonucleic acid
SIV   Simian immunodeficiency virus
TNF   Tumor necrosis factor
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